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 Abstract 
 
Background: 
Sepsis is a systemic illness caused by microbial invasion of normally sterile parts 
of the body. In haematological malignancies, patients are more prone to 
developing infections due to defects in the neutrophil count and function which 
occur as a part of the neoplastic process or due to chemotherapy. The presence of 
neutropenia calls for other means of defence including the innate immune system. 
Genetic studies have attempted to examine the relationship between particular 
genes involved in innate immunity and susceptibility to infections. Genes involved 
in the host defence mechanism such as pathogen presentation, recognition and 
phagocytosis result in the initiation of a cascade of events ending in the innate 
immune system activation. Chitotriosidase and nucleotide oligmerization domain 
(NOD2) are two genes suggested to have a possible role in the innate immune 
response against bacterial and fungal infections. Studies of acute lymphoblastic 
leukaemia (ALL) and NOD2 mutations have been conducted in allogenic transplant 
patients in order to examine any association with the incidence of relapse, survival 
and graft versus host disease. The occurrence of NOD2 variants are also 
implicated in the onset or progression of different malignancies via its effect on 
immune system.  
 
Purpose gene:  
The aim of our study was to explore the effect of mutations in genes involved in the 
innate immune system in relation to incidence and outcome of sepsis, prevalence 
of particular microorganism, and depth and duration of neutropenia in patients with 
haematological malignancies. The study aimed to identify mutations in 
chitotriosidase and NOD2, individually, and then looked at the synergetic effect of 
 both mutations, given previous evidence of molecular interaction between the gene 
products. We also looked at NOD2 mutation in non-transplanted ALL patients so 
as to evaluate the effect of this mutation on outcome and prognosis.  
 
Methods: 
The study was carried out in the RFH in patients diagnosed with haematological 
malignancies. Blood was collected and DNA extracted. Genotyping identified 
chitotriosidase mutations while NOD2 missense mutations (SNP8 and SNP12) 
were determined by pyrosequencing. 
In the study of NOD2 mutations and ALL outcome, samples were collected as a 
part of UKALL-12 trial-MRD study in patients with the diagnosis of ALL. The NOD2 
mutations (SNP8, SNP12 and SNP13) were identified by genescanning. 
 
Results: 
The incidence of febrile events with positive (p=0.031) or negative growth for any 
organism cultures (p=0.029) was increased in patients with chitotriosidase 
mutations. These results were most significant during periods of neutropenia; 
febrile events with bacterial isolates (p=0.015) and without (p=0.007). 
During periods of normal neutrophil count the incidence of fevers with positive 
bacterial cultures was also increased in patients with NOD2 mutation,(p=0.017).  
The incidence of fevers without positive cultures was decreased (p=0.029). There 
were no significant differences in CR, incidence of relapse or OS in ALL patients 
with NOD2 mutations. 
 
 
 Conclusions: 
This study suggests an association between chitotriosidase mutations and the 
incidence of febrile events (with or without positive bacterial cultures) in 
neutropenic patients. The NOD2 mutation was found in association with an 
increased incidence of fevers with bacterial organisms identified and a decreased 
incidence of fever of unknown origin in non-neutropenic patients.  
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Chapter  1 
 
General Introduction 
1.1.  Introduction 
Neutropenia is known to occur in haematological malignancies either as a 
complication of the disease process or of chemotherapy.2 Consequently, 
neutropenic patients are at increased risk of severe infections. 
The body’s defences depend on the innate immune system which consists of 
physical barriers and cells such as monocytes.3 The effectiveness of these cells is 
determined by a variety of genes which influence processes such as immune 
recognition, phagocytosis and cell signalling and include genes such as 
chitotriosidase and nucleotide oligmerization domain (NOD2). It has been found 
that mutations in the NOD2 gene influence the ability of the cells to respond to 
bacterial infections.4, 5 Likewise recent studies revealed increased susceptibility in 
chitotriosidase deficient patients to fungal and gram negative organisms.6, 7 In the 
present study we explored the relationship between the developments of infection 
in patients with haematological malignancies who carry mutations in chitotriosidase 
or NOD2 genes. We then analysed the effect of gene mutations on the process of 
infection, occurrence of sepsis, prevalence of microorganisms, and the duration 
and outcome of these events. We also examined the effect of the mutation on the 
duration of neutropenia. 
Since recent studies have shown conflicting results on the effect of NOD2 mutation 
on allogenic transplant outcome in translocation negative acute lymphoblastic 
leukaemia (ALL) patients8-10 we also conducted a pilot study examining whether 
NOD2 mutations affect disease outcome and prognosis. 
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1.2.  Haemopoietic malignancies 
The haemopoietic malignancies are clonal diseases that derive from a single cell in 
the marrow or peripheral lymphoid tissue which has undergone genetic alteration 
through a multistage process.11 The combination of genetic and environmental 
influences may determine the individual risk of developing malignancy, however in 
the majority of cases the cause is unknown, and neither a genetic susceptibility nor 
an environmental agent is apparent.11, 12 Haemopoietic malignancies are broadly 
divided  into B and T lymphoid and myeloid; and depending upon onset and 
course, into acute and chronic (see appendix-3).13  
In this study we examined the impact of NOD2 mutation in the outcome of 
Philadelphia negative ALL. Additionally, we studied the impact of chitotriosidase 
and NOD2 mutation first as a risk factor for developing any of the haemopoietic 
malignancy and then we looked into the risk of contracting infections in the same 
group of patients. 
 
1.2.1. Aetiology of haemopoietic malignancies 
1.2.1.1. Inherited factors 
Leukaemia is greatly increased in incidence in some genetic syndromes and 
diseases, either due to chromosomal abnormalities,14 immunodeficiency15 or both. 
Examples include Klinefelter’s syndrome,16 Bloom’s syndrome,14 and Ataxia 
telangiectasia.14, 15 Neurofibromatosis type-1 is believed to  increase  risk of 
juvenile myelomonocytic leukaemia by 200-500 fold.17 
Down’s syndrome is associated with 10-30 fold increase in the frequency of acute 
leukaemia.18 The associations are also present between Wiskott-Aldrich 
syndrome15 and lymphoid granulomatosis and Fanconi’s anaemia and 
myelodysplastic syndromes.14 There is a clear association of enteropathy-type T-
cell lymphoma with Coeliac disease.19 
  
Familial tendency in haematopoietic malignancies such as acute myeloid 
leukaemia (AML), chronic lymphocytic leukaemia (CLL), Hodgkin’s lymphoma (HL), 
non-Hodgkin’s lymphoma (NHL), and multiple myeloma (MM) have been 
investigated in several studies where increased risk in some families with 
estimated range of 1.5-4.0 fold was observed.20, 21 These observations suggests 
that a recessive mode of inheritance as well as shared environment during 
childhood and adolescence may play a role in familial non-Hodgkin lymphoma.21 
The risk of NHL was also increased in subjects with family history of cancers of the 
liver, breast and kidney.20  
 
1.2.1.2. Environmental influences 
Two studies22, 23 have examined whether exposure to environmental factors vary 
between individuals with and without family history of hematopoietic cancer. In 
these studies, homosexual behaviour, drug use, exposure to pesticides and other 
occupational contaminants, history of liver diseases, and alcohol consumption22 
were more strongly associated with NHL among men with family history of 
hematopoietic cancer than among those without such history, indicating a possible 
interaction between genetic susceptibility and some non-genetic risk factors. 
Diet had been described in connection with haematological malignancies. 
Increased risk of NHL  was associated  with dietary intake of dairy products, fried 
or red meat, and coffee, and decreased risk with dietary intake of fruits and 
vegetables.24 Eating disorders have been connected to leukaemia due to 
malnutrition and subsequent impaired immunity.25 
Radiation exposure is associated with all types of leukaemia (chronic 
myeloproliferative diseases, chronic myelomonocytic leukaemia, acute myeloid 
leukaemia), and survivors of the atom bomb explosions in Japan are evidence of 
such association.26 Chronic exposure to ultraviolet light,27 trichloroethylene,28 
uranium,29 pesticides,30 benzene31 as well as cigarette smoking,32 have been 
linked to increased incidence to NHL, leukaemia and other cancers. Cigarette 
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smokers have an increased risk of 2-folds in developing AML and myelodysplastic 
syndromes.32, 33 An increase was also found for follicular lymphoma among female 
smokers.34 
Increased risk of NHL  was also seen in conditions leading to immunosuppressant 
either due to diseases, treatment or both, examples of such are Sjögren’s 
syndrome,35 organ transplant,36 inflammatory bowel disease37, 38 and rheumatoid 
arthritis.39 The risk was stronger when the treatment included cyclosporine-A and 
azathioprine.36-38 Rheumatoid arthritis has also been linked to the development of 
IgA myeloma.40 
Agents involved in the treatment of malignancies can themselves predispose the 
patient to secondary lymphohematopoietic malignancies. Cytogenic agents may 
play a part in the causation of chronic myelomonocytic leukaemia, myelodysplastic 
syndromes and acute myeloid leukaemia. Alkylating agents, melphalan, 
procarbazine and nitrosoureas predispose individuals to acute myeloid leukaemia, 
especially if combined with radiation, or if used in the treatment of lymphocytic or 
plasmacytic disorders. Epipodophyllotoxins such as etoposide,  is associated with 
secondary leukaemias with balanced translocation  such as MLL (mixed-lineage 
leukaemia) 11q23.14, 41 
 
1.2.1.3. Infections 
The mechanism by which infection lead to the development of tumours is unclear, 
but an abnormal immune response to infection has been suggested by 
epidemiological studies.42 Viral infection is  known  to cause several types of 
haemopoietic malignancies.43, 44 Epstein-Barr virus (EBV) has been implicated in 
lymphoma including; endemic Burkitt’s lymphoma,45 post transplant 
lymphoproliferative disease (PTLD) which develops during immunosuppressive 
therapy after solid organ transplantation,36 mature (peripheral) B-cell neoplasms 
and several others.42 Hepatitis B virus (HBV),46 hepatitis C virus (HCV),47 
Helicobacter pylori (H. pylori), human immunodeficiency virus (HIV),48 retrovirus 
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human type 149 and human herpes virus 850 are all associated with different types 
of lymphoma. 
 
1.3.  Acute lymphoblastic leukaemia (ALL) 
1.3.1. Incidence and Etiology 
ALL has a bimodal age distribution51 being the most common malignancy in 
childhood and accounting for 30% of all cancers and 80% of all leukemia.51, 52 Peak 
incidence is highest in children aged 2-6 years. In adulthood the incidence is fairly 
low, but rises gradually with half the cases being under 50. ALL is rare over the 
age of 70.52 ALL is seen more commonly in males than females. It is 30% higher in 
boys compared to girls.52 
Delayed exposure to infectious agents in children of higher socioeconomic status 
may also predispose them to ALL.52 Increased risk is also seen after exposure to 
radiation, e.g. Chernobyl tragedy and in genetic conditions such as Down’s 
syndrome which carries 20 fold increased risk.52  
Little is known about the aetiology of childhood leukaemia, but is likely to involve 
an interaction between inherited susceptibility, environment, haemopoietic 
development and chance. The concept that some cases of ALL originate in utero 
comes from genetic studies of identical twins with concordant leukaemia, with 
results suggesting transplacental exposure to certain mutagens may be important 
in initiating events in some cases. But for leukaemia to emerge additional genetic 
alterations, such as genetic polymorphisms of certain enzymes capable of 
detoxifying carcinogens, or leukaemia-specific fusion-gene sequences are 
required.53, 54  
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1.3.2. Pathogenesis and Prognostic factors 
1.3.2.1. Prognosis: 
Prognosis usually depends on clinical factors including clinical presentation and 
biological characteristics such as age, performance status, white blood cell (WBC) 
count, organ involvement, leukaemia cell immunophenotype, cytogenetics and time 
to achieve complete remission (CR). Tolerance for intensive chemotherapy may 
contribute to the poor results in adults compared to childhood leukaemia.55  
ALL is fatal in days or weeks if untreated depending on the extent of bone marrow 
failure, related blood cytopenias, the effect of circulating blast cells and their 
metabolites on vital organs and the degree of central nervous system (CNS) 
involvement.52  
Complete remission can be achieved in 70-80% of patients. Around 10-20% 
(depending upon age) of patients die early during induction treatment and a further 
10% could be refractory to remission-induction programs. In addition, more than 
half of the patients who achieve a complete remission are expected to relapse, and 
only a minority can achieve a second long lasting remission. The overall chance of 
cure is approximately 20-40% in adults newly diagnosed with ALL.55  
Presentation age and leukocyte count in B-lineage ALL are the clinical features 
most consistently associated with prognosis.54 In general, as patients age 
increases, the prognosis worsens. Age over 50-60 years is usually considered as 
unfavourable prognostic indicator with survival not exceeding 0.20 at 3 years. 
Adolescents and teenagers under 20 years of age do nearly as well as the 
paediatric ALL population and are best treated on childhood rather than adult 
programs.52  
Elevated cell count reflect a higher tumour mass and is a negative prognostic sign 
depending on the type of study and whether absolute blast count or total white 
blood cell count was employed.52  
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The time to response and disease sensitivity to treatment (chemo-radiotherapy) is 
the primary determinants for survival. Patients achieving CR in 4-5 weeks, 
evidence of slow peripheral blood (day 7) or bone marrow (day 14) blast cells 
clearing, or a poor prednisone response carry a significant better outcome.52, 56 
Time to platelet recovery (TPR) within 60 days may be another favourable clinical 
prognostic marker.52, 56 Among patients with MLL rearranged ALL, infants younger 
than one year of age fare considerably worse than older children.53  
 
1.3.2.2. Immunophenotyping ALL Precursors 
ALL accounts for 80% of paediatric leukaemias,53, 57 comprises of two cell lineages.  
B-cell lineage comprises approximately 85-90% of ALL, while T-cell lineage 
account for 10% of all ALL cases.13 In childhood ALL B-cell lineage account for 
approximately 75% of cases less than 18 years of age.58 While T-cell ALL account 
for 15%  with predominance in males beyond 10 years of age.59 Roughly 75% of 
adult ALL are of B-cell lineage, while T-cell lineage constitutes approximately 25% 
of adult ALL cases.13, 52  
 
1.3.2.3. Age 
Age is a well known prognostic factor in ALL,60 with initial remission in most 
patients, but ultimately over 25% of patients will relapse and only 10% of bone 
marrow relapses will have the chance to survive.57  
Prognosis in childhood ALL has continuously improved over the last 25 years with 
CR rate exceeding 90% and the current cure rate being 75-80%.60 In adults, 
although CR rates of 65-85% may be achieved,55 survival rate at 5 years is still 
between 20 and 40%.60 ALL response duration is frequently short, with only 20-
30% of patients becoming long-term survivors.55  
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1.3.2.4. Gender 
Overall males with ALL fare more poorly than females.59  The male gender 
influence over mortality has been observed in several studies.60 including 
Baccarani M et al. in which it is concluded that the association of male gender and 
advanced age (  30years), were major determinants of higher death rate.61  
Although the incidence of ALL is 2 folds higher in white children than black 
children, but the latter are less fortunate in prognosis.59  
 
1.3.2.5. WBC count & other blood parameters 
The WBC counts reflect early disease progression, this seems particularly 
important  in B-lineage ALL, as long-term remission remains rare in patients with 
high WBC counts given standard chemotherapy.60 In patients with B cell precursor 
ALL, an age of 1-9 years with low WBC count (<50x109/l) confers a favourable 
prognosis, while for T cell ALL, age and WBC count have little clinical 
significance.59  
Castagnola et al. found that the only factor affecting disease free survival (DFS) 
was a high WBC count at presentation. While shorter overall survival (OS) 
statistically correlated with higher WBC counts, long time to achieve CR, and older 
age.55 Persisting lack of haematopoietic recovery in the bone marrow (BM) even 
without the presence of leukemic blasts after 7 or 14 days of induction therapy , is 
highly an indicator of disease recurrence.59  
Diagnostic lactase dehydrogenase (LDH) level also represents the initial tumour 
mass and  has been shown to have  an influence on CR,60 although a clear impact 
on overall survival has not yet been demonstrated.60  
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1.3.2.6. Cytogenetics 
Combined immunophenotypic-cytogenic evaluation allows the identification of 
chromosomal aberrations including the most common chromosomal translocations 
like t(9;22)/Ph (~25% of patients) and t(4;11)/MLL-AF4 positive (~8% of patients) 
B-cell ALL.52 These techniques can also distinguish between minimally 
differentiated AML, ALL (including identification of B-cell and T-cell ALL)  and acute 
megakaryoblastic leukaemia.13 Genetic abnormalities are important prognostic 
factors within precursor B lymphoblastic neoplasms.62 Cytogenetic aberrations are 
less frequent in T-lineage ALL, the most frequent involve 14q11 breakpoints.52  
The Philadelphia chromosome (Ph) is a shortened chromosome 22 generated by a 
balanced chromosomal translocation t(9;22), which involves the ABL-1 and BCR 
(Break-point cluster region)  fusion genes. Prognosis in ALL Philadelphia positive is 
generally dismal for adolescents, but is relatively favourable in children 1 to 9 years 
old with low WBC count at diagnosis.59 Although complete haematological 
remission occurs in approximately 70% post chemotherapy induction, few sustain 
this remission, as most patients relapse early. The long-term survival rate in adult 
patients does not reach 20%.63 Recently studies showed that some cytogenetic 
abnormalities of ALL blasts are the most important long-term survival prognostic 
factors.60 Patients with (Ph+) and/or BCR-ABL-1 fusion gene ALL have extremely 
poor prognosis, with long-term survival rates ranging from 35% to 40% in children 
to less than 20% in adults.64 Additionally most patients have other abnormalities 
such as heterogenous karyotypes. Whether secondary aberrations carry additional 
pathogenetic or prognostic information is not yet clear.63  
The single most frequent cytogenetic aberration in childhood ALL is hyperdiploidy 
(>50 chromosomes), comprising one quarter of all cases and only 6% of all cases 
in adult ALL.53, 59  
ALL with chromosomal rearrangements; t(4;11) is rare in adults (3-4%). It is 
associated with hyperleukocytosis and the presence of the immature B-ALL 
subtype.52 Childhood Ph+ ALL or the t(4;11)/MLL-AF4 fusion are considered to 
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have very high risk ALL and do worse in infants younger than 1 year compared to 
children 1 year of age or older.59, 65 Other recurrent chromosomal abnormalities 
have been described in adult ALL, but with low frequency and unclear prognosis 
relevance. 
ALL B lineage and prognosis are summarised in table 1.1. 
 
Table 1.1. Acute lymphoid leukaemias; Prognostic markers in Precursor B cell (adapted)13  
Cytogenics Genetics  Prognosis 
t(9;22)(q34;q11.2) 
t(4;11)(q21;q23) 
t(1;19)(q23;p13.3) 
t(12;21)(p12;q22) 
t(10;14), t(14q11-q13) 
ALL-hypodiploid 
ALL-hypodiploid >50 
Hyperdiploid 
BCR/ABL 
AF4/MLL 
PBX/E2A 
TEL/AML1 
Unfavourable 
Unfavourable 
Unfavourable 
Favourable 
Favourable 
Unfavourable 
Favourable 
Favourable 
 
1.4. Therapy related complications in 
haematological malignancies 
1.4.1. Neutropenia & infections in Haematologic Patients 
The leading cause of treatment-related mortality among patients with 
haematological malignancies undergoing chemotherapy is multi-organ failure due 
to systemic infection during neutropenia.66 Most neutropenic patients with infection 
present with fever as the first symptom. However, there is a variety of causes for 
febrile conditions. Apart from infection, reactions to drugs or blood products as well 
as tumour-associated fever are all possible underlying mechanisms.67  
Neutropenic patients  often fail to develop symptoms and signs of infection due to 
their blunted inflammatory response.66, 67  
Occasionally, an infection may develop in the absence of fever, as with Clostridium 
spp, or if the patient receiving corticosteroids.67 Alternatively fever may be the initial 
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and often the only sign of infection. Approximately 50-60% of febrile neutropenic 
episodes in neutropenic patients are classified as fever of unknown origin (FUO) as 
they never have clinical or microbiological evidence of infection.67  
The duration and severity of neutropenia are both important and influence not only 
the frequency and severity of infection but also the response to therapy and overall 
outcome.67  
Susceptibility to infection increases when the absolute neutrophil count (ANC) falls 
below 1000 cell/mm3 and with the further fall of ANC  500 cell/mm3 the risk 
becomes greater. Many patients with haematological disorders (e.g. acute 
leukaemia) have defects in neutrophil function despite adequate or increased 
numbers of neutrophil. Chemotherapy induced neutropenia is often superimposed 
on other immunological deficits that might be present because of the underlying 
malignancy.67  
Bloodstream infections (BSIs) directly affect clinical course and outcome in patients 
with cancer, prolonging their hospital stay and significantly increasing mortality.68 
Among patients with underlying cancer diseases, those with haematological 
malignancies are more prone to infectious complications due to interactions of 
host/environment/antimicrobial prophylaxis/treatment related factors.68 
Haematologic patients with BSIs still fear poor outcome despite advances in 
antimicrobial therapy and supportive care.68, 69  
The incidence of BSIs in neutropenic patients with the diagnosis of FUO ranges 
from 11% to 38%. The clinical manifestation may range from transient bacteraemia 
to fulminate septic shock in those patients.70  
The types of infections that afflict neutropenic patient undergoes periodic changes, 
geographic and instituitional differences,67 as seen in the change of pathogens in 
the last two decades, with the shift of organism spectrum, from Gram-negative 
bacteria as a cause of approximately 70% of bacteraemia in the 1970s to Gram-
positive organisms causing approximately 70% of episodes by the late 1980s and 
1990s. Recently some hospitals have experienced an increase in multidrug 
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resistance pathogens.66 Gram-negative bacillary catheter-related blood stream 
infections (CRBSIs) caused by organisms such as Escherichia coli (E coli), 
Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter spp., 
Acinetobacter spp., and Stenotrophomonas maltophilia have been reported. 
Although infections due to Gram-negative organisms usually emerges from a non-
catheter-related source, such as nosocomial urinary tract infection, nosocomial 
pneumonia, or intra-abdominal infection.71 The skin organisms such as Coagulase-
negative staphylococci (mainly Staphylococcus epidermidis) and the oral viridans 
(or alpha-haemolytic) streptococci (principally Streptococcus mitis and 
Streptococcus oralis) account for most of the isolates from blood cultures and lead 
the cause of CRBSIs. The prominence of the staphylococci is attributed to the 
widespread use of indwelling intravenous-access devices which often remain in 
place for weeks and even months and the association of Staphylococcus aureus 
with high rate of deep-seated metastatic infections, including septic thrombosis and 
endocarditis. The occurrence of oral mucositis induced by more intensive 
chemotherapy is associated with bacteraemia due to viridans streptococci that 
normally reside on the surfaces of the oral cavity.71, 72  
Infections are predominantly bacterial during the early phases of neutropenia. The 
spectrum of infections change to fungal with prolong neutropenia, and the 
administration of multiple courses of broad-spectrum antibiotics. Yeasts such as 
Candida spp. and Trichosporon spp. and molds such as Aspergillus spp., the 
Zygomycetes, and Fusarium spp. are the usual causes of fungal infections.67  
Viral infections are uncommon, but herpesviruses (HSV, VZV, CMV, HHV6) and 
community respiratory viruses are the most frequent pathogens.67  
 
 1.4.2.  Intravascular catheter 
Vascular catheters are becoming an essential tool for the care and management of 
chronically and critically ill patients. Vascular catheter-related infections are the 
leading cause of nosocomial BSIs and are associated with substantial morbidity 
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and mortality.71, 73 Catheter related infections (CRI) are often difficult to treat, as 
they are mostly caused by organisms resistant to antimicrobial agents that are 
embedded in the catheter layers and sheath.73  
 
1.4.2.1. Source of infections 
The most common source of colonization of intravascular catheters is the skin and 
catheter hub. In the long term catheters the lumen of the hub or the bell of the port 
is the major source of infection.73  
The skin insertion site is the major source of colonization and contamination with 
spp. of Coagulase negative Staphylococcus, in the case of short term catheter. 
Whereby organisms such as Staphalylococcus aureus71  migrate along the 
external surface of the catheter and the intercutaneous and subcutaneous 
segments, leading to colonization of the intravascular catheter tip which may lead 
to bloodstream infection. The microbes that colonize the catheter hubs and the skin 
surrounding the insertion site are most commonly cause of CRBSIs.74  
 
1.4.2.2. Clinical manifestations                                                                    
The clinical manifestations of CRIs can be systemic or local, occurring at the 
insertion site or tunnel track.71 Signs and symptoms of local catheter infections are 
often characterized by inflammatory manifestations which are frequently absent in 
neutropenic patients, signs including induration, erythema, warmth, and pain or 
tenderness at or around the catheter exit site.71, 75 Systemic catheter infections 
present with signs and symptoms of bacteraemia or fungaemia, such as fever, 
chills, and hypotension.71 Clinical manifestations of CRIs, such as fever, chills and 
hypotension,71 are sensitive but not specific for a diagnosis, whereas local 
manifestations are specific but not sensitive.76  
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1.4.2.3. Diagnosis 
Microbiological evidence is essential in pointing catheters as the source of 
bloodstream infections and the diagnosis of CRBSIs in patients with neutropenia. 
Diagnostic approaches can be divided into two major groups: those necessitating 
catheter removal and those that can be done without the removal of the catheter.71 
A definite diagnosis of intravascular CRIs cannot be complete by clinical criteria 
alone, but usually removing the catheter for quantitative catheter-tip culture is 
necessary. Only 15-25% of central venous catheters (CVCs) removed with the 
suspicion of infection proved to be the actual source of infection.77  
The differential quantitative blood cultures from samples drawn simultaneously 
from the catheter and a peripheral vein, is another test which minimize the risks 
associated with the removal of the old catheter and placement of a new catheter at 
a new site.77 Currently the gold standard for the diagnosis of catheter related 
bloodstream infection and in cases were catheter removal is undesirable, is the 
quantitative blood culture techniques.75, 76  
 
1.4.3. Sepsis 
Sepsis describes a complex clinical syndrome that results from a harmful or 
damaging host response to infection, as a result from systemic inflammatory 
response (SIR).78, 79 Sepsis develops when the initial, appropriate host response to 
an infection becomes amplified, and then dysregulated.78, 79 
Rapid activation of humoral cascade systems (complement, coagulation, kallikrein-
kinin system) and of cells that support the inflammatory reaction (granulocytes, 
monocytes, lymphocytes, macrophages, endothelial cells) is the key event in 
pathogenesis of sepsis. Production and release of inflammatory mediators and 
vasoactive or cytotoxic molecules is the result of such activation79 (Figure 1.1). 
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The onset is often insidious: clinical features may include fever, mental confusion, 
transient hypotension, diminished urine output or unexplained thrombocytopenia.78, 
79
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Figure 1.1.Cell surface recognition of lipopolysaccharide (LPS):  
LBP: LPS-binding protein signal via Toll-like receptor 4 (TLR4) after sensing the LPS. LPS  
is also sensed by other cell surface molecules including: Macrophage scavenger receptor  
(MSR), CD11b/CD18 and ion channels.  
NOD proteins (nucleotide oligomerization domain), are intracellular receptor to bacterial  
LPS, in response it initiates a cascade that activates NF  B signalling. Figure adapted.78  
  
 
Untreated, failure of renal or respiratory systems, coagulation abnormalities, and 
profound unresponsive hypotension may develop.78  
Bacterial motifs called pathogen-associated molecular patterns (PAMPs) and are 
the microbial components that are recognized by the innate immune system. This 
recognition initiates injury.78 In Gram-negative bacteria, lipopolysaccharide (LPS; 
known also as endotoxin) is a major component of the outer membrane and is 
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constructed of a lipid bilayer, separated from the inner cytoplasmic membrane by 
peptidoglycan (PGN). The LPS molecule is embedded in the outer membrane and 
linked to the hydrophobic lipid portion. The lipid A portion of the molecule serves to 
anchor LPS in the bacterial cell wall (figure 1.1.).78 Under physiological conditions 
changes in the lipid A structure occur which correlate with the ability to activate 
host cell membranes; the active forms take the shape of truncated cone, whereas 
the inactive molecules assume a lamellar structure and become progressively 
more cylindrical.78  
Gram-positive bacteria have no endotoxin, but do contain PGN and lipoteichoic 
acid on their cell wall, which account for their biological activity. Both peptidoglycan 
and lipoteichoic acid are pro-inflammatory and have the ability to bind to cell 
surface receptors. Although they are much less active than LPS, but can induces 
septic shock due to their production of potent exotoxins.78  
 
1.4.3.1. Definition of sepsis 
The international standard definition of sepsis is the same definition suggested in 
1994 by the consensus conference of the American College of Chest Physicians 
and the Society of Critical Care Medicine (ACCP/SCCM). Sepsis is defined as a 
systemic inflammatory reaction induced by microorganisms invading the blood 
stream and/or their toxins released from a focus of infection. Severity, response to 
treatment and outcome are determined by the presence and extent of organ 
dysfunction and development of septic shock, which is associated with the worse 
prognosis. Septic shock is defined by volume refractory hypotension; decrease 
organ perfusion despite adequate fluid substitution and mental alteration.79  
 
1.4.3.2. Incidence of sepsis 
Prospective studies assumed more than 90% of febrile neutropenic episodes fulfil 
the criteria of sepsis according to the (ACCP/SCCM) consensus definition. 
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Accordingly, the incidence of neutropenic sepsis secondary to intensive 
myelosuppressive chemotherapy is around 70-100%.80 The incidence of sepsis in 
this group is related to the pre-treatment of the patient, intensity of chemotherapy, 
the degree and duration of neutropenia and overall performance status.79 In the 
majority of studies, the incidence of neutropenic infections due to bacteria has 
been reported to be 10-30%.79 
 
1.4.3.3. Prognostic factors in leucocytopenic patients with sepsis 
Disease-associated defects in the immune defence mechanisms account for the 
high incidence of invasive infections in patients diagnosed with haematological 
malignancies. Examples are chronic lymphocytic leukaemia and multiple myeloma 
which are associated with humoral defects, while Hodgkin’s lymphoma are 
associated with cellular defects.79  
Other disease or treatment associated risk factors are: The severity and duration of 
neutropenia following cytotoxic chemotherapy. Skin and mucosal barriers and as a 
result of invasive diagnostic procedures, and catheters insertion can be disrupted, 
leading to increased risk of CRBSIs (staphylococci, fungi). Mucosal dryness due to 
decreased production of saliva or retention of secretion, facilitate the growth of 
pathogenic microorganisms. Malnutrition, parenteral nutrition, hospitalization, 
immunosuppression and antibiotic pretreatment all predispose to nosocomial 
infections.79  
 
1.4.4. Diagnosis 
1.4.4.1. Bacteraemia 
Bacterial infections are life threatening in neutropenic patients. It is critical in this 
set of patients to diagnose or rule out infection. The most common parameter is the 
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acute phase, C-reactive protein (CRP). This protein concentration is elevated in 
almost all cases of microbial infections and within 24hrs.81  
Microbiology laboratory plays a definite and important role in the diagnosis of 
infections in neutropenic patients. Such an analysis of various biological 
examinations: blood cultures (B/Cs), throat swabs. Washes from mouth and nose, 
sputum, saliva and bronchial secretions obtained either by bronchoscopy, 
bronchalveolar lavage (BAL) or catheters. Methods permitting the diagnosis of an 
infection by copro-cultures, cytobacteriological examination of urine, samples of 
respiratory origin, cytobacteriological examination of cerebrospinal fluid...) (see 
appendix-4; A.4.1.).82, 83  
Simultaneous quantitative B/Cs; involves obtaining paired blood cultures drawn 
simultaneously from the CVC and the peripheral vein, this method found to be the 
most accurate test for diagnosis of CRBSIs (figure 1.2.).71  
 
1.4.4.2. Gastrointestinal infections 
Acute abdominal signs and symptoms are seen in up to 5% of all cancer patients 
undergoing cytostatic treatment. The definite causative organism is only diagnosed 
in one third. Organisms are Gram-negative aerobes (e.g. Pseudomonas 
aeruginosa, E. coli) and anaerobes (e.g. Clostridium (Cl) spp), rarely Candida spp, 
H. simplex or cytomegalovirus.3 Enterocolitis accounts for almost 50% of the 
gastrointestinal infections in neutropenic patients (neutropenic colitis) and is the 
most common. Presentation is with painful abdomen, nausea, subileus or ileus.3 
Cl. difficile toxin is identified in 10–45% in patients with diarrhoea after 
chemotherapy. While Gram-positive cocci and Gram-negative rods (e.g. E. coli, 
Klebsiella spp) were grown in the blood of 80% of patients with neutropenic 
enterocolitis.3  
Abdominal symptoms and complications such as abscesses, perforation or ascites 
should have a proper clinical examination, an abdominal X-ray, blood cultures as 
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well as cultures of faeces including Cl. difficile toxin A & B and cultures of Cl. 
difficile. Abdominal computed tomography (CT) scans, abdominal X-rays using a 
water soluble contrast medium and abdominal sonography (USG). An endoscopy 
should be considered if no diagnosis was reached. These tests should only be 
conducted in patients with diarrhoea or suspected Cl. difficile associated ileus.3  
 
1.4.4.3. Skin infections 
In skin and soft tissue infections, the whole body surface and the visible mucosa 
need to be examined. If the infection is localized a microbiological diagnosis with 
an appropriate specimen (swabs, pus, and effusion) can be reached. If systemic 
infection is suspected, empirical antibiotic regimen should be initiated after 
obtaining blood cultures. Where fungal infection is suspected a skin biopsy should 
be tested cytologically, and in treatment refractory disease or uncertain diagnosis 
Gram staining and culture should be carried out.3  
Urinary tract infections (UTI) showed no differences in neutropenic or non-
neutropenic patients. The diagnosis and treatment follows the same guidelines as 
for non-neutropenic patients except for empirical antibiotic treatment duration (7-10 
days), started immediately after specimens for microbiological analyses have been 
taken.3  
 
1.4.4.4. Pulmonary fungal infections 
Pulmonary infiltrates is a known complication of intensive chemotherapy and 
occurs in 15-25% of all patients with profound neutropenia. Within five days after 
the onset of fever they become apparent in almost two third of the patients. Febrile 
neutropenia associated with pulmonary infiltrates are at particular high risk of 
mortality. This risk increases if neutropenia is prolonged (>10days) or diagnosis 
and so treatment are delayed.83, 84  
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 The past decade had raised hope for an early non-invasive detection of pulmonary 
fungal infections with development of new techniques. Techniques based on 
detection of fragments of fungal cells by molecular methods and Aspergillus 
galactomannan Sandwich ELISA test.83, 85  
Radiological detection of lung infiltrates by conventional chest radiographs occurs 
in less than 10% of persistent fevers despite antimicrobial therapy whereas 
simultaneous CT scans, in particular high resolution techniques, suggest 50% of 
these patients may have pathological lung findings.83  
It is recommended in cases of positive chest radiography to perform bronchoscopy 
with BAL in the affected area of the lung. In order to specify the cause of the 
infiltrates further, an additional thoracic CT may provide useful information. If chest 
radiograph continues to be normal, CT of the lungs should be performed within 24 
hours. High-resolution (HT-CT) techniques are superior to spiral-CT scans in 
detection of any pathological findings. Although recently thin-section multislice CT 
is more in use in many institutions as it combines the potential of both techniques. 
If pulmonary infiltrates are confirmed by CT, a bronchoscopy with BAL should 
follow.83  
For pulmonary infiltrates which cannot be identified by imaging techniques, fibre 
optic bronchoscopy with BAL and microbiology and non-culture based techniques, 
and which do not respond to antimicrobial therapy, trans-bronchial biopsy or open-
lung biopsy should be considered. Patients with undiagnosed lung infiltrates do 
require histological identification (e.g. suspected invasive aspergillosis or non-
infectious lung infiltrates). The presence of thrombocytopenia calls for open lung 
biopsy; whereas platelet counts greater than 50,000/L, a transbronchial biopsy may 
be performed, but if aspergilloma is suspected then transbronchial biopsy is 
contraindicated. Data from the literature show a complication rate of 10 to 15% 
after open lung biopsy.83 Histological diagnosis of invasive aspergillosis from lung 
tissue obtained by biopsy or autopsy, is considered a “gold standard”.83  
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1.4.4.5. Viral infections 
Viral infections in patients with the diagnosis of haematological malignancy 
(leukaemia and lymphoma) are associated more with cellular immunosuppression 
than with neutropenia. Primary infections, reinfection and reactivations can occur. 
The most prevalent viral pathogens are herpesviruses (HSV, VZV, CMV, HHV6), 
particularly Cytomegalovirus (CMV) which can produce severe infections with high 
morbidity and mortality, such as hepatitis, pneumonia and gastrointestinal tract 
involvement. Adenoviruses, respiratory syncytial virus (RSV), as well as HHV6 are 
benign viruses normally, but in the immunocompromised host can be a cause of 
significant respiratory infections. Other viruses with documented infections in 
neutropenic patients are; influenza and parainfluenza viruses.67, 86  
 
1.4.5. Prophylaxis 
Intravascular Catheter-Related Infections: the recommendations designed to 
reduce the infectious complications associated with intravascular use are as 
follows; (1) educating and training health care providers who insert and maintain 
catheters, (2) using maximal sterile barrier precautions during central venous 
catheter insertion and use, (3) using a 2% chlorhexidine preparation for skin 
antisepsis, (4) avoiding routine replacement of Central venous catheters (CVCs) as 
a strategy to prevent infection, and (5) using antiseptic/antibiotic-impregnated short 
term CVCs if the rate of infection is high despite adherence to other strategies.87  
 Studies on chemoprophylaxis with Quinolone has proven to reduce the frequency 
of documented Gram-negative infections, but occasionally may lead to an increase 
in Gram-positive infections.67 Trimethoprim-sulfamethoxazole (TMP-SMZ) has 
shown to be highly effective in the prevention of pneumonitis due to Pneumocystis 
carinii.88 Fluconazole reduces the frequency of both superficial and systemic 
infections with limited efficacy against Candida krusei, some strains of C. glabrata 
and molds. While Itraconazole  has proven more effective than Fluconazole for 
long time prophylaxis of invasive fungal infections, with significant reduction in the 
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frequency of systemic fungal infections due to Candida spp., and a decrease in 
candidiasis-related mortality.88  
AmBisome 3mg/kg/day three times per week may be given as an alternative in 
patients with previously documented fungal infection or in patients required 
voriconazole as treatment (see appendix-4, A.4.1.). Most patients with 
haematological malignancy have already been exposed to viral infections, which 
undergo latency and reactivated with immunosuppression, Aciclovir is frequently 
given prophylactically.88  
 
1.4.6. Granulocyte colony stimulating factors 
Hematopoietic colony-stimulating factors (CSFs), such as granulocyte CSF (G-
CSF) and granulocyte–macrophage (GM-CSF), may be administered along with 
chemotherapy for their properties as to promote proliferation, differentiation and 
function of progenitor and mature cells of myeloid lineage. As well as stimulating 
the bactericidal function of mature neutrophils.89  
Clinical trials have shown CSFs to shorten the neutropenic period and reduce 
incidence of febrile neutropenia in high risk patients by 50%. Other studies 
evaluating the role of CSFs administration in the treatment of febrile neutropenia 
have shown a reduction in the incidence of episodes of prolonged neutropenia or 
hospitalization. Subset analysis in two of the trials showed the greatest benefit in 
patients with profound neutropenia (ANC <100/mm3) and/ or documented 
infection.89 Patients at higher risk of delayed haematological recovery or with 
severe infection are the most likely to benefit from the therapeutic use of CSFs as 
suggested by these studies.89  
 
 
 
  
1.4.7. Management 
Different institutions apply different policies for febrile neutropenic management, 
the following policy is followed by the Royal free hospital (RFH) in which this study 
took place (for diagnosis and management RFH policies see appendix-4).  
 
 
 
        Figure 1.2. Diagnosis and management of febrile neutropenic episode (modified;  
        see appendix-4, A.4.1.). 
        Abbreviations: ANC; absolute neutrophil count, B/C; blood culture, CT; computed  
        tomography, CVC; Central venous catheter, CxR; chest x-ray, HL; hickman line, hrs;  
        hours, -ve; negative, +ve; positive, inf; infection R; treatment,  
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1.4.7.1. Febrile neutropenia 
When fever (>38.5°C or 38°C x2 (2hours apart)) occurs in the context of 
neutropenia (ANC <0.5 x109/l), empirical antibiotic therapy with -lactam 
(meropenem) is started immediately after the collection of two blood cultures 
(B/Cs), drawn from two separate sites. Other investigations include urine, chest x-
ray (CxR), and specimens from clinically suspicious sites.  Blood cultures are 
repeated every 24 hours while the patient is febrile (see appendix-4, A.4.1.) and 
(figure 1.2.). Itraconazole level measurement is performed if patient is on 
itraconazole prophylaxis, and Galactomannan can be requested. Results can take 
up to three days to become available and this will be used to guide the empirical 
antifungal therapy after 96 hours (see appendix-4, A.4.1 & A.4.2.).  
When a definite bacteraemia has been diagnosed (two or more sets of B/Cs 
positive for the same organism) antibiotic therapy is rationalized according to 
sensitivity (see appendix-4, A.4.1.). The duration of treatment with the same 
antibiotic does not exceed ten days. If fever is unresponsive after ten days, a 
change of antibiotic and discussion with a microbiologist is highly recommended. 
The patient should receive seven days course of the appropriate microbial 
sensitive antibiotic, with at least four days fever free (see appendix-4, A.4.1.).  
The physician needs to consider the possibility of CVC removal, antibiotic cover, 
the type of antimicrobial therapy, according to organism sensitivity and the duration 
of antimicrobial therapy.71 Infections caused by Coagulase-negative 
Staphylococcus spp. can be treated with glycopeptides antibiotics for 14-15 days, 
without catheter removal.71  
Diarrhoea if proved to be due to Cl. difficile is treated orally by either metronidazole 
or vancomycin.77 Standard therapy is for 10-14 days depends on symptoms,3 (see 
appendix-4, A.4.1.). If the fever is unresponsive after ten days, a change of 
antibiotic and discussion with a microbiologist is highly recommended. Patients to 
receive seven days course of the appropriate microbial sensitive antibiotic, with at 
least four days fever free. In case of persistent fever despite 96 hours 
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administration of appropriate antibiotics, then other causes are considered. Most 
likely causes are fungal infection. The presence of non productive cough and the 
association with pulmonary infiltrates, necessitate an early BAL arrangement, and 
a HR chest CT (see appendix-4, A.4.1.). 
If B/C has grown Candida, the patient should have an upper abdominal high 
resolution CT scan and an ophthalmological examination of their fundi (for the 
detection of choroidoretinitis / endophthalmitis), (see appendix-4, A.4.2.). If fever 
has responded to empirical antifungal treatment, this is continued till neutrophil 
recovery (ANC  0.5 x109/l),(see appendix-4, A.4.1.). 
The azoles (fluconazole, itraconazole, variconazole and posaconazole) has 
became standard therapy for invasive candidiasis.90 While the echinocandins 
(caspofungin, micafungin and anidulafungin) are fungicidal against C. Albicans and 
non-albicans90 and they are considered along with fluconazole  as effectious and 
saver alternative to the polyenes; amphotericin B.71, 91  
Febrile neutropenia with lung infiltrate are treated with -lactam antibiotics. While 
pneumocystis carinii pneumonia respond to treatment with  TMP/SMX 
(Trimethoprim-sulfamethoxazole).83 In presumed CRI (bacteraemia or fungaemia) 
antibiotic treatment is modified according to isolates continues for at least 10-14 
days or longer if patient is neutropenic, and in case of tunnel and exit site infection 
until infection is resolved. Catheter removal should be considered if cultures remain 
positive after 48 hours of therapy or if proven infection with fungi, staphalococcus 
aureus, bacillus spp., pseudomonas or mycobacterium spp. In the absence of a 
source of infection, Hickman line removal should be considered. Other infections 
such as viral infections should always be first investigates appropriately, and 
managed accordingly if proven present, (see appendix-4, A.4.1.). Uncommon 
pathogens such as corynbacterium spp are treated with vancomycin, carbapenem 
or TMP-SMZ, while mycobacterium spp susceptibility varies by species.91  
With severe life-threatening infections, focal lesions unresponsive to appropriate 
antibiotic therapy, or expected prolong neutropenia and delayed haematological 
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recovery; granulocyte transfusions may be useful and beneficial in those patients 
for its stimulating effect on the depleted neutrophils89 (see appendix-4, A.4.1.). 
 
1.4.7.2. Febrile non-neutropenia 
Patients with febrile non-neutropenia should be investigated and treated as any 
other. Their infections and management do differ from neutropenic patients. Fever 
is investigated and confirmed by two sets of B/Cs. Treatment follows the empirical 
guidelines and is modified when an organism is identified. Levels of itraconazole 
are measured if patient is on itraconazole prophylaxis. Catheter related, exit site or 
tunnel infections management is the same as neutropenic patients (appendix-4, 
A.4.1.). 
 
1.5.  The role of genes in innate immunity 
The immune system consists of two closely related and yet different responses- 
innate and adaptive immunity.92 Mammalian innate immune recognition occur 
through toll-like receptors (TLRs) and NOD2 proteins,93 which allows the 
phagocytes to recognize and react to a component of bacterial peptidoglycan 
(PGN) and muramyldipeptide (MDP).94 Several lines of evidence have led to the 
hypothesis that impaired immunity initiates the cascade of events resulting in 
Crohn’s disease (CD).95  
 Chitotriosidase is another component of the innate immune system, recently 
implicated in anti-fungal responses.7 Involvement of chitotriosidase in the anti-
pathogenic responses are suggested as activity of this enzyme was raised in 
neonates with fungal, bacterial and viral infections.6 Other evidence was also seen 
in children undergoing treatment for AML, as children with mutant gene allele for 
chitotriosidase showed higher risk for gram negative infections.96 These pathogens 
can be sensed by NOD2 and TLR. This finding was the basis of a study which 
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showed that chitotriosidase can contribute to TLR and MDP-dependent innate 
immune response required for eradication of protozoan parasites, nematodes, 
fungi and bacteria.97  
The main aim of our study was to explore the Chitotriosidase and NOD2 genes and 
to look into the extent of it influence on innate immune response, in their wild type 
and mutant status and also in neutropenic and non-neutropenic patients 
undergoing chemotherapy for haematological malignancy.  
 
1.6.  Chitotriosidase 
1.6.1. Identification & Expression 
Chitin is a glycopolymer present as a structural component of many species such 
as parasitic nematodes, microfilarial sheat, fungi cell walls, insects, gut lining and 
the exo-skeleton of all types of arthropods.98 Gaucher disease is an inherited 
metabolic disorder that exhibits marked elevation of activity of chitotriosidase in 
their plasma and hence the identification of a human phagocyte specific chitinase 
named chitotriosidase98, 99 with the capacity to hydrolyze artificial chitotriosidase 
substrates.100 Chitotriosidase can be synthesised in large amounts by tissue 
macrophages under an appropriate stimulus.98 It is largely secreted as a 50-kDa 
(molecular mass) active enzyme containing a C-terminal chitin binding domain. In 
macrophages some enzyme is converted by carboxyl-terminal proteolytic 
processing into the C-terminal truncated 39-kDa isoform with hydrolase activity that 
accumulates in lysosomes of these cells. The 50 kDa chitotrisidase isoform is also 
synthesized by progenitors of neutrophilic granulocytes and stored in their specific 
granules.98, 99 The C-terminal domain of 50-kDa chitotriosidase mediates a strong 
binding to chitin, enabling it to cleave chitotriose and hydrolyze colloidal chitin to 
yield chitobiose, in distinction from 39-kDa isoform which lack this ability.101 At least 
two distinct types of chitinase are expressed in humans. Chitotriosidase 1 (CHIT1) 
was the first identified. Only recently, a second chitinase called acid mammalian 
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chitinase (AMCase) has been identified in humans.98 The expression pattern of 
both chitinases vary completely, CHIT1 is exclusively produced by phagocytes, 
and increases in conditons involve macrophages activation,102 whereas AMCase is 
expressed in alveolar macrophages and in the gastrointestinal tract.103  
Chitotriosidase enzyme belongs to the family 18 of glycosyl hydrolases. It is an 
endoglucosaminidase that cleaves and shows transglycosylation activity towards 
chitin, a polymer of N-acetyl-D-glucosamine7 and shares significant sequence 
identity from various non-mammalian species like plants, bacteria, fungi, 
nematodes and insects.7, 98 Recombinant chitotriosidase has been found to inhibit 
hyphal growth of chitin-containing fungi such as Candida and Aspergillus species. 
This ability along with its specific expression by phagocytes suggests a 
physiological role in defence against chitin-containing pathogens.7, 98 Other findings 
indicate that chitotriosidase can play an important role during the immunological 
innate response  and in other diseases in which the inflammatory processes may 
be a key element.7, 104, 105  
 
1.6.2. Structure 
The Chit gene is located on chromosome 1p13,103 whereas the locus of the crystal 
structured101 human chitotriosidase gene ois found on chromosome 1q32.103 The 
gene consists of 12 exons and spans about 20 kb of genomic DNA. Exon 11 can 
be alternatively spliced. This exon is usually skipped in the splicing process 
generating the predominant mRNA form encoding the 50 kDa protein. In 
macrophages, a different form of mRNA is rarely produced as a result of a lack of 
exon 11 skipping (39 kDa)99, 106 (figure 1.3. ). 
Other inactive members of the mammalian chitinase protein family in human have 
been identified: human cartilage glycoprotein 39 (HCgp-39/ YKL40), YKL39, and 
oviductin (specific glycoprotein). Although other homologies were observed 
between the four human chitinases, chitotriosidase was the only one observed with 
glycosyl hydrolase activity, and the lack of catalytic acidic amino acid residues. The 
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speculations that this family may play a role in chemotaxis and tissue remodelling 
is yet to be confirmed.98  
AMCase is another mammalian chitinase. It is characterized by an acidic pH 
optimum and extreme stability at acid pH. AMCase is relatively abundant in the 
gastrointestinal tract (stomach) supporting a possible role as providing a physical 
barrier and protection against pathogens and food particles as well as facilitating 
digestion. Its presence was also observed in the lung but to lesser extent with the 
possibility of the involvement in lung inflammation.98 AMCase and the human 
macrophages chitinase, do not only share the same 18 glycosyl hydrolases, the N-
terminal catalytic core domain of 39kDa and a C-terminal chitin binding domain, but 
also 52% sequence identity and the additional α/β folds. Given the differences in 
expression and the stability of the additional mammalian chitinase at pH of around 
2, it is likely that AMCase compared with its human analogue chitotriosidase has a 
different role.98  
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 Figure 1.3. Genomic structure of Chitotriosidase gene. Composed of 12 exons. Exon 1  
contains the first nucleotide of the longest chitotriosidase cDNA. Exon 11 usually skips in  
the   splicing process, generating the mRNA encoding the 50-kDa protein stored in the  
neutrophilic  granulocyte progenitors. Alternatively spliced mRNA encodes a 40-kDa ChT  
that is identical  to the 39-kDa isoform generated by proteolytic processing of the 50-kDa  
ChT. Lack of exon 11 skipping form the 39-kDa isoform is formed and accumulates in the  
macrophages lysosomes. Figure adapted1 
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1.6.3. Polymorphism 
Deficiency in chitotriosidase activity is seen in different ethnic groups. Inheritance 
is frequently recessive. The defect was found to be 24-bp duplication in exon 10 
that activates a cryptic 3’ splice site in the same exon, causing the formation of an 
abnormally spliced mRNA with an in-frame internal deletion of 87 nucleotides 
(figure 1.4.). The spliced mRNA encodes an enzymatically inactive protein that 
lacks an internal stretch of 29 amino acids.106 Incidence of the mutation in 
chitotriosidase  allele is 37% present in Ashkenazi Jews and Dutch individuals, 
whereas both populations were about 6% homozygous for this allele.106 Studies 
performed in a Portuguese population showed approximately 40% of the general 
population are heterozygous, while 6% were homozygous for the chitotriosidase 
activity deficiency.107 Recently two other polymorphisms in chitotriosidase beside 
24bp duplications were identified; G354R and A442V. These two polymorphisms 
were found predominantly in African descent individuals, and is associated with 
reduced chitotriosidase activity.108 Chitotriosidase reduced activity is also found in 
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Figure 1.4. The differences between the normal and the mutant chitotriosidase gene.  
Exon 10 contains 24-bp duplicate in the mutant gene. Figure adapted1 
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3–5% of individuals in the general population due to the presence of a null allele in 
the chitotriosidase gene.106  
The multi-ethnic occurrence and prevalence of chitotriosidase gene mutation 
suggests that the enzyme is redundant in man and that this mutation is relatively 
ancient in evolution. Chitotriosidase deficient individuals showed no  chitotriosidase 
in all materials tested including plasma, urine, leukocytes, and tissues, indicating 
that this mutation is the predominant cause of chitotriosidase deficiency.106  
According to the absent enzyme activity in the homozygote individuals for the 
mutant allele and the approximate half activity in the heterozygous, it appears that 
chitotriosidase deficiency in humans is autosomal incompletely dominant disorder. 
Macrophages from chitotriosidase deficient individuals when cultured contain very 
little mRNA and secrete almost no chitotriosidase protein.1  
 
1.6.4. Chitotriosidase function & disease associations 
1.6.4.1.  Chitotriosidase and immunity 
Tissue macrophages are placed in almost all organs, protecting the 
microenvironment and are considered an important element in the host defence. 
Under pathological or physical conditions macrophages are capable of 
synthesizing and producing large amount of chitotriosidase.98 It represents 
approximately 1% of the total protein secreted by the macrophages.99  
In order to elicit the cellular response and observe the activity level of 
chitotriosidase, a study based on the increased cytocidal activity against 
intracellular microorganism in the IFN-  and TNF-  treated macrophages was 
carried out. In this study macrophages treated with IFN- , TNF-  and LPS showed 
upregulation of chitotriosidase gene expression.109  
Evidence of enhanced chitotriosidase activity was also demonstrated after IL-12 
injection in chimpanzee.110 Since IL-12 is a potent immune regulatory cytokine that 
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is crucially involved in a wide range of infectious diseases (viral, bacterial and 
intracellular parasitic infestation),111 it is reasonable that the elevated levels of IL-
12 modulate the macrophage activity, stimulating their microbicidal function 
through a pathway involving chitotriosidase activity.112 This idea can be supported 
by the studies showing that in malaria protective immunity is mediated by a 
cascade of events involving IL-12113 and the raised chitotriosidase level in African 
children effected with malaria (42%) compared to the control in the same group 
(12.24%)112 (table1.2.). In addition, prolactin which is structurally related to 
cytokines had also shown the ability to up-regulate CHIT1 mRNA expression in 
human macrophages.114  
Studies have revealed the activity of chitotriosidase against chitin-containing 
pathogens. It was found to inhibit the growth of Cryptococcus neoformans by 
causing hyphal tip lysis in Mucor rouxii. In Candida albicans it prevented the 
occurrence of hyphal switch by exhibiting the chitinolytic activity towards it’s cell 
wall chitin and colloidal chitin.7, 98 Furthermore, increased chitotriosidase activity 
was found in the plasma and urine in neonates with systemic fungal infections6 
(table 1.2.). GM-CSF treated macrophages, showed increased chitotriosidase 
transcripts, and beneficial effects in fungal infections, promoting chitotriosidase 
release from Polymorphnuclear neutrophils (PMNs) through exocytosis of specific 
granules.7  
Studies by Eijk et al7 on chitotriosidase deficiency showed improved survival in a 
neutropenic mouse model of systemic Candidiasis and Aspergillosis after use of 
recombinant chitotriosidase. These findings suggest a possibility of treating life 
threatening fungal infections with recombinant chitotriosidase in mutant allele 
carriers.7 The other study in chitotriosidase deficient patients was in 
immunocompromised patients due to chemotherapy, and the increase 
susceptibility to gram negative bacterial infections.96 Chitotriosidase deficiency has 
been linked to increase susceptibility to parasitic infections, as seen in the high 
incidence of human filariasis due to Wuchereria bancrofti in deficient patients115 
(table 1.3.). 
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As seen from the above studies chitotriosidase released from either the specific 
granules in neutrophils or activated macrophages, is involved in innate immunity 
and the immunological response  required for the eradication of protozoan, 
nematodes, fungi and bacteria.7, 97 Other members of chitinase family are also 
likely to be involved in the immune response. 
 
1.6.4.2. Chitotriosidase and Gaucher Disease 
Gaucher disease (GD) is an autosomal recessive lysosomal disorder. It is due to 
deficient activity in the lysosomal enzyme, β-glucosidase (glucocerebrosidase), a 
lysosomal hydrolase. Deficiency of this enzyme leads to the accumulation of 
glucocerebrosides in the lysosomes of macrophages, resulting in lipid-laden 
macrophages referred as Gaucher’s cells.100, 116 Gaucher disease is the most 
common lysosomal storage disorder with high prevalence among Ashkenazi Jews, 
1/885 compared to 1/100,000 in other populations.116 There are three clinical types 
of GD. The most common, is the chronic non-neuropathic type-1 form of the 
disease, which shows highly variable signs, symptoms and course. Presentation 
could be due to visceral, haematological or skeletal involvement.100, 116 
Accumulation of lipid-laden macrophages (Gaucher’s cells) in the affected 
individuals causes the development of hepatosplenomegaly, bone lesions and, 
occasionally, neurological abnormalities. Patients with GD need regular 
assessment of the biochemical variables, as abnormalities reflect the extent of 
bone or visceral involvement. Some biochemical variables have been found to be 
of value in monitoring both the course of the disease and the response to 
treatment.100 The most prominent biochemical abnormality is the marked elevation 
of plasma chitotriosidase activity, and it was first observed by Hollak and co-
workers  in the plasma samples of untreated type-1 GD.100 In the same study there 
was a slight elevation in chitotriosidase activity even in asymptomatic 
glucocerebrosidase-deficient individuals while Alkaline phosphatase (AP) was well 
within the control range100 (table 1.2.). 
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Enzyme-replacement therapy has proven to be effective in improving the clinical, 
haematological and biochemical (plasma markers) parameter of GD patients. 
Plasma chitotriosidase activity is a useful biomarker of macrophages activity 
(phagocytic activity of lipid laden macrophages) for monitoring GD patients for its 
correlation with disease severity, activity and its sensitivity to treatment.117  
More modest elevations in plasma chitotriosidase have been noted in some other 
inherited lysosomal storage disorders, especially sphingolipidoses such as 
Niemann Pick, GM1-gangliosidosis, and Krabbe’s disease118 (table 1.2.). 
 
1.6.4.3. Chitotriosidase & bronchial asthma 
Since the identification of the second chitotriosidase-AMCase and its expression in 
the alveolar macrophages98 have been in progress to see if inflammation in the 
lung and pathogensis of bronchial asthma is associated with this finding. Recently 
an association of AMCase polymorphisms and haplotypes with paediatric bronchial 
asthma was observed119 (table 1.2.). This was followed by another study of the 
amino acid variants Gly 102Ser and Ala 442Gly, as well as the 24 bp duplication 
within CHIT1 in the pathology of bronchial asthma, which showed no such 
association in Caucasian children.120  
Chitotriosidase activity was found to be significantly higher in active sarcoidosis 
than inactive form of the disease. This finding could indicate that chitotriosidase 
may be a useful marker in measuring and monitoring disease activity.121  
 
1.6.4.4. Chitotriosidase & thalassemia 
Beta thalassemia patients need regular blood transfusions leading to iron overload 
and an enormous expansion of the reticulo-endothelial system. High plasma levels 
of chitotriosidase, comparable to the levels found in GD patients, were found in 
10% of patients with β-thalassemia major. Level of chitotriosidase varies with the 
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type of thalassemia and the degree of requirement for transfusion. Modest 
elevation of chitotriosidase was found in the patients with β-thalassemia 
intermedia. The increase of plasma chitotriosidase activity in β-thalassemia major 
patients could be related to iron-mediated damage to the lysosomal apparatus. In 
β-thalassemia the amount of abnormal transfused red blood cells exceeds the 
macrophages degrading capacity. As a consequence, phagocytes of β-thalassemia 
patients become laden with membranous lipid material, macrophages activation 
and  increased chitotriosidase production122 (table 1.2.). 
 
1.6.4.5. Chitotriosidase & Coronary artery disease  
Atherosclerosis is an inflammatory disease that is characterized by progressive 
deposition of lipids in the arterial wall. Pathogenesis involves endothelial cells 
activation and monocytes infiltration of the vessel wall. The monocytes differentiate 
into macrophages and accumulate lipids from the circulation and form the so called 
foam cells.123 Recently studies showed a clear connection between chitotriosidase 
activity and lipid-laden macrophages inside human atherosclerotic vessel wall 
reflecting its severity and extend. It was more prominent in the atherothrombotic, 
and stroke group.124 An increase in the serum chitotriosidase activity was found to 
be age depended. This could be explained by the gradual progression of 
atherosclerotic process.123 There was no association between plasma 
chitotriosidase level and plasma lipid level before and after lipid lowering treatment. 
These suggest that inflammation related chitotriosidase activity is associated with 
the atherosclerotic process and extent of coronary artery disease123 (table 1.2.). 
 
1.6.4.6. Chitotriosidase & Neurodegenerative Disorders 
The heterogeneous nature of both Alzheimer’s disease (AD) and stroke and the 
inflammatory aspects of the pathogenesis of these diseases are prominent. 
Inflammatory pathogenesis is mainly based on the association of the presence of 
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activated immune cells necessary for an immune response and the finding of 
raised levels of pro-inflammatory cytokines.105  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder showed a 
significant increase in chitotriosidase level, as an expression of immune activation 
in AD patients and to the ischemic injury in stroke patients.105 In stroke the 
increase clearly correlates with the clinical-radiological severity of the stroke. 
Chitotriosidase is a specific indicator of the macrophage activation which may be of 
importance for future therapeutic intervention in stroke aimed at the immune 
response in these events125 (table1.2.). 
Sotgiu et al126 in his study showed that macrophage-derived enzyme 
chitotriosidase is significantly elevated in multiple sclerosis (MS), and the plasma 
and cerebrospinal fluid level parallels with the clinical MS symptoms and 
deterioration. In addition, intrathecal chitotriosidase activity better correlates with 
the extent of CNS damage than macrophage-derived markers.126 Together, these 
findings add to the evidence of a local, self-sustaining immune and inflammatory 
response within cerebrovascular disorders105 (table 1.2.). 
 
1.6.4.7. Chitotriosidase & non-alcoholic steatohepatitis 
The initiating event in NASH (non-alcoholic steatohepatitis) seems to involve early 
lipid accumulation and lipid peroxidation in the hepatocytes, followed by Kupffer 
and HSC (human hepatic stellate cell) activation, liver cell injury, inflammation, and 
eventually hepatic fibrosis. Kupffer cells are a source of proinflammatory cytokines, 
and the only source of chitotriosidase expression in liver. In fact, the highest levels 
of chitotriosidase was observed in patients with the highest degree of hepatic iron 
accumulation, as confirmed by the high correlation observed between 
chitotriosidase and ferritin levels in both Kupffer cell lysates and plasma of NASH 
patients. It appears that the increase of chitotriosidase in Kupffer cells may reflect 
iron mediated damage to lysosomes, suggesting that the physiological function of 
chitotriosidase probably lies in regulating the acute phase response, and that it is 
   
not only a biochemical marker of macrophage activation but can also be regarded 
as an important player in the inflammatory process104 (table 1.2.). 
 
Table 1.2. Studies relating chitotriosidase activity in diseases in patients with wild type allele 
Disease Reference No of patients Increased baseline 
activity 
Gaucher disease Hollak100 32 Decline with treatment 
Fabry disease Vedder127 29 males 
38 females 
Minor  elevation 
Not 
Krabbe disease Wajner118 9 Plasma  
GM1-gangliosidosis Wajner118 19 Plasma 
Sarcoidosis Brunner121  With disease activity 
Fungal infections Labadaridis6 
Masoud128 
8 
55 
Plasma & urine 
No association 
Bacterial infections Labadaridis6 15 Plasma & urine 
Malaria falciparum Barone112 67 Plasma 
Thalassemia Barone122 72 Plasma 
Atherosclerosis Artieda124 153 Plasma 
Coronary artery 
disease 
Karaday123 200 Plasma 
Strokes Sotgiu125 44 Correlate with severity 
Alzheimer’s disease 
Cerebrovascular 
dementia 
Di Rosa105 40 
40 
Increase expression, 
and enzyme activity 
Multiple sclerosis Sotgiu126 77 Correlate to severity 
NASH 
Simple steatosis 
Malagurnera104 40 
20 
Markedly increase 
Mod. elevation 
Asthma Bierbaum119 322 AMCase involvement 
in pathophysiology 
 
 
 
Table 1.3. Increase susceptibility of infections with chitotriosidase mutant gene. 
Disease Reference No of patients Decrease activity 
W. bacrofti Choi115 216 Correlate with 
susceptibility 
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1.7.  NOD2 gene 
In 1996 (using genetic linkage studies), a Crohn’s disease-susceptibility gene locus 
on chromosome 16q12 was identified. Named IBD1 (inflammatory bowel disease 
locus 1) it lies in the pericentrometric region. It may be inherited in a recessive 
manner, and is specially associated with Crohn’s disease (CD).129 The NOD2 
(nucleotide oligomerization domain) gene within the IBD1 locus was discovered by 
two groups in 2001 (Hugot et al130, & Ogura et al4), who showed that mutations of 
the NOD2 gene were strongly associated with CD.4, 130 Hugot et al130 screened 235 
CD families to identify the NOD2 gene on the IBD1 locus and the three 
polymorphisms associated with CD using a positional-cloning strategy, based on 
linkage analysis followed by linkage disequilibrium mapping130 (figure 1.5.). 
Ogura et al,4 identified the NOD2 whilst investigating apoptotic proteins, and 
intuitively considered NOD2 a candidate gene on the IBD1 locus as this gene is 
located in the peak region of linkage on chromosome 16 that is associated with 
CD.4  
 
1.7.1. NOD2 Protein 
1.7.1.1. The structure of NOD2 protein 
The NOD2 gene encodes a protein of 1040 amino acids. It is composed of two N-
terminal caspase recruitment domains (CARD) (residues 28-220), fused to 
centrally located nucleotide-binding domain (NBD) (residues 273-577) containing 
consensus nucleotide-binding motifs, followed by 10 tandem leucine-rich repeats 
(LRRs) (residues 744-1020)131 (figure 1.5.). 
The NOD2 protein is a member of a large family of intracellular proteins, the NOD 
proteins. They are distrributed widely in nature, so far over 20 NOD containing 
proteins have been identified in humans (figure 1.6.), plants and nematodes. The 
disease resistance (R) proteins seen in plants are involved in plant host defence 
   
against pathogens.131 The family also include NOD1. Both NOD1 and NOD2 are 
close relatives and have similar structures except for the number of CARDS (figure 
1.6.), as NOD2 is the first protein to contain two CARDs.131 The majority of animal 
and plant NOD-LRR proteins are comprised of three distinct functional domains: 
CARD; an amino-terminal effector domain involved in signalling, NBD; a centrally 
located regulatory NOD domain, and carboxyl-terminal LRRs that serve as a 
ligand-recognition domain (figure 1.5.).132 Alternatively the NOD-LRR proteins are 
also known as the CATERPILLER (CLR) an acronym for CARD, transcription 
enhancer, R (purine)-binding, pyrin, lots of leucine repeats. A family that have been 
implicated in intracellular recognition of bacterial components.132  
 
1.7.1.2. CARD domain 
The caspase recruitment domain (CARD) is a protein fold consisting of a six 
membered -helical bundle. The CARD domain facilitates caspase aggregation 
and activation at the onset of apoptosis.133 These effector domains are involved 
in homophilic interactions with downstream signalling molecules.132 Proteins 
containing CARDs, or related motifs, are centrally involved in assembling protein 
complexes that drive activation of either caspases or IκB kinase (IKK) by 
facilitating close proximity of their molecules, linking these proteins to multiple 
signalling pathways and biological functions. The CARDs are responsible for 
oligomerization with both self and other proteins. It is physically associated with 
RICK (serine/threonine kinase), through homophilic CARD-CARD interactions.132-
134
 RICK bind to the IKK complex through IKK . This interaction induce 
phosphorylation of IKK  and/or IKK  subunit, which subsequently results in 
nuclear factor kappa B (NF-κB) activation.135  
 
 
 
   
 
 
Figure 1.5. Domain structure of NOD2. Illustrating the site of protein truncation;  
showing    CARD, NBD, and ten LRRs. Numbers indicate residue positions.  
Figure adapted.4, 130  
 
 
Figure 1.6. The domain structure of the NOD proteins in human. Most NOD proteins are 
composed of variable amino-terminal effector-binding domains (EBD), a centrally located 
nucleotide-binding oligomerization domain (NOD) that mediates self-oligomerization, and 
a carboxyl-terminal ligand-recognition domain (LRD). The number of leucine- rich repeats  
(LRRs) varies in NOD proteins. Other abbreviations: PYD; pyrin domain,BIR; baculoviral  
inhibitor-of-apoptosis repeat,APAF-1; apoptotic protease activity factor 1.  
Figure adapted.132  
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1.7.1.3. NOD domain 
The centrally located nucleotide oligomerization domain (NOD) of NOD2 mediates 
self-oligomerization leading to NF-κB activation.134 The NOD domain contains 
structural motifs found in a class of nucleoside triphosphatases (NTPases) referred 
to as the ATP-binding cassette (ABC) proteins. The ABC region in all NOD proteins 
includes catalytic residues with binding site motifs which are essential for binding 
phosphate residues and magnesium ions. They are also predicted to be involved in 
hydrolysis of nucleotides, ATP, deoxyATP (dATP) and/or GTP.132, 136  
 
1.7.1.4. LRR (leucine-rich repeat) domain 
The plasma membrane toll like receptors (TLR) play an important role in the 
recognition of pathogen-associated molecular patterns (PAMPs) and mediating 
innate immunity activation.137 Plant disease-resistant (R) proteins have C-terminal 
LRRs that are similar to toll like receptor-leucine rich repeat (TLR-LRR) and are 
essential for defense and pathogen recognition. These cytosolic proteins recognise 
distinct effector molecules of wide array pathogens including bacteria, fungi and 
viruses. It is currently suggested that the NOD2-LRR perform a similar function.131, 
138
 Each of the 10 LRRs of NOD2 encode predicted  helix and  sheet sequences 
that are consistent with the prototypical horseshoe-shaped structure of R protein 
LRRs. The functional role for the LRRs of NOD1 and NOD2 remains unclear.131  
 
1.7.2. NOD2 protein Function and role in immunity  
The NODs and plant R proteins structural similarity led to functional studies that 
suggest the NOD2 function is as an intracellular receptor to bacterial 
lipopolysaccharide (LPS) and peptidoglycan (PGN). Furthermore, they suggest that 
the LRR motifs are not only essential for the recognition, but also for the response 
to LPS and muramyl dipeptide (MDP); (a basic PGN motif that is common to both 
gram positive and gram negative bacteria and is known to induce pro-inflammatory 
   
cytokines), by NOD2 and the subsequent initiation of a cascade that activates NF-
κB signalling (figure 1.1.). These findings were consistent with the evidence that 
LPS interacts with the LRR domains of R proteins and TLR with subsequent NF-κB 
activation.93, 138, 139  
NF-κB stimulation results in nuclear translocation of the nuclear factor and genes 
which include TNF  and interleukin-12 (IL-12), pro-inflammatory cytokines which 
are seen in abundance in CD. NF-κB binding sites are also found on the NOD2 
promoter region and studies have shown that the cytokines TNF  and IFN  can 
up-regulate NOD2 expression.140  
The extracellular TLRs can recognise specific PAMPs, and so is their involvement 
in the innate immune response. The antigen-presenting cells (APCs) receptor, 
NOD2, and the CARD-containing RICK (serine/threonine kinase) transduces 
signals from receptors of both innate and adaptive immune system in response to 
PAMPs and the intracellular recognition of PGN motifs.141, 142 These result in NOD1 
and NOD2 olgmeraziation, which induce RICK, the serine/threonine kinase, 
recruitment via CARD-CARD interactions and NF-κB activation. NODs and RICK 
interact via their respective CARD domains, and induce recruitment of the IκB 
kinase (IKK) complex of IKK , IKK , IKK  to the central region of RICK and the 
sequestration of the NF-κB transcription factors inhibitory proteins; IKK complex. 
Active NF-κB is released and translocated to the nucleus inducing the transcription 
of various pro inflammatory cytokines, a result of the proteolytic degradation of IKK 
proteins and IκB phosphorylation.94, 141-143  
 
1.7.3. NOD2 Protein Expression 
1.7.3.1. Blood 
Initially NOD2 expression was thought to be restricted to monocytes in comparison 
to NOD1 which is ubiquitously expressed in tissues.131 But later studies observed 
  
the expression in other blood leukocytes, namely granulocytes, dendritic cells and 
to lesser extent T lymphocytes, although not as abundantly as monocytes.144  
 
1.7.3.2. Intestine 
1.7.3.2.1. Epithelial Cells 
Expression of NOD2 mRNA in the intestinal epithelial cells was soon investigated. 
Observations showed NOD2 mRNA and protein expression was upregulated by 
TNF  and IFN  in intestinal epithelial cells and in primary colonic epithelial cells.140  
1.7.3.2.2. Paneth Cells 
Lala et al demonstrated NOD2 mRNA and protein expression in Paneth cells in the 
small intestine with the greatest intensity in the terminal ileum. The NOD2 
expression was increased in patients with inflammatory bowel disease in the 
terminal ileum Paneth cells, and colon due to the presence of metaplastic Paneth 
cells.145  
 
1.7.4. NOD2 mutations 
Using transmission disequilibrium test and case-control analysis, followed by 
pedigree disequilibrium130 three single nucleotide polymorphisms (SNPs) were 
identified in the LRR domain and are association with CD:  a frameshift mutation 
caused by cytosine insertion in exon 11 (SNP13) at nucleotide position 3020 
(3020insC) resulting in a frameshift at the second nucleotide of codon 1007, and 
substitution of proline for leucine in the tenth LRR, followed by a premature stop 
codon. The two other SNPs (SNP8 & SNP12) in NOD2 are point mutations 
encoding amino acid substitutions. SNP 8 substituting Cytosine for Tryptophan at 
nucleotide position 2104. SNP 12 substituting Guanine for Cytosine at nucleotide 
position 2722. These two mutations, SNP8 & SNP 12, encode for amino acid 
substitutions, Tryptophan substituted for Arginine at codon 702 (Arg702Trp) and 
   
Arganine substituted for Glycin at codon 908 (Gly908Arg). These three major 
mutations all occur within or near the LRR-encoding region of the gene. Over 30 
other much rarer amino acid polymorphisms occurring near or within LRR-
encoding region of the gene have also been described.130, 132  
 
1.7.5. Disease mutation associations 
1.7.5.1. NOD2 mutations and Crohn’s disease 
Crohn’s disease (CD) is a chronic inflammatory disorder that affects any part of the 
gastrointestinal tract, from the oropharynx to the perianal area. It is characterized 
by alternating periods of active inflammation and remission. Due to the transmural 
inflammation complications such as abscesses, fissures, fibrosis, fistulas, strictures 
and bowel obstruction may occur. Crohn’s disease susceptibility alleles, located in 
the third part of NOD2 gene, two missense, SNP8 the 2104C T, and SNP12 the 
2722G C, and a frameshift 3020insC, SNP13, represent 82% of the mutant 
chromosomes in CD.146  
In a comparative study of NOD2 allele frequencies in 3575 healthy Caucasian 
individuals from sixteen different centres from Europe, North America and 
Australia, significant heterogeneity between centres was found with Australia and 
Finland having the lowest frequencies of known variants while Belgium and 
Canada has the highest. NOD2 risk alleles are absent from Japanese and Korean 
populations and in Han Chinese. The pattern that emerges from these studies both 
of disease groups and healthy controls suggests that CD occurs at quite variable 
rates across geographical regions and that in some populations where NOD2 risk 
allele carriage rates are at a high, those alleles are present in up to 50% of 
individuals with CD. Nevertheless the incidence of CD in populations with 
substantial carriage of risk alleles, such as Belgium and Canada is remarkably 
similar to those with lower rates, suggesting that CD occurs in those groups 
because of other genetic susceptibilities.147 Economou et al meta-analysis 
quantified distinct risk for CD for the three common NOD2 variants, and showed 
   
increase odds to 2 fold with SNP8, 3 fold by SNP12, and 4 fold by SNP13 in non 
Jewish descent Caucasians.148 The carriage of at least two heterozygote variants 
or homozygote mutation increased the risk to 20 fold,148, 149 and in another study 
up to 40 fold.146 The overall frequency allele in CD was 0.2% for SNP8, 0.3% for 
SNP12 and 0.4% for SNP13.150  
Hampe et al estimated that about 18% of the genetic risk in the CD population can 
be attributed to this mutation,151 while Economou et al  found a modest impact of 
NOD2 mutations on familial CD,148 and colonic CD.149 There is a strong association 
with stenosing CD and ileal disease location.145, 148 In adult population, association 
between NOD2 mutation and early-onset of disease has been observed and in 
children, NOD2 mutation confers an increased risk of surgery, fistulising and 
fibrostenosing disease behaviour have also been  described148, 152, 153 (table 1.4.). 
 
1.7.5.2. Blau Syndrome 
Since the association between NOD2 mutations and CD was identified, other 
disease has been investigated in correlation with NOD2 mutation.147  
Blau syndrome (BS) is a rare autosomal dominant disorder characterized by early 
onset granulomatous arthritis, uveitis and skin rash.154 Linkage analysis has 
identified the susceptible locus for BS mapped to chromosome 16; NOD2. Blau 
syndrome susceptibility occurs due to mutations in the NBD of protein in contrast to 
CD in which mutations are in the LRR domain155 (table 1.4.). 
Three types of missense point mutations in the NOD2 have been discovered in BS 
families147, 154, 155 NOD2 mutant proteins that are found in patients with BS are 
defective in their response to bacterial components and induce  increased basal 
NF-κB activity. In contrast to CD associated NOD2 variants which have normal or 
reduced levels of basal activity.93  
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Table 1.4. Studies performed in NOD2 to determine mutation and disease association 
Disease Reference No of patients Relative risk 
Crohn’s Disease Hugot130 
Ogura4 
 
Economou148  
235 families 
56 families 
 
42 studies 
Risk rise; 2-4 folds in 
heterozugote & 20 folds in 
homozygote. 
Familial CD; slight risk 
(OR 1.49, 95%CI 1.18-1.87). 
Stenosing CD mod risk (OR 
1.94, 95% CI 1.61-2.34). Small 
bowel CD (OR 2.53, 95% CI 
2.01-3.16)  
Blau Syndrome Miceli-Richard155 4 families Disease gene 
Sarcoidosis Kanazawa154  10 families Association with early 
progressive form 
Colorectal cancer Kurzawski156 
 
Suchy157 
Tuupanen158 
556 pt  
 
607 pt 
1042 
Risk  increase >50 yrs 
OR 2.2, CI 1.23-4.10 
OR1.39, CI 0.91-2.14 
No association 
MALT risk in H pylori Rosenstiel159 511 pt OR 2.4, CI 1.2-4.6 
Breast cancer Lener160 
 
Huzarski161 
4107 pt 
 
462 
Increased susceptibility 
(not quantitated) 
5 fold risk <50 yr 
NHL Forrest162 904 pt  OR 3.1, 95% CI 1.1-8.8 
Sepsis Ahrens163 
 
Brenmoehl164 
356 infant 
 
132 pt 
Borderline. OR 32, 95% CI 1.0-
10.4 
Increased mortality 
GvHD Holler8 
 
Mayor9 
      
 
                               
Sairafi10 
169 pt 
 
196 pt 
 
 
                    
455 pt 
TRM (both mutant); OR 6, 95% 
CI 2.6-14.1 
OS; OR 1.617, CI 1.080-2.421. 
Decrease DFS; 1.603, 1.079-
2.381. Increase relapse; 2.579, 
1.538-4.323 
No association 
Psoriatic arthritis Rahman165 187 pt OR 2.97, CI 1.61-5.47 
Allergic rhinitis 
Atopic dermatitis 
Increased IgE level 
Kabesch166 1872 3 fold risk 
2 fold risk 
Coronary heart 
disease 
EL Mokhtari167 900 pt No association 
Lung CA Lener160 389 pt No association 
SLE Ferreiros-Vidal168 189 No association 
Behcet’s disease Ahmad169 374 No association 
Multiple sclerosis Sawcer170 631 No association 
Ankylosing spondylitis Van der Paardt171 113 pt No association 
Rheumatoid arthritis Ferreiros-Vidal172 210 pt No association 
Pulmonary TB Stockton173 320 pt No association 
Periodontitis Laine174 104 pt No association 
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1.7.5.3. Graft versus Host Disease 
Studies have observed differences in the outcome of patients receiving stem cell 
transplant when the donor, recipient or both carries NOD2 mutation. Holler et al 
studied the outcome of gastrointestinal graft versus host disease (GvHD) and 
transplant-related mortality. At one year, they observed a significant increase in 
these parameters compared to wild type NOD2 patients. The overall incidence of 
GvHD increased when the donor carries the mutant gene with further dramatic 
increase when both donor and recipients are carriers of the mutation. As a 
consequence, cumulative incidence of one year transplant related mortality 
increased from 20% with wild type NOD2 in both donor/recipient, to 49% when the 
recipient is mutant for the allele, to 59% when the donor is mutation positive, and 
83% if both donor and recipient revealed mutations.8 Recently another study 
showed no direct effect on GvHD, although overall survival was decreased as well 
as disease free survival which was contributed to increase relapse incidence. The 
association of NOD2 mutations characterized by a diminished NF-κB response, 
however, with GvHD and transplant related mortality suggest a predominant role of 
an impaired monocyte/macrophage response resulting in dysregulation of 
inflammation and impaired microbial response of the gastrointestinal epithelium 
and possible sepsis8, 9 (table 1.4.). 
 
1.7.5.4. Sepsis 
The NOD2 mutation has been studied in relation to infective events in adults and 
infants of very low birth weight.163, 164 In relation to the three NOD2 mutations; 
Brenmoehl et al observed increased sepsis related mortality rate from 31% in the 
wild type NOD2 patients, to 36% in the two missense mutations, to 57% in the 
frameshift Leu1007fsinsC patients.164 In very low birth weight infants, sepsis rate 
was higher in the frame-shift NOD2 mutation, with sepsis rate of 33% vs 13.2% 
non-carriers, with a trend to repeated episodes and blood culture proven sepsis in 
this group163 (table 1.4.). A recent study conducted in the ICU admitted patients 
  
(774 pts) showed the presence of at least one variant of NOD2 have reduced the 
phagocytosis function by monocytes rendering patients at higher risk of 
bacteraemia than the patient with the wild type genotype.175  
 
1.7.5.5. Malignancies 
Innate immunity and altered host immune response to microbial agents and 
molecular patterns was implicated as a cause of increase risk of developing NHL162  
and H. pylori induced mucosa-associated lymphoid tissue (MALT) lymphoma in 
NOD2 mutant patients.159 There are reports suggesting an association between 
NOD2 frameshift mutation and non-Crohn’s disease colorectal cancer risk at  >50 
years of age,156 and another study associated breast cancer with first degree 
relatives with lung cancer to NOD2 risk alleles.160 Both studies were based on 
Polish population, and need further validation (table 1.4.). 
 
1.7.5.6. Autoimmune diseases and Inflammatory Diseases 
A number of autoimmune diseases have shown linkage to the pericentrometric 
region of chromosome 16; including NOD2, disease such as rheumatoid arthritis 
and systemic lupus erythematous (SLE). As a result various investigators have 
tested specific diseases for the common CD NOD2 mutations.147 No reports so far 
exist suggesting an association between NOD2 and rheumatoid arthritis,172 SLE,168 
Wegener’s granulomatosis,176 Behcet’s disease,169 or MS.170 NOD2 mutations 
have been associated with susceptibility to psoriatic arthritis165 but not to 
ankylosing spondylitis.171 Sarcoidosis had showed no association with NOD2 
mutation in its asymptomatic naturally disappearing form, but this association was 
positive with the early progressive form of the disease.154  
There seems to be an association with increased IgE levels, allergic rhinitis and 
atopic dermatitis.166 For certain polymorphisms there is an association with 
protection against development of asthma of allergic rhinoconjunctivitis.177 With 
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regards to infectious diseases, no association has been identified between NOD2 
gene mutations and pulmonary tuberculosis173 or periodontitis174 (table 1.4). 
 
1.8.  This study 
Genetic variants resulting in subtle changes in healthy individuals might be of 
greater significance in immunocompromised patients. We have chosen to study 
two genes (chitotriosidase and NOD2) involved in innate immunity and their 
influence on the risk of serious infections. 
Innate immunity is a rapid and general response to injury. It relies on the detection 
of microbial motifs by presenting cells, such as macrophages, neutrophils and NK 
cells.  
Phagocytosis, triggers both degradation of pathogens and presentation of 
antigens, stimulation of membrane bound receptors, TLR, by microbial 
components triggers expression of several genes involved in immune responses 
and activation of innate immune system.94, 137  
Toll like receptors (TLR’s) ) are a family of pattern recognition receptors that sense 
motifs found in microbial pathogens called pathogen associated molecular patterns 
(PAMPS) and initiate immune defense against those pathogens. The majority of 
TLR’s are expressed on the surface of myelomonocytic cells. The recognition of 
PAMPS by toll like receptors leads to the activation of the NF-κB signalling 
pathway.94, 137  
Phagocyte specific chitotriosidase plays a role in innate immunity by degradation of 
chitin-containing pathogens (fungi, nematodes and insects).106 This enzyme is 
located in specific granules of human PMNs and macrophages and rises in 
response to various infectious stimuli.98, 99 Chitotriosidase showed increased 
activity in neonates not only with fungal but also with bacterial infections reflecting 
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phagocyte activation.6 Patients with mutant allele and the resulting decrease 
enzyme activity may have increase susceptibility to such infections.102  
The microbial motifs (PAMPs), LPS from the gram negative bacterial wall138 and 
the PGN found in bacterial wall of both gram negative and gram positive,139 are 
also recognised by the cytoplasmic proteins (NOD2) as a part of their innate 
immunity role. 
A recent study showed that the NOD2 mutation reduces the phagocytic activity of 
monocytes and has a possible role in increasing the risk of bacteraemia. This risk 
was synergistic with the presence of mutant TLR.175  
In another study, the release of chitotriosidase from specific granules in neutrophils 
occurred following PGN stimulation, and this was contributed to TLR and MDP-
dependent innate immune response, while NOD2 activation induced chitinase 
expression in macrophages.97  
As mentioned above chitotriosidase and NOD2 could play a role in innate immunity 
via their effects on the phagocyte specific regulation, with the contribution of TLR. 
Patients with the diagnosis of haematological malignancies become neutropenic 
and immunocompromised due to chemotherapy. In this period they become highly 
susceptible to infections with different organisms which may have a serious impact 
in their prognosis. 
In this study we looked into the innate immune genes, chitotriosidase and NOD2 in 
order to try and find out the weight of defect in the immune system that can be 
produced by their mutation. We tried to find a relation between susceptibility to 
infection, prevalence of organisms, and infection outcome. We first evaluated this 
relationship for each gene separately before determining if the presence of both 
mutations in an individual has a negative synergistic effect on the immune system.  
Neutrophils are phagocytic cells containing potent antimicrobial peptides and 
proteolytic enzymes. They play an important role in acute inflammatory response, 
resolution of inflammation and assisting in the killing and digestion of 
   
microorganisms. They are important for the clearance of infected foci before the 
appearance of macrophages, the chronic response cells.178, 179 In this study we 
focused on patients who were likely to be rendered neutropenic by chemotherapy 
and / or their disease. By looking at the natural history of infection during the 
neutropenic phase it might be possible to uncover a relationship of to mutations in 
NOD2 and chitotriosidase when the patient is at their most vulnerable to effects on 
the innate immune system. 
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Chapter 2 
 
Materials:  
See appendix-5 
 
General Methods 
2.1.  Study approval:  
The study (genetic determinants of sepsis in haematological malignancy) was 
ethically approved by the central office for research ethics committees (REC Ref: 
06/Q0501/56-Date 3/4/06. R&D ID:7414-Date 28/6/08).  
 
2.1.1.  Study population: 
Patients were recruited from the Royal Free haematology in-patient wards initially. 
Later recruitment involved the day care unit and out-patient department at the 
Royal Free Hospital (RFH).  
 
2.1.2. Inclusion criteria:  
Specific criteria for recruitment of patients were applied and were as follows: 
1. Age: 18 years or older.  
2. Diagnosis of acute leukaemia, lymphoma, myelodysplasia, multiple 
myeloma or aplastic anaemia.  
3. Able to give informed consent. 
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2.1.3. Exclusion criteria:  
The following exclusion criteria were applied while recruiting patients in this study. 
1. Age below 18 years. 
2. Non-haematological malignancy. 
3. Globally immunocompromised patients, including those with HIV/AIDS 
and agammaglobulinaemia. 
4. Patients receiving immunosuppressive treatment except as explicitly part 
of their chemotherapy for their haematological malignancy. Patients 
included in this criterion are patients with organ transplant and allogenic 
bone marrow transplant. 
5. Other severe co-morbidity, including congestive cardiac failure grade III 
(New York heart association classification), severe obstructive airways 
disease, Child B or C liver failure, short gut syndrome, active 
inflammatory bowel disease  or liver disease.  
6. Patients who were considered by the haematology team to be in a 
terminal phase of their condition. 
7. Unable to give informed consent.  
 
2.2.  Patient recruitment  
2.2.1.  Case finding:  
The clinical research fellow (LS; myself) attended the weekly hematology ward 
round to prospectively ascertain new cases, and follow up established cases 
including admissions to the hematology inpatient wards (Compston and Calthorpe 
wards). 
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Later in the course of the study patients were recruited from the hematology day 
care unit (OACS) and the outpatient department to enhance recruitment. In the 
case of those patients who had already commenced chemotherapy, data was 
collected from the date of their initial presentation and the diagnosis of malignancy. 
 
2.2.2.  Patient approach and consent:  
The total number of patients approached by the clinical research fellow (LS) was 
310.  257 patients were initially deemed eligible and consented to the study. After 
scrutiny of available data and their history a further 53 patients were excluded. 
Unavailable data was the cause of exclusion in 20 patients, either due to long 
history or patients referred from other hospitals. Other reasons are listed in table 
2.1. 
 
Table 2.1. Final disposition of patients enrolled in the study.   
Causes of exclusion Number of patients 
Eligible for the study 204 
Allogenic bone marrow transplant 22 
Unavailable data 20 
Not on chemotherapy (under observation only) 8 
Immunosuppression (HIV, or post-transplant) 3 (1,2) 
 
All patients deemed to fulfill the inclusion criteria were approached by the clinical 
research fellow, introduced to the study, and provided with written explanatory 
materials of a patient information sheet, consent form and an invitation letter 
(appendix-1). The patient was given at least 24 hours (depending on the patient’s 
circumstances and general condition) prior to consent. The patient and relatives 
were allowed the opportunity to ask for more questions before handing back the 
consent.  
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2.2.3.  Follow up and data collection: 
All patients who consented to participate in the study had a single 10ml anti-
coagulated blood sample drawn during routine clinical venepuncture initially. In 
some cases the anticoagulated sample drawn for full blood count testing was 
utilized to avoid further venepuncture. Later and due to difficulty of obtaining 
sufficient DNA (immunosupressed and/or neutropenic), arrangements were made 
by the clinical research fellow (LS) to collect samples obtained from patients for 
complet blood count from the haematology laboratory. For most patients multiple 
samples (3-5) were needed necissating multiple visits to the laboratory. The 
processing of the sample is described separately.  
Follow up of the patients in hospital was recorded by the clinical research fellow 
(LS) in a clinical record collection data sheet (appendix-2), with the patient 
demographics (hospital number, sex and date of birth), haematological diagnosis, 
chemotherapy (myelosuppressive and myelostimulation), date of admission and 
discharge. The following were documented daily- white cell and absolute neutrophil 
count, highest and lowest daily body temperature, any diagnosis of sepsis; 
including details of the source and results of microbiological culture and imaging 
investigations, and antibacterial and antifungal therapy. There was no necessity to 
interview or examine the patient. 
The outcome of inpatient hospital stay (i.e. survival, resolution of septic episodes) 
was recorded at the end of the stay. Follow up of all the patients was performed 
using paper and electronic records until the study was concluded (appendix-2). For 
patients recruited prospectively the follow up until death or end of the study ranged 
from 5-22 months. For patients who had already commenced chemotherapy at 
study entry follow up extended up to 4 years. 
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2.3.  Laboratory analysis of blood samples:  
A 10ml EDTA anticoagulated blood sample was processed, RBCs were lysed, the 
DNA was extracted using Puregene DNA Purification kit, and stored frozen at (-
20)°C all done by the clinical research fellow (LS). The DNA was used to determine 
the genotype of the NOD2 and chitotriosidase genes using PCR-based techniques. 
 
2.4.  Data Analysis: 
At the end of each hospital visit patient data sheets (appendix-2) were collected by 
the clinical research fellow (LS) for data extraction and analysis. The following 
variables were collected: daily absolute neutrophil count with note of any 
neutropenia (neutrophil count below 0.5x109/L) and the duration of neutropenia in 
days. Febrile episodes based on RFH protocols (fever of 38°C in two occasions 
within 24 hours, fever of 38.5°C in one occasion). Presumed or determined source 
of sepsis; intravenous catheters (peripheral or central), respiratory or 
gastrointestinal. Any documented bacteraemia, fungaemia or viraemia within or 
outside of a neutropenic episode. Relevant imaging findings (including CxR, CT, 
USG abdomen). Details of antimicrobial / antifungal therapy and response. Survival 
to discharge, or death in hospital. NOD2 and chitotriosidase genotype. 
In cases where the discharge occurred before the end of antimicrobial therapy, the 
outcomes were determined by following the patient’s records. There was no 
necessity for patients to attend the hospital solely for this study.  
Analysis was performed using Microsoft office excel 2007. Univariate statistical 
analysis was used to determine the potential association of genetic mutations with 
increased risk of fever, bacteraemia, fungaemia, and adverse outcome following 
sepsis. Data was also analyzed separately for those patients who were 
neutropenic and those who were not. Frequency distribution analyses were done 
by Chi squared and Fisher exact test using web calculator. P value of 0.05 
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considered significant. (http://www.physics.csbsju.edu/stats/fisher.form.html) 
(http://www.physics.csbsju.edu/stats/contingency_NROW_NCOLUMN_form.html)  
 
2.5.  Confidentiality: 
Complete patient confidentiality was maintained at all times. No personal data was 
stored in connection to samples. Only the clinical research fellow (LS) and 
immediate supervisor had access to raw data. All samples were stored in secure 
freezer in a secure laboratory and all remaining material was destroyed at the end 
of the study.  
 
2.6.  Red cell lysis solution:  
Whole blood was placed in a sterile falcon tube, labeled with a unique laboratory 
identification number. The sample was diluted by adding PBS 1:1 and centrifuged 
for 10 minutes at 1400 rpm. The supernatant was removed; the pellet was 
dislodged and the tube was topped up with RBC lysis solution (Gentra Puregene; 
Wales;UK). Sample was then incubated on ice for 20-30 min and centrifuged to 
produce a white pellet. Latter the supernatant was discarded and the pellet 
dislodged. Steps were followed by the clinical research fellow (LS) as per the 
manufactures’ guidelines. 
 
2.7.  Extraction of DNA:  
After breaking up the pellet, the cell lysis solution (Gentra Puregene; Wales;UK) 
was added to the cells. The amount of cell lysis solution was noted and left 
overnight. Protein precipitation solution (Gentra Puregene; Wales;UK) was added 
at one third of the volume of cell lysis and incubated in ice for 20-30 minutes. 1ml 
aliquots were dispensed into 1.5ml microcentrifuge and centrifuged at 13000 rpm 
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for 10 min. A pellet was formed with a clear supernatant. The supernatant was 
poured into a labeled 15 ml tube and isopropanol (equal in amount to cell lysis 
solution) was added. The tube was inverted until the DNA started to precipitate. 
Excess Isopropanol was removed and 1ml isopropanol with the DNA was poured 
into a new labeled 1.5ml microcentrifuge tube and centrifuged at 13000rpm for 1 
minute. DNA appeared as a white pellet at the bottom after being centrifuged. 
Excess isopropanol was discarded and 1 ml of 70% ethanol was added to the DNA 
pellet and centrifuged at 13000rpm for 1 min and then poured out. The DNA pellet 
was left air dried at room temperature, by covering the opening of the tube with 
some pierced film leaving it overnight. Once dry, at least 50µl of double distille 
water (Gentra Puregene; Wales;UK) was added to the DNA pellet and allowed to 
resuspend. 
The DNA concentration was checked by the clinical research fellow (LS) using the 
Nanodrop according to the manufacturer’s protocol. If the concentration was 
greater than 200ng/µl, then it was brought down by further addition of DNA 
hydration solution. The DNA concentration was written on worksheet and at the 
side of the tube and stored at -20°C. Steps were followed as per the manufactures’ 
guidelines. 
 
2.8. Chitotriosidase genotyping:  
2.8.1.  Stock regents: 
Oligonucleotide Primers (Sigma Genoys; Texas;USA ) arrived lyophilized and were 
reconstituted with ddH2O as specified on the certificate of analysis to a 100µM 
concentration. Primers were then diluted 1:10 in ddH2O to give working 
concentration of each primer, and stored at (-20)ºC. 
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2.8.2.  Chitotriosidase Genotyping Process: 
PCR was carried out in a total volume of 23µl per reaction, containing 2.5µl of 15 
mM MgCl2, 2.5µl of 10x Reaction Buffer, 0.5µl of 10 mM of each primer 
(chitotriosidase F and R), 0.5µl of 2mM dNTP, 0.25µl of (5 µ/µL) taq polymerase 
(Bioline ltd; London;UK), and 16.25µl ddH20 to make up to the final volume.  
2µl of 100-200 ng/µl genomic DNA was added to the appropriate tubes and 2µl of 
sterile water to the blank tube and centrifuged. The PCR conditions for 
chitotriosidase were as follow: Denature 96ºC for 5 minutes runs for 1 cycle. This 
was followed by 35 cycles of; denaturing at 96ºC for 45 seconds, annealing at 61ºC 
for 45 seconds followed by extension at 72ºC for 45 seconds. The final extension 
was carried away at 72ºC for 10 minute for 1 cycle followed by 4ºC in finitely.  
20µl of each PCR product was mixed with 4µl of bromophenol blue loading buffer 
to promote visualization on the gel.Gel electrophoresis was performed on 1.5% 
agrose gel (0.75gram agrose powder (Bioline ltd; London;UK), in 50ml of 0.5 TBE, 
5 µL ethidium promide) in 0.5xTBE buffer at 150V for one hour. 1.5µl of the DNA 
ladder (Bioline ltd; London;UK) was loaded into the last well. The gel was 
photographed on the gel imaging system (Gel Doc 2000 (BioRad; California, USA)) 
and results were interpreted (figure 2.1.). 
 
1     2    3    4 5   6   7    8    9   10   11   12 
 
 
 
 
 
 
 
Figure 2.1. Chitotriosidase genotyping: Gel 
visualization of PCR fragments size; 1; The 
DNA ladder (IV), 2 The blank (ddH2O) control, 
3 The positive control (GD; homozygote for the 
mutation), 5,7,8 are wild type chitotriosidase. 
6,11,12 are heterozygote for chitotriosidase. 9 
is homozygote. 
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PCR fragments sizes are: wild type chitotriosidase 75 basepair (bp); heterozygous 
for chitotriosidase mutation at 75bp+99bp and homozygous for chitotriosidase 
mutation at 99bp. The clinical research fellow (LS) carried out the methods as per 
the manufactures’ guidelines. 
 
2.9.  NOD2 genescanning 
2.9.1.  Stock regents: 
Oligonucleotide Primers (vh bio; Edinburgh; UK) arrived lyophilized and were 
reconstituted with sterile water as specified on the certificate of analysis to a 
100µM concentration. Primers were then diluted 1:10 in ddH2O to give working 
concentration of each primer, and stored at (-20)ºC. 
 
2.9.2.  NOD2 Genescanning using ABI 3130 
PCR was carried out in a total volume of 19µl, and two reactions were prepared in 
1.5 microcentrifuge tubes. The 1st reaction containing the common exon and the 
wild type primer and the 2nd reaction contains the common exon and the SNP 
primer. Master mix reagents are prepared as follow; ddH2O 11.9µl, 10x buffer 2µl, 
15mM MgCl2 2µl, 2mM dNTPs 1µl, either primer WT or SNP (0.4 µM) 1µl, 
Common primer (0.4 µM) 1µl, last taq polymerase 0.1µl.  
Two sets of 250µl thin walled PCR tube were labeled for each primer mix 
(WT/SNP). Each containing the number of samples to be tested, and two controls: 
positive control either mutant for the SNP set or wild type, and a blank. 
In each tube 2µl of 100-200 ng/µl genomic DNA was added to the appropriate 
tubes and 2µl of ddH2O to the blank tube. All tubes were briefly centrifuged and 
placed into the PCR machine / thermal cycler PCR conditions applied to all were 
the same except for the annealing temperature. Denature 94ºC for 5 minutes for 1 
cycle,  then 25 cycles of denature at 94ºC for 30 seconds, annealing at xºC (table  
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Table 2.2. Annealing temperature for each exon in NOD2 genotypes. 
Annealing temp Wild type SNP 
Exon4 (SNP8) 69°C 65°C 
Exon8 (SNP12) 65°C 65°C 
Exon11 (SNP13) 70°C 65°C 
 
 
    
Figure 2.2. Genescan trace figure: shows typical trace of genescan assay.  
   The x axis shows size of the fragment. The y axis shows intensity.  
   The small orange peaks are the size standard, represent fragments of different sizes.  
   The colour of the peak is dependent upon which base is present at the loci of interest as  
   the two forward primers (Wild type or SNP) are fluorescently labelled. 
   The first 2 lines show a homozygote mutation with a green peak. 
   The last 2 lines are wild type NOD2 genotype with the blue peak. 
   The middle 2 lines, where the two primers peaks (green and blue) appear it indicate  
   heterozygote mutation. 
   The missenses and frameshift mutations are both detected by genescanning in the same  
   manner. 
    
    
 
Homozygote 
Hetrozygote 
Wild 
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2.2.) for 30 seconds followed by extension at 72ºC for 45 seconds. The final 
extension was 72ºC for 5 minute to run 1 cycle, followed by 4º C in finitely.  
For genescanning, a mixture was prepared of 10µl HiDi formamide (AB applied 
Biosystems; California;USA) and 0.75µl of size standard (AB applied Biosystems; 
California;USA) vortex mixed before and frequently while pipetting. 10.75µl of the 
mixture was placed into the wells of a PCR microplate (96-well plate suitable for 
ABI 3130) (Axygen Scientific; California;USA) suitable for use in a machine (ABI 
3130) capable of fragment analysis via capillary electrophoresis), followed by 1µl of 
PCR product.   
The plate was denatured at 94ºC for 5 minutes and placed in the plate base (AB 
applied Biosystems; California;USA) with plate septa (AB applied Biosystems;  
California;USA) and a plate retainer (AB applied Biosystems; California;USA), 
within the appropriate instrument for fragment analysis. The polymer-3130 POP7 
(AB applied Biosystems; California;USA) was used containing 3.5ml or 7ml (figure 
2.2). The capillary electrophoresis analyzer was operated by the clinical research 
fellow (LS) as instructed in the manufacturer’s handbook. 
 
2.10.  Sequencing of PCR products180 using ABI 3130 
The DNA template was first labelled by incorporation of four fluorescent dyes (one 
for each dNTP) using a PCR primer extension technique. Labelled DNA was then 
electrophoresed through a 34cm capillary tube containing a premade polymer. 
Two PCR reactions were prepared in 1.5ml centrifuge tubes each. The 1st reaction 
contains the reverse primer and the 2nd reaction the forward primer. Master mix 
regents were prepared as follows; sterile water 5.5µl, 5x sequencing buffer 2µl (AB 
applied Biosystems; California;USA), Big Dye (version 1.1, Applied Biosystems) 
0.5µl, and 1µl of either primer (forward or reverse). In a 96-well plate suitable for 
ABI 3130 master mix of 9µl was added to each well. The DNA amplicon sample 
was diluted in double distilled water 1:30 and then 1µl was added to the master 
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mix. The plate was sealed firmly with adhesive film (AB applied Biosystems; 
California;USA) and left to spin down in centrifuge. 
A full plate cover (AB applied Biosystems; California;USA) was placed on top of the 
plate, and then placed in a hot-lidded PCR machine-Tetrad & Dyad blocks (MJ 
Research;Aberdeen;UK) PCR sequencing amplification was carried out as follows: 
95°C for 4minutes to run 1 cycle, 24 cycles of 95°C for 10 seconds, 50°C for 5 
seconds, and 60°C for 4 minutes. 
 
Figure 2.3. DNA sequencing: The term DNA sequencing refers to methods for determining  
the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, in a molecule of  
DNA.  DNA sequencing technology using dye-based (DNA is labelled by incorporation of four  
fluorescent dyes) sequencing methods with automated analysis. 
 
To ensure desalting and removal of the remaining labeled dNTPs and 
unincorporated dye terminators 2µl of 3Mmol Na Acetate, 2µl of 125Mmol EDTA 
and 50µl of 100% Ethanol was added to each well and left at room temperature for 
15 minutes before spinning the plate at 3400 rpm for 30 minutes at 10°C. The plate 
was immediately inverted on a towel in the plate holder of the centrifuge and pulse 
spun inverted till the machine reached 1000 rpm. DNA was then washed with 70µl 
of fresh 70% Ethanol (stored at -20°C) and spun at 3400 rpm for 15 minutes. The 
plate was immediately inverted on a towel in the plate holder of the centrifuge and 
pulse spun inverted till the machine reached 1000 rpm. Pellets were allowed to dry 
on the top bench for 15-20 minutes, while the manager/sample sheet was 
prepared. The Ultra run programme was used if the product size was less than 
500bp, or rapid run programme if the size was greater than 500bp, .Before running 
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the plate, the samples were resuspended in 10µl HiDi formamide by pipetting it up 
and down about 5-6 times with the sample in the first four wells, of the first run. 
Mixing was not required for the rest of the wells since HiDi formamide denatured 
samples in 20-25 minutes. Plates were stored at -20°C until ready to run and only 
re-suspended in 10µl of HiDi formamide just before running the samples. Before 
running the samples, the plate was assembled along with the black plate base, a 
plate septa and a plate retainer. For ABI 3130 sequencing machine the polymer-
3130 POP7 was used containing 3.5ml or 7ml (figure 2.3.). 
 
2.11.  Pyrosequencing 
Primers for the pyrosequencing assays were designed using Pyrosequencing 
Assay Design Software 1.0.6. (Biotage Ltd). Oligonucleotide Primers (vh bio; 
Edinburgh;UK) arrived lyophilized and were reconstituted with sterile water as 
specified on the certificate of analysis to a 100mM concentration. Primers were 
then diluted 1:10 in ddH2O to give working concentration (10mM) of each primer, 
and stored at (-20)ºC. Each primer set consisted of a Forward (F1), a Reverse (R1) 
and a Sequencing Primer (S1). 
The PCR reaction was prepared in a total volume of 20 l, containing 2 l of 15mM 
MgCL2 and 10xbuffer. 1 l of 2mM dNTP,  1 l of each 10mM primer (F1/R1), 0.1 l 
taq polymerase,  11.9 l of ddH2O and 1 l of 100-200ng/ l genomic DNA. 
The solution was incubated in the G-Storm thermal cycler (Biotage;Virginia;USA)at 
94°C for 3 minutes, followed by 32 cycles of denaturing 94°C for 40 seconds, 
annealing 60°C for 40 seconds and elongation 72°C for one minute. Followed by 
10 minutes elongation at 72°C and stored in finitely at 10°C. 
All PCR products were analysed by standard gel electrophoresis on a 1.5% agrose 
gel with SybersafeTM DNA gel stain (invitrogen; Oregon;USA) prior to 
pyrosequencing figure 2.4.). 
   
 
       1 (2-8)  9 (10-16) 
 
 
Figure 2.4. NOD2 PCR product visualization:   
In the 1.5% agrose gel at 100bp for exon 4, 
and 8 while 150bp for exon11, hyperladder IV 
was used. B for blank (ddH2O). 1 and 9 are 
wells containing blanks. Wells (2-8) are exon 4 
products, and (10-16) are exon 8 products. The 
lower row is products of exon 11 along with the 
blank. 
 
 
 
 
Figure 2.5. Pyrosequencing trace.The 
dATP (dNTP component) is used as a 
substitute for the natural deoxyadenosine 
triphosphate (dATP) since it is efficiently 
used by the DNA polymerase. As the 
process continues, the complementary DNA 
strand is built up and the nucleotide 
sequence is determined from the signal 
peaks in the Pyrogram trace (adapted from 
the web) 
 
 
Pyrosequencing is an alternative to geneScan, and allows nucleotides at the loci of 
interest to be quantified. The assay involves a Binding Reaction containing 15-20 
l PCR product, 38 l of Binding Buffer (Biotage;Virginia;USA), 2 l of Streptavidin 
Sepharose beads (GE healthcare; Sweden) and 20 l of ddH20. The plate is 
shaken for 15 min in a plate shaker (WebScientific; Cheshire;UK) at 1300 rpm. 
Following this, the purification step involves washing with 0.2M NaOH, 70% 
Ethanol and 10X Washing Buffer (Biotage) according to the manufactures’ 
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guidelines. The final step before analysis is the Annealing reaction; 24.2 l 
Annealing Buffer (Biotage) and 0.8 l of sequence primer (S1) are aliquoted in to 
PyroMark™Q24 Plates (Biotage) and the bound Streptavidin Sepharose-PCR 
product is placed in the wells. The plate is heated at 80oC for 3 minutes and then 
placed in the PyroMark Q24 (Biotage) for SNP analysis as per the manufactures’ 
guidelines by the clinical research fellow (figure 2.5.). 
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Chapter 3 
 
Chitotriosidase as genetic determinant of sepsis in 
haematological malignancy 
 
3.1.  Introduction 
Infection remains a significant cause of morbidity and mortality in patients with 
haematological malignancy. This may be a result of either the effect of the disease 
process itself on defensive mechanisms or as a sequel of chemotherapy. Other 
risk factors include immune suppression, mucosal damage, and indwelling 
catheters. Bacterial pathogens and fungal infections are associated with increased 
risk of mortality.96  
It is possible that genetic variation may result in heterogeneity in the 
proinflammatory cytokine profile disturbing the balance of circulating cytokines and 
influencing the inflammatory response thereby rendering an individual more 
susceptible to infections.96  
Human Chitotriosidase is a fully active chitinase, expressed by activated 
macrophages. It was first discovered in the plasma of patients with Gaucher 
disease.7  
Gaucher disease is the most prevalent lysosomal storage and results from an 
autosomal recessive defect, leading to deficient activity of lysosomal hydrolase, -
glucocerebrosidase. The accumulation of glucocerebroside occurs within the 
lysosomes of macrophages resulting in accumulation of Gaucher cells within the 
reticuloendothelial system especially liver, spleen and bone marrow. There are 
three types of GD, the commonest is type 1 where presentation is heterogeneous 
and slowly progressive. The symptoms developing towards adulthood include 
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haematological abnormalities, skeletal pathology and hepatosplenomegaly. Type 1 
disease has historically been defined by the absence of central neurological 
involvement however recently an association with Parkinson’s disease has been 
detected. Types 2 and 3 are rarer forms of the disease and manifest significant 
neurological features. The onset in the most severe type 2, is at infancy 3-6 
months with death before the age of 2 years. Type 3 manifests in childhood and 
although less severe than type 2, treatment usually fails to improve the 
neurological symptoms. Haematological and skeletal manifestations may also 
occur.116  
Human polymorphs and mature macrophages are the main source of 
chitotriosidase, being secreted from their lysosomes.7  Chitin is a major structural 
component of the cell walls of fungal pathogens,181 analogous to some plant 
chitinases, recombinant chitotriosidase has been found to inhibit hyphal growth of 
chitin-containing fungi such as Candida and Aspergillus, and improved survival in 
neutropenic mice models with such systemic fungal infections.7, 106, 182 The role in 
degradation of chitin-containing pathogens as antifungal action and the 
chitotriosidase expression by phagocytes suggests a physiological role in defence 
against such infections.106, 182  
Immune compromised individuals show an increased risk of life-threatening fungal 
infections. Induction of chitotriosidase expression in the mature macrophages and 
PMNs following GM-CSF treatment had shown improved anti-fungal response by 
inhibiting growth of C. neoformans and C. albicans due to the chitinolytic activity 
towards the cell wall chitin.7 Chitotriosidase has been found to be elevated in 
plasma of neonates with systemic candidiasis,6 and associated with bacterial 
infection in bone marrow (BM) transplant and in endemic areas for filarial 
parasite.115 It is up-regulated both at the level of RNA and protein activity following 
stimulation with prolactin, IFN-  and TNF .109 IL-12 injection in chimpanzees is 
also associated with enhanced chitotriosidase activity. This suggests a possible 
role of chitotriosidase during responses to infection.114  
   
Chitotriosidase deficiency is inherited as autosomal recessive and is multiethnic 
occurrence.106 About 30-40% Caucasian population bears the mutation caused 
by24 duplication in exon 10 in which 6% are homozygote.106, 107 Another two 
polymorphisms (G354R and A442V) are found predominantly in African decent and 
are associated with reduced chitotriosidase activity.108  
In the present study we examined the presence or absence of chitotriosidase 
mutation in patients with haematological malignancies, as patients with such 
diagnosis are prone to neutropenia and are rendered immunocompromised by 
treatment. Evaluation of chitotriosidase mutations in relationship to infection and 
sepsis was studied in this group of patients in relation to absolute neutrophil count 
(neutropenic or non-neutropenic). The infectious pathogen and outcome of 
infection were analysed according to mutant status immune defences and the 
susceptibility of developing bacterial and fungal infections. 
 
3.2.  Hypothesis: 
Our hypothesis is that patients carrying mutations in chitotriosidase, a mediating 
innate immunity gene, are at increased risk of infection and sepsis during periods 
when they are neutropenic. 
 
3.3.  Objectives: 
1)  To determine the effect of chitotriosidase gene status on the 
incidence and outcome of sepsis in patients with haematological 
malignancy, including those with leukaemia, lymphoma, and myeloma.  
2)  To compare the effect of chitotriosidase gene status on the incidence 
and outcome of sepsis in patients with haematological malignancy who 
are neutropenic and those who are not. 
   
3) Prevalence of organisms. 
4)  Correlate neutrophil function and duration of neutropenia with the 
chitotriosidase genotypes. 
 
3.4.  Materials and methods: 
General material and methods are described in Chapter 2. 
Inclusion and exclusion criteria are also described in chapter 2. 
Recruitment of patients with haematological malignancy was performed in the 
RFH. 
The study was ethically approved by the central office for research ethics 
committees (REC Ref: 06/Q0501/56-Date 3/4/06. R&D ID:7414-Date 28/6/08). All 
patients gave informed consent. They were followed up during their in-patient stay.  
Clinical data were collected daily by the clinical fellow. Observations were recorded 
including ANC, temperature, related investigations (microbial and imaging) to 
determine the source and type of sepsis, and antimicrobial management.  
Investigation and data of patients recruited from the out-patient department or after 
patients discharge were recorded electronically or from paper medical records by 
the clinical research fellow (LS).  
DNA was extracted and genotyped for chitotriosidase, according to methods 
mentioned in chapter 2. 
 
3.5.  Statistics: 
P value was calculated by the Chi square, and by Fisher exact if figures  10 if 
comparing two dimensions. P value of 0.05 considered significant.  
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P value differences were calculated in four proportions. The Wild type: 
Heterozygote: Homozygote proportion is mentioned in this chapter while the Wild 
type: Mutant, Wild type: Heterozygote, Wild type: Homozygote proportions are 
mentioned in appendix 4. 
Mean, median and calculation along with graphs were prepared using Microsoft 
excel. 
 
3.6.  Results: 
3.6.1.  Incidence of chitotriosidase mutation: 
Mutation: Out of the 204 patients, 122 (59.80%) were wild type for chitotriosidase 
and 82 (40.20%) were mutated. Of the 82 mutant genotype patients 71 (34.80%) 
were heterozygote and 11 (5.39%) were homozygote for the mutation (table 3.1.). 
 
3.6.2.  Demographic characteristics: 
A total of 204 patients were included in this part of the study. Males accounted for 
59.31% and females for 40.69% (p=0.443). The age ranged between 18-81 years 
at the time of diagnosis (table 3.1). The age and gender distribution did not differ 
between wild type and mutated genotype patients. 
 
3.6.3.  Range of Diagnoses 
In this study population the diagnosis of lymphoma accounted for 52.45%, acute 
and chronic leukaemia (lymphoblastic and myeloid) for 30.39%, multiple myeloma 
and plasma cell malignancies for 15.69%, and other malignancies for 1.47%. There 
   
were no significant differences in the diagnosis between the genotypes (table 3.2. 
& figure 3.1).  
 
Table 3.1. Demographic characteristics in the study population. The number of patients and 
proportion by sex and age at diagnosis of haematological malignancy in relation to chitotriosidase 
gene status.  (M: male, F: female) 
Chitotriosidae 
gene status 
Sex Age at diagnosis 
 M F 18-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 
Total; 204 
% 
121 
59.31 
83 
40.69 
5 
2.45 
19 
9.31 
24 
11.76 
28 
13.73 
53 
25.98 
49 
24.02 
23 
11.27 
3 
1.47 
Wild type; 122 
59.80 % 
75 
61.48 
47 
38.52 
2 
1.64 
14 
11.47 
14 
11.47 
15 
12.30 
35 
28.69 
30 
24.59 
11 
9.02 
1 
0.82 
Mutant; 82 
40.20 % 
46 
56.10 
36 
43.90 
3 
3.66 
5 
6.10 
10 
12.20 
13 
15.85 
18 
21.95 
19 
23.17 
12 
14.63 
2 
2.44 
 
Table 3.2. Diagnosis of different haematological malignancies in our study population. The 
number of patients and frequencies (%) of the total in relation to the chitotriosidase gene status. 
The p value calculation by Chi square and Fisher exact tests comparing wild type: mutant. 
Chitotriosidase status Diagnosis 
 Lymphoma Multiple 
myeloma 
Acute 
Leukaemia 
Chronic 
Leukaemia 
Other 
Total; 204 (%) 107 
(52.45%) 
32 (15.69%) 51 (25%) 11 (5.39%) 3 (1.47%) 
Wild type; 122 
(59.80%) 
67 (54.92%) 17 (13.93%) 27 (22.13%) 8 (6.56%) 3 (2.46%) 
Mutant; 82 (40.20%) 40 (48.78%) 15 (18.29%) 24 (29.27%) 3 (3.66%) 0 
P 0.389 0.401 0.248 0.176 0.212 
Table 3.3. Outcome of the patients included in the study in relation to chitotriosidase gene 
status. (CR: complete remission, PR: partial remission, Allo: allogenic transplant, On R: still on 
treatment at last follow up.)  
Chitotriosidase 
gene status 
Outcome 
 CR PR Allo Death On R Relapse Progressive 
Total;204 
% 
60 
29.4% 
42 
20.59% 
33 
16.18% 
36 
17.65% 
17 
8.33% 
9 
4.41% 
7 
3.43% 
Wild type: 122 
(59.80%) 
34 
27.8% 
28 
22.95% 
19 
15.57% 
21 
17.21% 
11 
9.02% 
7 
5.74% 
2 
1.64% 
Mutant: 82 
(40.20%) 
26 
31.7% 
14 
17.07% 
14 
17.07% 
15 
18.29% 
6 
7.32% 
2 
2.44% 
5 
6.10% 
  
Figure 3.1. 
 
Diagnosis of different 
haematological 
malignancies. 
Frequencies in relation 
to chitotriosidase 
genotype. 
 
 
 
 
 
 
Figure 3.2. 
 
Outcome of 
haematological 
malignancies in the 
study population in 
%, in relation to 
chitotriosidase 
genotype. 
 
3.6.4. Outcome of the haematological malignancy in relation to 
chitotriosidase status 
Out of the total 204 patients, 29.41% entered complete remission, 20.59% partial 
remission while 17.65% patients died due to the treatment or disease. 16.18% 
patients received allogenic bone marrow transplant, and 4.41% relapsed whilst the 
   
study was still in process, 8.33% patients were still on treatment by the end of the 
study and data analysis. 3.43% of the patient responses were progressive or 
refractory to treatment. The different outcomes did not show any significant 
differences between chitotriosidase wild type and mutant genotypes. Complete 
remission (CR), allogenic transplant, deaths and progressive course, p=0.555, 
0.776, 0.843 and 0.086 respectively (table 3.3. & figure 3.2.). 
There may be a trend towards a progressive course of disease in patients with the 
chitotriosidase mutation (p=0.086).  
 
3.6.5.  Analysis of episodes of neutropenia (EoN): 
Neutropenia was defined as an absolute neutrophil count (ANC)  0.5x109/L. 
Patients receiving chemotherapy became neutropenic during the course of 
therapy. Neutropenia was analysed according to its incidence and duration for 
each genotype. We also looked into the number of patients per genotype 
developing neutropenia and the frequency of neurtopenic episodes in these 
patients. 
3.6.5.1. Number of patients with neutropenic episode per genotype: 
The total number of patients developing episodes of neutropenia in the wild type 
group was 103 out of 122 (84.43%) whilst in the mutant genotype 65 out of the 82 
patients (79.27%) became neutropenic during their treatment. 54 out of 71 
(76.06%) of the heterozygote became neuropenic at some point, while all the 
homozygote 11 patients (100%) had one or more neutropenic episodes. There 
were no statistically significant differences between the chitotriosidase genotypes, 
(table 3.4.). 
3.6.5.2. Number of neutropenic episodes per genotype: 
There were 453 episodes of neutropenia in total, 282 episodes out of the 453 
occurred in the wild type chitotriosidase patients, while 171 out of the 453  
   
occurred in the mutant genotype patients. There was no statistical difference in the 
proportion of each genotype exhibiting episodes of neutropenia (table 3.5.). 
The number of neutropenic episodes per patient was slightly higher in the mutant, 
homozygote but was not significant by statistical tests (table 3.5.). 
 
Table 3.4. Total number of patients (Pts) and total patients with episodes of neutropenia (EoN) 
in each chitotriosidase genotype.  % of neutropenic patients within each genotype. The p was 
calculated by Chi square. 
Total patients          
=204 
Wild type 
=122 
Mutant 
=82 
Heterozygote 
=71 
Homozygote 
=11 
Total patients (%) 122 (59.80%) 82 (40.20%) 71 (34.80%) 11 (5.39%) 
Pts with EoN in each 
genotype (p= 0.098) 
103 
(84.43%) 
65 
(79.27%) 
54 
(76.06%) 
11 
(100%) 
 
Table 3.5. Episodes of neutropenia (EoN) analysed by different chitotriosidase genotypes. 
The p value was calculated by t-test. 
Total episodes of neutropenia  = 
453 
Wild type  Heterozygote Homozygote 
Total pts / genotype 122 71 11 
Total neutropenic episodes  
P (wild type: mutant)=0.21 
282 135 36 
Total neutropenic days 
P (wild type: mutant)=0.18 
2845 1332 266 
Range  
Episodes of neutropenia / patient 
Neutropenic days per patient 
 
0-11 
0-109 
 
0-7 
0-50 
 
1-13 
1-33 
Median 
Episodes of neutropenia/patient 
Neutropenic days/patient 
Day/episode 
 
2 
13 
6.5 
 
2 
10 
5 
 
2 
19 
9.5 
 
3.6.5.3. Duration of neutropenic episode: 
The duration of neutropenic episodes varied, between patients. We calculated the 
total number of days of neutropenia for each genotype, to try to evaluate if the 
chitotriosidase mutation affected the time to neutrophil regeneration. The total 
    
number of neutropenic days for each genotype were 2845, 1332 and 266 in the 
wild type, heterozygote and homozygote patients respectively (table 3.5.). 
The number of neutropenic days per episode was slightly higher in the homozygote 
mutant genotype (median: 6.5, 5, and 9.5 days per episode for the wild type, 
heterozygote and homozygote respectively). The total duration of neutropenia per 
patient was longer in the mutated homozygote patients (mean 24.18 days, 
compared to median 19 days). Again, although suggestive, there were no 
statistically significant differences (table 3.5.). 
Overall we found no statistically significant differences between the different 
chitotriosidase genotypes and the occurrence of neutropenic episodes.  
 
3.6.6.  Analysis of febrile events: 
A febrile episode was diagnosed, if fever of 38.5°C or greater occurred on one 
occasion or fever of 38°C occurred on two occasions (with or without neutropenia). 
To determine if the occurrence of fever was affected by the chitotriosidase 
mutation. We analysed the incidence of febrile events per genotype then the 
number of patients in each genotype who development such febrile events in 
relation to presence and/or absence of neutropenia.  
3.6.6.1 Febrile neutropenic events (FNE):   
The total number of febrile events throughout all genotypes was 316; 202 febrile 
events occurred during neutropenia while 114 occurred in the absence of 
neutropenia. (table 3.6.). 
There were no statistical differences in the proportion of patients developing febrile 
events, either neutropenic or neutropenic, or both for all genotypes (table 3.6.). 
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The number of febrile neutropenic events (event/neutropenic episode) per patient, 
per episode of neutropenia and per days of neutropenia was almost the same in all 
genotypes, p=>0.05 (table 3.7.). 
 
Table 3.6. Total febrile events in each genotype.  Proportions of patients (Pts) out of each 
chitotriosidase genotype with febrile events whilst neutropenic (FNE), non-neutropenic (FNnE), 
either (FNE or FNnE) or both (FNE & FNnE). The p value calculated by the Fisher exact test 
compares the wild type: heterozygote: homozygote proportions.  
Total Wild type Mutant Heterozygote Homozygote 
Total pt 204 (%) 122 (59.80%) 82 (40.20%) 71 (34.80%) 11 (5.39%) 
Total Febrile events = 316 
(%;events genotype/total 
event) 
199 
(62.98%) 
117 
(37.02%) 
101 
(31.96%) 
16 
(5.06%) 
Total FNE = 202             
(%;events genotype/total 
event) 
126   
(62.38%) 
76     
(37.62%) 
63    (31.19%) 13      (6.43%) 
Total FNnE = 114           
(%;events genotype/total 
event) 
73     
(64.04%) 
41     
(35.96%) 
38    (33.33%) 3        (2.63%) 
Pts with FNE (% pts of FNE/ 
genotype). P = 0.466 
73     
(59.84%) 
42     
(51.22%) 
36    (50.70%) 6      (54.55%) 
Pts with FNnE (% pts of FNnE/ 
genotype). P = 0.834 
47     
(38.52%) 
29     
(35.37%) 
26    (36.62%) 3      (27.27%) 
Pts with either febrile events 
P = 0.559 
56    
(45.90%) 
37    
(45.12%) 
30    (45.25%) 7      (63.64%) 
Pts with both febrile events. 
P = 0.424 
33    
(27.05%) 
17    
(20.73%) 
16     (22.54%) 1        (9.09%) 
 
3.6.6.2. Febrile non-neutropenic events (FNnE):  
114 events of non-neutropenic fever occurred.  The number of patients with febrile 
events not associated with neutropenia were 47 out of the 122 in the wild type 
(38.52%) and 29 out of the 82 in the mutant genotype (35.37%). There was no 
statistical difference between genotypes (table 3.6., 3.8. & & appendix-6;A.6.1).  
For details of the development of non-neutropenic fever in relation to 
chemotherapy (appendix-6; A.6.2. &  A.6.3.). 
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3.6.6.3. Analysis of patients developing either febrile (neutropenic or non-
neutropenic) event:  
There was no statistical significance in the proportion of patients who developed 
any febrile event either in the presence or absence of neutropenia. There was 56 
(45.90%) patients in the wild type, 30 (45.25%) in the heterozygote and 7 (63.64%) 
in the homozygote genotypes (table 3.6. & appendix-6;A.6.1.). 
3.6.6.4. Analysis of patients developing both febrile (neutropenic and non-
neutropenic) events:  
The number of patients developing febrile events both while they are neutropenic 
and non-neutropenic during their course of therapy were 33 (27.05%) in the wild 
type group and 17 (20.73%) in the mutant variant (heterozygote 16 (22.54%) and 
in the homozygote 1 (9.09%)), p=>0.05 (table 3.5. & appendix-6;A.6.1.). 
 
Table 3.7. Number of febrile neutropenic events (FNE) by different chitotriosidase genotypes. 
The p value calculated by t-test. 
Total febrile neutropenic events = 202 Wild type Heterozygote Homozygote 
Number of febrile neutropenic events. 
P (wild type: mutant)=0.27 
126 63 13 
Range per patient 0-5 0-7 0-4 
Median  
Number of events/patient 
Event/episode of neutropenia 
Event/neutropenic days 
             
 
1 
0.5 
0.077 
 
1 
0.5 
0.1 
 
1 
0.5 
0.053 
 
Table 3.8. Number of febrile non-neutropenic events (FNnE) analysed by different 
chitotriosidase genotypes. The p value calculated by t-test. 
Total febrile non-neutropenic events=114 Wild type Heterozygote Homozygote 
Number of febrile non-neutropenic events. 
P (wild type: mutant)=0.23 
73 38 3 
Range per pt 0-6 0-4 0-1 
Median; number of events per pt 0 0 0 
 
 
     
3.6.7. Analysis of the types of organism cultured  
The likelihood of having positive cultures with a particular organism (bacteria, virus 
or fungus) was analysed according to the number of febrile events, the number of 
episodes of neutropenia and the number of patients within each genotype. 
 
3.6.7.1. Analysis of organism cultured per febrile events in the presence 
and/or absence of neutropenia. 
Here the number of febrile events in relation to the organism isolated was 
calculated in order to evaluate organism prevalence, in different chitotriosidase 
genotypes in the presence and/or absence of neutropenia. 
1- Number of febrile events with positive bacterial culture 
Diagnosis of positive bacterial culture was considered if patients grew gram 
positive or gram negative bacteria from their blood or central line with the presence 
of fever, with or without neutropenia. If a patient with multiple febrile events grew 
the same organism within 5 days with or without neutropenia then this was 
considered as the same infection and not a new febrile event. 
Febrile events with positive bacterial cultures occurred more frequently in patients 
with the mutant genotype. There was a significant difference between the three 
proportions (wild type, heterozygote and homozygote) regardless of neutropenic 
state (p=0.031). The heterozygote genotype had the most febrile events (62.38%) 
with statistical significance (p=0.037). (Table 3.9.1., figure 3.3. & appendix-6 
A.6.10.). 
A similar pattern observed when comparing positive bacterial cultures during febrile 
events associated with neutropenia. Statistically significant differences were 
observed between wild type, heterozygote and homozygote (p=0.015). The 
heterozygote genotype has the highest rate of events 67% (table 3.9.2., & figure 
3.3. appendix-6 A.6.11.).  
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However febrile events (FNnE) with positive bacterial cultures occurring in the 
absence of neutropenia were found to be highest among the homozygote genotype 
66.67%. There was no significant difference between the wild type and mutant 
genotypes (p=0.48). (table 3.9.3., figure 3.3. & appendix-6 A.6.12.). 
2- Number of febrile events with the diagnosis of proven or probable invasive 
fungal disease (IFD) 
Invasive fungal infections can be categorised as possible, probable or proven.183  
Diagnosis of proven invasive fungal disease (IFD) is made by histopathalogical, 
cytopathalogical or direct microscopic examination of body material and fluids. The 
diagnosis of probable IFD is made by combination of radiological appearance, 
cytology, microscopic examination, culture, BAL and two positive Galactamannan. 
The diagnosis requires host factor, clinical and mycological criterion.183 Given the 
low total number of events in this study proven and probable IFD will be considered 
as one entity. 
Possible IFD is diagnosed when host factors and clinical criterion are present with 
the absence of mycological criterion.183 Since in this group it is common to have 
host and clinical criterion possible IFD is analysed under the category of febrile 
events with negative cultures (see below) analysis as sole entity see appendix-6 
A.6.6. 
If febrile events in a patient had multiple isolates of the same fungal pathogen this 
was considered a continuation of the infection and not a new diagnosis.  
The number of febrile events with proven or probable diagnosis was too small to 
give a clear picture (tables 3.9.1., 3.9.2., 3.9.3., figure 3.3., and Appendix-6 
A.6.10., A.6.11., A.6.12.). 
3- Number of febrile events due to viral isolates  
There were a few documented viral infections as a cause of febrile events possibly 
due to the difficulty in isolating and identify relevant organisms. 
   
 
The proportional febrile events with isolated viruses did not statistically differ 
between the genotypes (tables 3.9.1., 3.9.2., 3.9.3., figure 3.3., and Appendix-6 
A.6.10., A.6.11., A.6.12.). 
4- Number of febrile events of unknown origin (culture negative) 
Febrile events without positive microbial culture including possible IFD diagnosis 
were considered in this category. 
Culture negative febrile events with (FUO) occurred frequently within the 
homozygote genotype 68.75%. There were significant differences between the wild 
type, heterozygote and homozygote genotypes (p=0.029) (table 3.9.1., figure 3.3.  
& appendix-6 A.6.10.). 
Similarly FUO associated with neutropenia were more likely in the homozygote, 
(77%) (p=0.007). Statistically there were significant differences between the wild 
type, heterozygote and homozygote genotypes and between the wild type and 
homozygote (p=0.008) (table 3.9.2, figure 3.3. & appendix-6 A.6.11.). 
Febrile non-neutropenic events showed no significant differences between all 
genotypes (table 3.9.3, figure 3.3. & appendix-6 A.6.12.). 
 
3.6.7.2. Analysis of organism cultured per episode of neutropenia 
Patients who develop neutropenia are prone to develop infections and become 
febrile. However not all patients develop fever whilst neutropenic. The reason for 
this is likely to be multifactorial with involvement of innate and adaptive immunity, 
the regimen of chemotherapy, endogenous colonisation and pathogen exposure. In 
this section the proportion of episodes of neutropenia during which patients 
became febrile for each genotype was calculated. 
There was a statistically significant difference in the number of neutropenic 
episodes with fever due to bacteria between the wild type and mutant populations, 
(wild type: heterozygote: homozygote proportion p= 0.018 and the wild type: 
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homozygote proportion p= 0.004). There were total of 69 (24.47%) episodes with 
positive bacterial growth out of the 282 episodes of neutropenia in the wild type. 2, 
(5.56%) in the homozygote, and (28.15in the heterozygote (table 3.10., figure 3.3. 
& appendix-6 A.6.9.). 
 
Table 3.9.1. Total febrile events regardless neutropenia in different chitotriosidase genotypes, 
and the type of identifiable organism if present. The p value by Chi square and Fisher exact tests: 
compares the wild type: heterozygote: homozygote proportions  
Total febrile events=316 Wild type; 
Total 
events=199 
Mutant;   
Total  
events =117 
Heterozygote; 
Total 
events=101 
Homozygote; 
Total 
events=16 
Total bacterial +ve events 
Bacterial +ve/febrile event % 
P= 0.031 
101 
50.75% 
68 
58.12% 
63 
62.38% 
 
5 
31.25% 
Total fungal +ve events 
Fungal+ve/febrile event % 
P = 0.705 
5 
2.51% 
0 
 
0 
 
0 
 
Total viral +ve events 
Viral +ve/febrile event % 
P = 0.214 
2 
1.01% 
2 
1.71 
2 
1.98 
0 
 
Total culture -ve events 
Culture –ve / febrile event % 
P = 0.029 
91 
45.73% 
47 
40.17 
36 
35.64 
11 
68.75 
 
 
 
Table 3.9.2 Total febrile neutropenic events in different chitotriosidase genotypes, and the type 
of identifiable organism if present. P value by Chi square and Fisher exact tests: compare the wild 
type: heterozygote: homozygote proportions. 
Total febrile neutropenic 
events = 202 
Wild type; 
FNE=126 
Mutant; 
FNE=76 
Heterozygote; 
FNE=63 
Homozygote; 
FNE=13 
Number of bacterial FNE 
Bacterial rate/FNE % 
P =0.015 
74 
58.73% 
 
45 
59.21% 
 
42 
67% 
 
3 
23% 
 
Number of fungal FNE 
Fungal rate / FNE% 
P = 0.609 
2 
1.6% 
 
0 
 
 
0 
 
 
0 
 
 
Number of viral FNE 
Viral +ve / FNE% 
P =  0.393 
1 
0.8% 
 
2 
2.63% 
 
2 
3.2 
 
0 
 
 
Number of culture -ve FNE 
Culture -ve rate / FNE% 
P = 0.007 
49 
38.89% 
 
29 
38.16% 
 
19 
30.16% 
 
10 
77% 
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Table 3.9.3. Total febrile non-neutropenic events in different chitotriosidase genotypes, and the 
type of identifiable organism if present. P value by Fisher exact tests: compares the wild type: 
heterozygote: homozygote proportions . 
Total febrile non-neutropenic events 
= 114 
Wild type 
FNnE=73 
Mutant 
FNnE=41 
Heterozygote 
FNnE=38 
Homozygote 
FNnE=3 
Number of bacterial FNnE 
Bacterial rate/FNnE% 
P = 0.144 
27 
36.98% 
 
23 
56.10% 
 
21 
55.26% 
 
2 
66.67% 
 
Number of fungal FNnE 
Fungal rate / FNnE% 
P =0.585 
3 
4.11% 
0 0 0 
Number of viral FNnE 
Viral +ve / FNnE% 
P =  1.000 
1 
1.36% 
 
0 
 
0 
 
0 
 
Number of culture negative FNnE 
Culture -ve rate / FNnE% 
P = 0.392 
42 
57.53% 
 
18 
43.90% 
 
17 
44.74% 
 
1 
33.33% 
 
 
 
 
Figure 3.3. Analysis of the types of organism cultured per total events (EoN, FN, FNE and 
FNnE) in each genotype. (1-Proportion of events with bacterial growth per chitotriosidase genotype, 
2-proportion of events with fungal growth per genotype, 3-proportion of events with viral infections 
per genotype, 4-proportion events with unidentified organism per genotype) (proportion is a 100 of 
percentage). 
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Table 3.10. Total episodes of neutropenia associated with febrile events in different 
chitotriosidase genotypes, and the type of identifiable organism if present. P values by Fisher exact 
tests compare the wild type: heterozygote: homozygote proportions.  
Episodes of neutropenia with 
febrile events. 
Wild type; Total 
EoN =282 
Mutant; Total 
EoN =171 
Heterozygote; 
Total EoN =135 
Homozygote; 
Total EoN =36 
EoN with bacterial FNE. (%) 
P value = 0.018 
69 
(24.47%) 
40 
(23.39%) 
38 
(28.15%) 
2 
(5.56%) 
EoN with probable/ proven 
fungal FNE. (%). 
P value= 1.000 
2 
(0.71%) 
 
0 
 
0 
 
0 
 
EoN with viral FNE.  
(%). 
P value= 0.412 
1 
(0.35%) 
 
2 
(1.17%) 
2 
(1.46%) 
0 
 
EoN with culture negative 
FNE. (%). 
P value= 0.190 
49 
(17.38%) 
 
30 
(17.54%) 
20 
(14.81%) 
10 
(27.78%) 
 
There was no significant difference between the total episodes of neutropenia due 
to proven and probable IFD, viral infection or culture negative events (table 3.10., 
figure 3.3. & appendix-6 A 6.9.). 
 
3.6.7.3. Analysis of organism cultured per patient 
In this section all patients developing febrile events were categorised according to 
the organism grown in their cultures. This analysis was carried out in the presence 
and/or absence of neutropenia. 
1. Patients with febrile events and cultures positive for bacteria:  
There were 38 wild type (31.15%) patients with febrile neutropenic events due to 
bacterial growth in the cultures and 20 mutant genotype patients (24.39%). The 
heterozygote variant accounted for 18 events (25.35%) while the homozygote 
variant for the other 2 events (18.18%). There were no statistically significant 
differences in the proportions of patients have positive bacterial cultures either 
when neutropenic or not neutropenic by any genotype (table 3.11.1., figure 3.4. & 
appendix-6; A.6.4.). 
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2. Number of patients with febrile events due to fungal pathogens:  
There were too few patients with the diagnosis of proven or probable IFD (and all 
within the wild type group) for full analysis. There were 2 (1.64%) patients with 
neutropenic febrile events and 3 (2.46%) patients in the non-neutropenic events.  
5 (4.10 %) patients had either neutropenic or non-neutropenic febrile events, while 
none had both febrile events with the diagnosis of proven or probable IFD, p=ns 
(table 3.11.2., figure 3.4. & appendix-6 A.6.5.). 
There were no statistically significant differences in the proportions of patients from 
each genotype having febrile neutropenic or non-neutropenic events attributed to a 
possible fungal infection, see appendix-6 A.6.6. 
3. Number of patients with febrile events due to viruses:  
There number of patients with documented viral infections as a cause of febrile 
events was small. The proportional of patients with isolated viruses as a cause of 
fever did not statistically differ between the genotypes (table 3.11.3., figure 3.4. & 
appendix-6 A.6.7.). 
 
Table 3.11.1. Patients with febrile events and positive bacterial cultures. FE in the presence or 
absence of neutropenia, in either or both, in different chitotriosidase genotypes. P values by Fisher 
exact test compare the wild type: heterozygote: homozygote proportions. 
Fever and positive bacterial cultures Wild type; 
Total =122 
Mutant 
Total=82 
Heterozygote 
Total =71 
Homozygote 
Total =11 
Patients with only neutropenic events. 
(%). P = 0.564 
38 
(31.15%) 
20 
(24.39%) 
18 
(25.35%) 
2 
(18.18%) 
Patients with only non-neutropenic 
events. (%). P =0.662 
13 
(10.66%) 
10 
(12.20%) 
8 
(11.27%) 
2 
(18.18%) 
Patients with events either neutropenia 
or non-neutropenic (%). P =0.779 
60 
(49.18%) 
38 
(46.34%) 
34 
(47.89%) 
4 
(36.36%) 
Patients with events, both whilst 
neutropenic & non-neutropenic (%).    
P = 0.503 
9 
(7.38%) 
 
8 
(9.76%) 
 
8 
(11.27%) 
 
0 
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Table 3.11.2. Patients with febrile events and proven or probable IFD. FE whilst neutropenic, 
non-neutropenic, either or both in different chitotriosidase genotypes. P values by Fisher exact test.: 
compare the wild type: heterozygote: homozygote proportions  
Fever with proven and probable IFD Wild type; 
Total=122 
Mutant 
Total=82 
Heterozygote 
Total =71 
Homozygote 
Total =11 
Pts with only neutropenic events. (%). 
P= 0.582 
2 
(1.64%) 
0 0 0 
Pts with only non-neutropenic events. 
(%). P =0.618 
3 
(2.46%) 
0 0 0 
Pts with total events either neutropenia 
or non-neutropenia (%). P = 0.283 
5 
(4.10%) 
0 0 0 
Pts with events, both whilst neutropenia 
& non-neutropenia.  
0 0 0 0 
 
 
Table 3.11.3. Patients with febrile events due to viral pathogens. FE whilst neutropenic, non-
neutropenic, either or both in different chitotriosidase genotypes. P values by Fisher exact test.: 
compare the wild type: heterozygote: homozygote proportions  
Fever and viral positive event Wild type; 
Total=122 
Mutant 
Total=82 
Heterozygote 
Total =71 
Homozygote 
Total =11 
Pts with only neutropenic events. (%). P= 
0.624 
1 
(0.82%) 
2 
(2.44%) 
2 
(2.82%) 
0 
Pts with only non-neutropenic events. 
(%). P = 1.000 
1 
(0.82%) 
0 0 0 
Pts with total events either neutropenia or 
non-neutropenia. (%). P = 0.701 
2 
(1.64%) 
2 
(2.44%) 
2 
(2.82%)     
0 
Pts with fever, both whilst neutropenia 
and non-neutropenia 
0 0 0 0 
 
Table 3.11.4. Patients with febrile events without identifiable organism. FE whilst neutropenic, 
non-neutropenic, either or both in different chitotriosidase genotypes. . P values by Fisher exact 
test.: compare the wild type: heterozygote: homozygote proportions  
Fever and culture -ve event Wild type; 
Total=122 
Mutant 
Total=82 
Heterozygote 
Total pts=71 
Homozygote  
Total =11 
Pts with only neutropenic events. (%). P= 
0.068 
27 
(23.13%) 
14 
(17.07%) 
10 
(14.08%) 
4 
(36.36%) 
Pts with only non-neutropenic events. 
(%). P= 0.243 
18 
(14.75%) 
10 
(12.20%) 
9 
(12.68%) 
1 
(9.90%) 
Pts with total events either neutropenia or 
non-neutropenia. (%). P= 0.058 
59 
(48.36%) 
27 
(32.93%) 
22 
(30.99%) 
5 
(45.45%) 
Pts with fever, both whilst neutropenia 
and non-neutropenia. (%). P= 0.214 
13 
(10.66%) 
3 
(3.66%) 
3 
(4.23%) 
0 
0 
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4. Patients with fever with no identified microorganism: 
Patients with febrile events without positive microbial culture including possible IFD 
diagnosis were considered in this category. 
The number of patients with only febrile neutropenic events and negative cultures 
was higher in the homozygote genotype. In comparing the wild type, heterozygote 
and homozygote, there was a trend towards significance, p=0.068.  
A significantly lower number of heterozygote patients had negative cultures than 
wild type in either neutropenic or non-neutropenic (p=0.018), see appendix-6 A.6.8. 
Patients with mutant chitotriosidase seemed not to exhibit any organism more than 
the wild type (this could be attributed to the small number of patients with 
documented diagnosis of fungal and viral infections). In contrast unidentified cause 
of fever (culture negative and possible IFD) was more prevalent in the wild type. 
 
3.6.8. Course and outcome of the febrile events in relation to 
chitotriosidase gene status 
The outcome of febrile events in different genotypes was analysed, in the presence 
and absence of neutropenia. In the 86 patients carrying the mutant genotype there 
were 76 febrile neutropenic events (FNE). These events comprise 279 febrile 
neutropenic days, 913 days of antimicrobial treatment with a median of 1 and 5 
respectively. Out of the 76 FNE in the mutant genotype 6 FNE necessitate 
Hickman line removal. All of these along with the number of events and patients 
ended with recovery, ITU admission and death showed no statistical significant 
differences in both wild type and mutant genotypes with FNEs (table 3.12.). As in 
the FNEs, the febrile non-neutropenic events (FNnE) showed no differences in the 
course and outcome in relation to events or number of patients. (table 3.12.).  
     
Chitotriosidase mutation showed no effect in the duration of febrile events or 
treatment required. The outcome of such febrile events in the presence or absence 
of neutropenia showed no significant differences. 
 
Table 3.12. Outcome of febrile events in relation to chitotriosidase gene status. (FNE: febrile 
neutropenic event, FNnE: febrile non-neutropenic event, R: treatment, HL: Hickman line, pts: 
patients, ITU: intensive treatment unit). P values calculated by Chi square and Fisher exact tests. 
Course & Outcome FNE= 126:76 FNnE= 73:41 
Genotype Wild 
type=122 
Mutant=86 Wild 
type=122 
Mutant=86 
Total febrile days/genotype 
P= 
551 
0.14 
279 248 
0.44 
159 
Total days of antimicrobial R 
P= 
1704 
0.13 
913 818 
0.25 
463 
Number of febrile events 
necessitated HL removal. 
P= 
12 
9.52% of 126 
0.190 
6 
7.89% of 76  
5 
6.85% of 73  
0.084 
7 
17.07% of 41 
Number of febrile events with 
complete recovery. P= 
118 (93.65%) 
0.768 
73 (96.05%) 66 (90.41%) 
0.133 
33 (80.49%) 
Number of pts with recovered 
febrile events. P= 
68 (55.74%) 
0.190 
40 (45.51%) 
of pts  
42 (34.43%) 
0.239 
23 (26.74%) 
of pts 
Number of febrile events ended in 
ITU. P= 
6 (4.76%) 
0.235 
2 (2.63%) 7 (9.59%) 
0.169 
6 (14.63%) 
Number of pts admitted to ITU 
P= 
6 (4.91%) 
0.195 
2 (2.33%) 5 (4.10%) 
0.215 
5 (5.81%) 
Number of febrile events ended in 
death. P= 
Febrile event : death 
ITU : death 
2 (1.59%) 
0.333 
2 
0 
2 (2.63%) 
 
1 
1 
2 (2.74%) 
0.109 
0 
2 
4 (9.76%) 
 
2 
2 
Number of pts died. 
P= 
2 (1.64%) 
0.356 
2 (2.34%) 2 (1.64%) 
0.195 
4 (4.65%) 
Median 
Fever days per patient 
Antimicrobial R days per patient 
Antimicrobial R days/fever days 
 
2 
9 
4.5 
 
1 
5 
5 
 
0 
0 
0 
 
0 
0 
0 
 
3.7.  Discussion: 
The chitotriosidase gene activities in infections have suggested its possible role in 
defence mechanisms. These activities include chitinlytic activity towards cell wall 
chitin of candida7 and upregulation activity in bacterial infections.98  
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The genes of all known members of chitinase protein family are located on 
chromosome 1 at 1q31-32.106 The frequency of mutation in this study was 40.20% 
in total, the heterozygote mutation accounted for 34.80% and homozygote for 
5.39%. Our figures were similar to previous studies.106, 107  
Several studies have shown predominance of haematological malignancies in 
males52, 184, 185 with either bimodal age of distribution as in leukaemia,51 steep 
increase in the incidence with age as in lymphomas185 or increase over the age of 
50 as seen in multiple myelomas.184 In this study males accounted for 59.31% of 
the haematological malignancies while females for 40.69%. In relation to 
chitotriosidase mutation, the incidence of haematological malignancies was 
56.10% in males and 43.90% in females carrying the mutation. 
Age at the time of diagnosis of haematological malignancy ranged between (18-82 
years). The incidence of haematological malignancy almost doubled above 71 
years from 9.84% in the wild type to 17.07% in the mutant. It is unclear whether 
chitotriosidase mutation aggravates the incidence of haematological malignancy in 
older people or affects the age of presentation. This could be addressed in a 
multivariate analysis of a larger cohort. 
Lymphoma was the most frequent diagnosis in our study. In the patients analysed 
there was a suggestion of worse out come in patients with the mutant 
chitotriosidase in terms of patients with refractory disease or a progressive course 
(mutant 6.10% vs wild type 1.64%).  
Neutropenia is a frequent sequel of myelosuppressive chemotherapeutic 
treatment. The duration of neutropenia is typically 7–10 days with variation as a 
result of the contribution of different factors such as; nature of the disease, intensity 
of the chemotherapeutic regimen and patient factors. These factors affect not only 
the duration but also the incidence of neutropenia.186 In this study neutropenia 
showed no statistical significance in occurrence and duration according to 
chitotriosidase genotype (84.43% and 79.27% in wild type and mutant genotypes 
respectively).  
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Infection resulting in fever occurs in malignancy due to disease associated defects 
affecting the neutrophil functions such as chemotaxis, phagocytosis and 
bactericidal activity. These defects become more pronounced with the fall of 
neutrophil count and render patient susceptible to opportunistic pathogens and 
subsequent morbidity.79  
The number of febrile events was analysed by genotype, and also by presence 
and/or absence of neutropenia. The proportion of patients with febrile events did 
not differ by genotype. Our findings suggest that overall susceptibility to infection 
resulting in fever is not affected by chitotriosidase genotype. Our original 
hypothesis was that defects in macrophage function due to chitotriosidase mutation 
may become more apparent during periods of neutropenia. It may be that longer 
periods of neutropenia are required to detect this effect. 
Studies show that only 10-20% of infections are microbiologically documented with 
identified pathogens in compromised patients.187 Pneumonia and pulmonary 
infiltrates accounts for 15-30% of clinically and/or radiologically documented fevers 
with the majority of these lacking microbiological identification.188 A further 50% are 
considered as fever of unknown origin (FUO)3, 189 and may include conditions such 
as neutropenic entercolitis and perirectal infection.189  
The prevalence of particular classes of microorganism positively detected in febrile 
patients was analysed with respect to chitotriosidase genotype for total number of 
febrile events, episodes of neutropenia and total patients. 
Fungal (proven or probable) and viral infections were too small in number to 
analyse fully.  
The analysis of febrile events in relation to classes of organism showed more 
positive bacterial cultures as well as unidentified causes (culture –ve) in patients 
with mutant chitotriosidase.  
Febrile events regardless neutropenia with positive bacterial cultures were more 
likely to occur in the mutant chitotriosidase genotype, increasingly in the 
   
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heterozygote genotype. While culture negative febrile events were at increase 
occurrence with the homozygote mutation (small group; 11patients). The 
prevalence of these organisms did raise in the presence of neutropenia for both 
mutant chitotriosidase genotypes.   
This finding could reflect the defects in macrophages cytocidal activity against 
microorganisms and the LPS upregulation109, 111, which became more pronounced 
with the presence of neutropenia.  
Innate immunity relies on phagocytic cells for the detection and clearance of any 
pathogen. The inflammatory response varies with different phagocytic cells. Acute 
inflammation with bacterial destruction and minimal cytokine production is carried 
by the neutrophils. While the macrophages are antigen presenting cells causing 
cytokines production and lead to chronic inflammation.179  
Chitotriosidase enzyme is mainly synthesised by macrophages and to lesser extent 
by neutrophilic granulocytes.98, 99 It is also considered a serum marker of 
macrophages activation.109, 114 These may reflect more the macrophages rather 
than the neutrophils status, and so may explain why neutrophils are less affected 
by the chitotriosidase activity. 
The heterogeneity in findings could be explained by the variety of malignancies 
and chemotherapy and the affect they exert on the neutrophils function as well as 
patient factors (age mental status and co-morbid disease).  
Overall the chitotriosidase mutation seems not to affect the course or the outcome 
of febrile events whatever the causative organism is. The duration of febrile event 
and antimicrobial therapy was no different in the genotypes nor outcome of such 
febrile events.  
 
3.8.  Conclusions: 
Our study suggests that mutation in chitotriosidase seems to have: 
     
No effect on the number of episodes of neutropenia or number of neutropenic days 
per patient. 
No effect on the number of febrile events per patient in the presence or absence of 
neutropenia. 
No effect on the in number of febrile events per episode of neutropenia. 
Patients carrying the mutation seem to be more susceptible to bacterial infections 
during the presence or absence of neutropenia.  
Patients with double mutations (homozygote) are more prone to develop febrile 
events with unidentified pathogens in the presence of neutropenia. 
Mutation in chitotriosidase seems to have no effect in overall course and outcome 
of febrile events. 
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Chapter 4 
 
NOD2 as genetic determinant of sepsis in  
haematological malignancy 
 
4.1.  Introduction 
Patients with haematological malignancies are at risk of infections due to defects in 
the bone marrow. Infections could develop due to either the defective neutrophils 
function as seen in acute leukaemia67 or immunological deficits of the underlying 
malignancy, multiple myeloma190 is an example. In addition, myelosuppression 
induced chemotherapy, expose those patients to quantitative neutropenia and the 
susceptibility of infections at unusual sites and by opportunistic pathogens 
considered non pathogenic in immunocompetent host.67 The depth and duration of 
neutropenia can influence type, frequency and severity of infection as well as 
response to therapy and outcome.66 The breakdown of the physical barriers 
externally (skin) and internally (mucous membrane), the use of steroids, and the 
necessity for indwelling catheters all as a part of the treatment, furthermore 
increase the liability to infections in the readily immunosuppressed patients.191, 192  
Sepsis describes clinical syndromes resulting from systemic inflammatory host 
response. The pathophysiological concept of sepsis suggests inappropriate 
immune response with the systemic release of pro-inflammatory and anti-
inflammatory mediators leading to systemic inflammatory response and systemic 
manifestations.78, 79  
Recent studies explored the genetic role in determining sepsis susceptibility, 
severity and outcome.164, 193 A number of genetic polymorphisms (single nucleotide 
     
polymorphisms; SNP) have been identified and were linked to risk of infection, 
organ dysfunction and mortality.164  
The first line of mucosal host defence detects invading pathogens through several 
pattern recognition receptors (PRR). Nucleotide binding oligomerization domain 
(NOD2) is an intracellular protein receptor that induce innate immunity cascade 
events in response to microbial pathogens invasion. It is a specific sensor receptor 
to muramyl dipeptides (MDP), peptidoglycans (PGN) and lipopolysaccharides 
(LPS), motifs derived from gram positive or gram negative bacteria.138, 139, 194 In 
addition NOD2 showed a bactericidal function, this was observed by the direct 
intracellular killing of Salmonella typhimurium in the intestinal epithelial cells.195 The 
bactericidal function was inefficient in patients of CD with the mutant NOD2 
compared to wild type.196 These properties suggest a link between bacterial 
detection, presentation and elimination. NOD2 is expressed in macrophages,131 
dendritic cells,144  intestinal epithelial140 and Paneth cells.145  
Crohns disease (CD) is a chronic inflammatory bowel disease. CD can affect any 
part of the intestine from mouth to anus with patchy transmural lesions.197 
Etiologically, it is a multifactorial polygenic disease with genetic association. Three 
SNPs mutations of NOD2 were identified in 30-50% of CD and 15-20% in healthy 
controls.152 The risk of developing CD is 2-4 fold with heterozygote mutation and 
risk further increases 20-40 folds in individuals with the homozygote mutation.146, 
148, 149
 Recently studies provided evidences suggesting the trigger of inflammation 
in CD is impaired innate immune response to intestinal microbial flora.95, 198 A 
mutation in NOD2 leads to an attenuated NF-κB activity and impaired immune 
response leading to functional impairment of the phagocytic cells, such as the 
impaired bactericidal function by the intestinal epithelial cells in CD associated with 
frameshift 3020insC SNP mutation.195 Other defects in innate immunity seen in CD 
include neutrophil chemotaxis,199 respiratory burst,200 and phagocytosis.201 The 
resemblance of CD to some infections such as intestinal tuberculosis suggested 
the infectious origin of this inflammatory disease, along with the clinical beneficial 
use of antibiotics.152  
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Evidence of impaired innate immune response by CD patients was observed by 
Marks et al. Patients with CD were subjected to intradermal injection of killed 
bacteria and were observed for local and general inflammatory response in 
comparison to healthy controls. CD patients provoked inadequate innate immune 
response, this was suggested by the less blood flow, lower cytokines production 
and reduced neutrophil accumulation at the site of the trauma.202  
Immunosuppression can render an individual more susceptible to infections as 
seen in patients with haematological malignancies. Neutrophils in this patient can 
be inadequate in their function due to the natural process of the disease or low in 
quantity, chemotherapy induced neutropenia. Patients with neutropenia are readily 
liable to infections, however not all neutropenic patients develop infections 
indicating a possible genetic role. The additive effects of inadequate neutrophil 
function, chemotherapy and genetic variation were the basis of our study. 
In this present study we identified the NOD2 status in patients with haematological 
malignancies and relate the impact of NOD2 mutation to the development of 
infection and sepsis. Evaluation of sepsis was studied in the same group of 
patients in relation to absolute neutrophil count (neutropenic or non-neutropenic), 
the causative organism, and outcome. 
 
4.2.  Hypothesis: 
Our hypothesis is that patients carrying mutations in NOD2, a gene mediating 
innate immunity, are at increased risk of infection and sepsis during periods when 
they are neutropenic. 
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4.3.  Objectives: 
1)  To determine the effect of NOD2 status on the incidence and 
outcome of sepsis in patients with haematological malignancy, including 
those with leukaemia, lymphoma, and myeloma.  
2)  To compare the effect of NOD2 status on the incidence and outcome 
of sepsis in patients with haematological malignancy who are 
neutropenic and those who are not. 
3) To examine the effect of NOD2 status on the prevalence of 
organisms in neutropenic and non-neutropenic patients with 
haematological malignancies. 
4)  Correlate duration of neutropenia with the NOD2 status. 
 
4.4.  Materials and methods: 
General material and methods are described in Chapter 2. 
Inclusion and exclusion criteria are also described in chapter 2. 
Recruitment of patients with haematological malignancy was performed in the 
Royal Free Hospital.  
The study was ethically approved by the central office for research ethics 
committees (REC Ref: 06/Q0501/56-Date 3/4/06. R&D ID:7414-Date 28/6/08). All 
patients gave informed consent. They were followed up during their in-patient stay.  
Clinical data were collected daily by the clinical fellow. Observations were recorded 
including ANC, temperature, related investigations (microbial and imaging) to 
determine the source and type of sepsis, and antimicrobial management. 
Investigation and data of patients recruited from the out-patient department or after 
patients discharge were recorded electronically or from paper medical records by 
the clinical research fellow (LS).  
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The number of patients included in this study was 201 from the 204 patients 
meeting the inclusion criteria. Exclusion of the three samples was due to low 
concentration and insufficient amount of DNA. These samples could not be 
replaced as 2 patients were deceased and one received allogenic BM transplant 
(BMTx). 
DNA was extracted from whole blood. NOD2 identification was carried out initially 
by gene scanning alternatively and due to technical difficulties this was replaced by 
pyrosequencing. Detection of SNP8 and SNP12 mutation (insertion) was 
successful by pyrosequencing. The SNP13 mutation (deletion/frameshift) was not 
included as the pyrosequencing software was not designed for deletion 
identification.Another reason and due to time limitation an alternative instituite or 
labratory could not be considered. Methods in detail are mentioned in chapter 2. 
 
4.5.  Statistics: 
The p value was calculated by the Chi square, and by Fisher exact if figures  10 if 
comparing two dimensions. The p value of 0.05 considered significant. 
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calculated between the wild type and mutant proportion. Mean, median were 
calculated along with graphs were prepared using Microsoft excel. 
 
4.6.  Results: 
4.6.1.  Incidence of NOD2 mutation: 
Mutation: Out of the 201 patients, 184 (91.54%) were wild type for NOD2 and 17 
(8.46%) were mutant. Of the 17 mutant genotype patients 7 (41.18%) were 
heterozygote for SNP 8. There was 12 patients with SNP 12 mutation, 11 (64.71%) 
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heterozygote and 1 (5.88%) homozygote for the mutation. 2 patients exhibited 
compound heterozygosity for SNP 8 and 12 (table 4.1.). 
In this study population, frequency of mutation was 3.48% heterozygosity for 
SNP8. While SNP12 frequent occurrence was 5.47% heterozygosity and 0.50% 
homozygosity for the mutation. 
 
4.6.2.  Demographic characteristics: 
A total of 201 patients were included in this section of the study. Males accounted 
for 59.20% and females for 40.80%. The age ranged between 18-81 years at the 
time of diagnosis (table 4.2.). No statistical differences were found in the gender, 
age or diagnosis distribution between NOD2 genotypes. 
 
Table 4.2.  Demographic characteristics in the study population. The number of patients and 
proportion by sex and age at diagnosis of haematological malignancy in relation to NOD2 status.  
(M: male, F: female). P value calculated by Fisher exact. 
NOD2 
status 
Sex Age at diagnosis 
 M F 18-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 
Total;201 
% 
119 
59.20 
82 
40.80 
5 
2.50 
19 
9.45 
24 
11.94 
28 
13.93 
52 
25.87 
47 
23.38 
23 
11.44 
3 
1.49 
Wild type; 
184 
91.54% 
111 
59.68 
73 
39.25 
5 
2.72 
17 
9.24 
23 
12.5 
26 
14.13 
46 
25 
43 
23.36 
22 
11.96 
2 
1.09 
Mutant; 17 
8.46% 
8 
47.06 
9 
52.94 
0 
0 
2 
11.77 
1 
5.88 
2 
11.77 
6 
35.29 
4 
23.53 
1 
5.88 
1 
5.88 
P= Mutation M:F  
= 0.209 
0.699 0.288 0.265 0.288 0.140 0.233 0.279 0.215 
 
Genotype 
 
SNP8 (%) SNP12 (%) 
Heterozygote 7 (3.48) 11 (5.47) 
Homozygote 0 1 (0.55) 
Table 4.1.  
The frequency of NOD2-SNPs mutations In 
201 DNA samples, the only homozygote 
mutation was in SNP 12. (2 patients 
exhibited compound heterozygosity for SNP 
8 and 12). 
     
Table 4.3. Diagnosis with different haematological malignancies in our study population. The 
number of patients and frequencies (%) in total in relation to NOD2 status. P value calculated by 
Fisher exact. 
NOD2 status Diagnosis 
 Lymphoma Multiple 
myeloma 
Acute 
Leukaemia 
Chronic 
Leukaemia 
Other 
Total 201; (%) 106 (52.74%) 32 (15.92%) 50 (24.88%) 11 (5.47%) 2 (0.99%) 
Wild type; 184 
(91.54%) 
97 (52.72%) 30 (16.30%) 47 (25.54%) 8 (4.35%) 2 (1.09%) 
Mutant; 17 (8.46%) 9 (52.94%) 2 (11.76%) 3 (17.65%) 3 (17.65%) 0 
P= 0.594 0.262 0.193 0.046 0.838 
 
 
 
 
 
Figure 4.1. 
 
Diagnosis of 
different 
haematological 
malignancies. 
Frequencies in 
relation to NOD2 
genotype. 
 
 
4.6.3.  Range of Diagnoses 
In this study population the diagnosis of all types of haematological malignancies 
showed no statistical significance except for chronic (lymphoblastic and myeloid) 
leukaemia. There were a small number of patients with lymphocytic or myeloid 
leukaemia and so we gathered all types into acute and chronic leukaemia. NHL 
accounted for 8 (47.06%) cases while AML (17.65%) accounted for all of acute 
leukaemia in the mutant NOD2. Chronic leukaemia (lymphoblastic and myeloid) 
     
diagnosis was higher in the mutant NOD2 with statistical significance, p=0.046 
(table 4.3. & figure 4.1.).  
 
Table 4.4. Outcome of the patients included in the study in relation to NOD2 gene status. (CR: 
complete remission, PR: partial remission, Allo: allogenic transplant, On R: still on treatment at last 
follow up). P value calculated by Fisher exact. 
NOD2 status Outcome 
 CR PR Allo Death On R Relapse Progressive 
Total 201;  
(%) 
60 
29.85% 
42 
20.90% 
32 
15.92% 
34 
16.91% 
17 
8.46% 
9 
4.48% 
7 
3.48% 
Wild type; 184 
(91.54%) 
54 
29.35% 
40 
21.74% 
29 
15.76% 
33 
17.94% 
14 
7.61% 
7 
3.80% 
7 
3.80% 
Mutant; 17 
(8.46%) 
6 
35.29% 
2 
11.76% 
3 
17.65% 
1 
5.88% 
3 
17.65% 
2 
11.76% 
0 
0 
P= 0.184 0.175 0.245 0.142 0.120 0.140 0.533 
 
 
 
Figure 4.2. 
 
Outcome of 
haematological 
malignancies in 
the study 
population in %, 
in relation to 
NOD2 
genotype.
4.6.4. Outcome of the haematological malignancy in relation to NOD2 
status 
Out of the total 201 patients, 29.85% entered complete remission, 15.92% ended 
receiving allogenic BMTx and 4.48% relapsed while the study was in progress. The 
different outcomes did not show any significant differences between NOD2 
   
 
genotypes. CR, allogenic transplant and relapse, p=0.184, 0.245 and 0.140 
respectively (table 4.4. & figure 4.2.). 
 
4.6.5.  Analysis of episodes of neutropenia (EoN): 
Neutropenia is known to occur with haematological malignancies, and additionally 
is common side effect of chemotherapy. Absolute neutrophil count of 0.5x109/L and 
duration longer than (7-10 days) increases the patient liability to infections. In this 
section neutropenia was analysed according to; incidence and duration for each 
genotype. We also looked into the number of patients per genotype developing 
neutropenia and the frequency of neutropenic episodes in these patients. 
4.6.5.1. Number of patients with neutropenic episode per genotype: 
The total number of patients developing episodes of neutropenia in the wild type 
was 153 out of 184 patients (83.15%) whilst in the mutant genotype 12 out of the 
17 patients (70.59%) became neutropenic during their treatment. There were no 
statistically significant differences between the NOD2 genotypes, (table 4.5.). 
4.6.5.2. Number of neutropenic episodes per genotype: 
There were 450 episodes of neutropenia in total, 419 episodes out of the 450 
occurred in patients carrying the wild type NOD2, while 31 out of the 450 in the 
mutant genotype patients. There was no statistical difference in the proportion of 
each genotype exhibiting episodes of neutropenia (table 4.6.). 
4.6.5.3. Duration of neutropenic episode: 
The duration of neutropenic episodes varied. We calculated the total number of 
days of neutropenia for each genotype, to evaluate if NOD2 mutation affected the 
time to neutrophil regeneration.  The total neutropenic days per genotype were as 
follow, wild type 4006 and mutant genotype 262 with no statistical differences 
(table 4.6.). Although range of neutropenic days per patient was longer in the wild 
     
type the median of neutropenic days per patient and the median of neutropenic 
days per episode did not differ between NOD2 genotypes (table 4.6.). 
 
Total patients = 
201 
Wild type =  
184 
Mutant =  
17 
Total patients (%) (91.54%) (8.46%) 
Pts with EoN in each 
genotype (p= 0.196) 
153 
(83.15%) 
12 
 (70.59%) 
Table 4.5.  
Total number of patients (Pts) 
and total patients with 
episodes of neutropenia (EoN) 
in each NOD2 genotype.  % of 
neutropenic patients within 
each genotype. P value 
calculated by Chi square 
 
Total episodes of neutropenia   
= 450 
Wild type  Mutant  
Total pts / genotype 184 17 
Total neutropenic episodes 
P (wild type: mutant)=0.16 
419 31 
Total neutropenic days 
P (wild type: mutant)=0.12 
4006 262 
Range  
Episodes of neutropenia / pt 
Neutropenic days per patient 
 
0-13 
0-218 
 
0-6 
0-78 
Median 
Episodes of 
neutropenia/patient 
Neutropenic days/patient 
Day/episode 
 
2 
10 
5 
 
2 
10 
5 
 
 
 
 
Table 4.6.  
Episodes of neutropenia 
(EoN) analysed by different 
NOD2 genotypes. P value 
calculated by t-test. 
 
4.6.6.  Analysis of febrile events: 
Fever of 38.5°C on one occasion or fever of 38°C on two occasions was diagnosed 
as infective febrile event and is a call for initiation of antibiotic cover. 
Occurrence of infection was analyzed in this section to determine if NOD2 mutation 
has any effect on such event occurrences. First we analysed the incidence of 
febrile events per genotype then the number of patients in each genotype who 
development such febrile events in the presence and/or absence of neutropenia.  
4.6.6.1 Febrile neutropenic events (FNE):   
   
 
The total number of febrile events was 309; 281 febrile events occurred during 
neutropenia while 28 occurred in the absence of neutropenia (table 4.7.). 
There were no statistical differences in the number of patients developing febrile 
events, neutropenic, non-neutropenic, or both for all NOD2 genotypes (table 4.7.). 
The number of febrile neutropenic event per episode or neutropenic days showed 
no statistical differences and was the same in all NOD2 genotypes (table 4.8.). 
4.6.6.2. Febrile non-neutropenic events (FNnE):  
The number of patients with febrile events not associated with neutropenia was 69 
out of the 184 in the wild type (37.5%) and 6 out of the 17 in the mutant genotype 
(35.29%). There was no statistical difference between NOD2 genotypes (table 
4.7.).  
The number of febrile neutropenic event per episode or neutropenic days showed 
no statistical differences and was the same in NOD2 genotypes (table 4.9.). 
4.6.6.3. Analysis of patients developing either febrile event:  
There was no statistical significance in the number of patients who developed a 
febrile event either with the presence or absence of neutropenia in NOD2 
genotypes, (table 4.7.). 
4.6.6.4. Analysis of patients developing both febrile events:  
The Number of patients developing febrile events both while they are neutropenic 
and non-neutropenic during their course of therapy showed no significant statistical 
differences (table 4.7.). 
 
4.6.7. Analysis of the types of organism cultured  
The likelihood of having positive cultures with a particular organism (bacteria, virus, 
fungus or unidentified organism) was analysed according to the number of febrile 
     
events, the number of episodes of neutropenia and the number of patients within 
each genotype. 
 
Total Wild type Mutant 
Total pt 201 (%) 184 (91.54%) 17 (8.46%) 
Total Febrile events 309 
(%;events genotype/total 
event) 
281 
(90.94%) 
28 
(9.06%) 
Total 196 FNE (%;events 
genotype/total event) 
178    
(90.82%) 
18        
(9.18%) 
Total 113 FNnE (%;events 
genotype/total event) 
103     
(91.15%) 
10        
(8.85%) 
Pts with FNE (% pts of FNE/ 
genotype pts). P = 0.436 
101    
(54.89%) 
11      
(64.71%) 
Pts with FNnE (% pts of 
FNnE/ genotype pts). P = 
0.857 
69        
(37.5%) 
6        
(35.29%) 
Pts with either febrile events 
P = 0.723 
84      
(45.65%) 
7        
(41.18%) 
Pts with both febrile events. 
P = 0.613 
44      
(23.91%) 
5        
(29.41%) 
Table 4.7.  
Total febrile events in each 
genotype.  Proportions of 
patients (Pts) out of each 
NOD2genotype with febrile 
events whilst neutropenic 
(FNE), non-neutropenic 
(FNnE), either (FNE or FNnE) 
or both febrile events (FNE 
and FNnE). P value calculated 
by the Chi square or Fisher 
exact test when figures are    
10, P value compares the wild 
type: mutant proportions.  
 
 
Total febrile neutropenic 
events = 196 
Wild type Mutant 
Number of febrile neutropenic 
events. P (wild type: 
mutant)=0.38 
178 18 
Range per patient 0-7 0-4 
Median 
Number of events/patient 
Event/episode of neutropenia 
Event/neutropenic days 
 
1 
0.5 
0.1 
 
1 
0.5 
0.1 
 
 
Table 4.8.  
Number of febrile neutropenic 
events (FNE) analysed by 
different NOD2 genotypes. P 
value calculated by t-test. 
 
Total febrile non-neutropenic 
events=113 
Wild type Mutant 
Number of febrile non-
neutropenic events 
P (wild type: mutant)=0.45 
103 10 
Range per pt 0-6 0-2 
Median;  
Number of events per pt 
 
0 
 
0 
 
Table 4.9.  
Number of febrile non-
neutropenic events (FNnE) 
analysed by different NOD2 
genotypes. P value calculated 
by t-test. 
 
     
4.6.7.1. Analysis of organism cultured per febrile events in the presence 
and/or absence of neutropenia. 
Here we calculate the number of febrile events in relation to isolated organism, in 
order to evaluate organism prevalence in NOD2 genotypes in the presence and/or 
absence of neutropenia. 
1- Number of febrile events with positive bacterial culture 
Diagnosis of positive bacterial culture was considered if patients grew positive or 
gram negative bacteria from their blood or central line with the presence of fever, 
with or without neutropenia. If a patient with multiple febrile events grew the same 
organism within 5 days with or without neutropenia then this was considered as the 
same infection and not a new febrile event. 
Febrile events with positive bacterial culture occurred in frequency of 80% in the 
mutant genotype compared to 40.78% in the wild type NOD2, these differences 
were highly significant in the absence of neutropenia (p=0.017). While this was not 
the case in febrile events associated with neutropenia or regardless and positive 
bacterial growth (table 4.10.1., 4.10.2., 4.10.3.). 
2- Number of febrile events with the diagnosis of proven or probable invasive 
fungal disease (IFD) 
Invasive fungal infections can be categorised as possible, probable or proven.183 
Diagnosis of proven IFD is made by histopathalogical, cytopathalogical or direct 
microscopic examination of body material and fluids. The diagnosis of probable 
IFD is made by combination of radiological appearance, cytology, microscopic 
examination, culture, BAL and two positive Galactamannan. The diagnosis 
requires host factor, clinical and mycological criterion.183 Given the low total 
number of events in this study proven and probable IFD will be considered as one 
entity. 
Possible IFD is diagnosed when host factors and clinical criterion are present with 
the absence of mycological criterion.183 Since in this group it is common to have 
    
host and clinical criterion possible IFD is analysed under the category of febrile 
events with negative cultures. If febrile events in a patient had multiple isolates of 
the same fungal pathogen this was considered a continuation of the infection and 
not a new diagnosis.  
The number of febrile events with proven or probable diagnosis was too small to 
give a clear picture (tables 4.10.1., 4.10.2., 4.10.3.). 
3- Number of febrile events due to viral isolates  
There were a few documented viral infections as a cause of febrile events possibly 
due to the difficulty in isolating and identify relevant organisms. 
The proportional febrile events regardless neutropenia with isolated viruses 
showed a trend (p=0.061) with occurrence of 7.14% in the mutant genotype 
compared to 1.07% in the wild type NOD2 genotype (tables 4.10.1., 4.10.2., 
4.10.3.).  
4- Number of febrile events of unknown origin (culture negative) 
Febrile events without positive microbial culture including possible IFD diagnosis 
were considered in this category. 
There were statistical differences (p=0.029) in the febrile events in the absence of 
neutropenia with unidentified organism between NOD2 genotypes. Such events 
occurred in frequency of 20% and 55.34% in NOD2 mutant and wild type 
respectively (table 4.10.1, table 4.10.2, table 4.10.3) 
Mutant NOD2 genotype and febrile events with the absence of neutropenia 
showed statistical significance. These events were related to mutant genotype in 
opposite way. Infection due to bacterial growth was high in incidence in the mutant 
NOD2, while fever with unidentified organism was lower in occurrence in the same 
genotype (table 4.10.3.).  
A trend of significance was also shown in the mutant genotype in febrile events 
regardless neutropenia and viral isolates (table 4.10.1.). 
     
Total febrile events=309 Wild type; Total 
events=281 
Mutant; Total 
events =28 
Total bact +ve events 
Bacterial +ve/febrile event 
% 
P value 0.396 
147 
52.31% 
17 
60.71% 
Total fung +ve events 
Fungal+ve/febrile event % 
P value 0.620 
5 
1.78% 
0 
Total viral +ve events 
Viral +ve/febrile event % 
P value 0.061 
3 
1.07% 
2 
7.14% 
Total culture -ve events 
Culture –ve / febrile event % 
P value 0.196 
126 
44.84% 
9 
32.14% 
 
Table 4.10.1.  
Total febrile events regardless 
neutropenia in different NOD2 
genotypes, and the type of 
identifiable organism if 
present. P value compare the 
wild type: mutant proportion. 
P value calculated by Chi 
square or Fisher exact for 
figures    10.  
 
Total febrile neutropenic 
events =196 
Wild type; 
FNE=178 
Mutant; 
FNE=18 
Number of bact FNE 
Bacterial rate/FNE % 
P value 0.461 
105 
59.55% 
 
9 
50% 
 
Number of fung FNE 
Fungal rate / FNE% 
P value 0.824 
2 
1.12% 
 
0 
 
 
Number of viral FNE 
Viral +ve / FNE% 
P value  0.229 
2 
1.12% 
 
1 
5.56% 
 
Number of culture -ve FNE 
Culture -ve rate / FNE% 
P value 0.992 
69 
38.76% 
 
7 
38.89% 
 
 
 
Table 4.10.2.  
Total febrile neutropenic 
events in different NOD2 
genotypes, and the type of 
identifiable organism if 
present. P value calculated by 
Chi square or Fisher exact for 
figures    10, compares the 
wild type: mutant proportion. 
 
Total febrile non-neutropenic 
events =113 
Wild type 
FNnE=103 
Mutant 
FNnE=10 
Number of bact FNnE 
Bacterial rate/FNnE% 
P value 0.017 
42 
40.78% 
 
8 
80% 
 
Number of fung FNnE 
Fungal rate / FNnE% 
P value 0.830 
2 
1.94% 
0 
Number of viral FNnE 
Viral +ve / FNnE% 
P value  0.912 
1 
0.97% 
 
0 
 
Number of culture negative 
FNnE 
Culture -ve rate / FNnE% 
P value 0.029 
57 
55.34% 
 
2 
20% 
 
 
 
Table 4.10.3.  
Total febrile non-neutropenic 
events in different NOD2 
genotypes, and the type of 
identifiable organism if 
present. P value calculated by 
Chi square or Fisher exact for 
figures    10, compares the 
wild type: mutant proportion. 
 
     
Episodes of neutropenia with febrile 
events. 
Wild type; 
Total EoN=419 
Mutant; Total 
EoN=31 
EoN with bacterial FNE. (%) 
P = 0.128 
98 
(23.39%) 
9 
(29.03%) 
EoN with probable/ proven fungal 
FNE. (%).  
P= 0.867 
2 
(0.48%) 
0 
EoN with viral FNE. (%). 
P v= 0.180 
2 
(0.48%) 
1 
(3.22%) 
EoN with culture negative FNE. (%). 
P v= 0.128 
70 
(16.71%) 
7 
(22.58%) 
 
Table 4.11. 
Total episodes of 
neutropenia associated 
with febrile events in 
different NOD2 
genotypes, and the type 
of identifiable organism 
if present. P values by 
Fisher exact tests 
compare the wild type: 
mutant proportions.  
 
 
4.6.7.2. Analysis of organism cultured per episode of neutropenia 
Patients with neutropenia can easily become febrile with the exposure to different 
organisms and the development of infections.  
In this section the proportion of episodes of neutropenia during which patients 
became febrile for each genotype was calculated. 
There were no statistical differences in the number of neutropenic episodes with 
fever due to any organism between NOD2 genotypes. All infections with pathogens 
such as bacteria, virus, fungal or even when cultures were negative to any growth 
were considered in this section (table 4.11., figure 4.3.). 
 
4.6.7.3. Analysis of organism cultured per patient 
In this section all patients developing febrile events were categorised according to 
the organism grown in their cultures. This analysis was carried out in the presence 
and/or absence of neutropenia. 
Number of patients with febrile event and identified or unidentified cause of such 
events showed no statistical differences in NOD2 genotypes in the presence of 
neutropenia.  
     
A trend of significance was seen in fever with positive bacterial culture in the 
absence of neutropenia in patients carrying the mutant genotype (table 4.12.1, 
4.12.2., 4.12.3., 4.12.4.). 
 
 
Figure 4.3. Analysis of the types of organism cultured per total events (EoN, FN, FNE and 
FNnE) in each genotype. (1-Proportion of events with bacterial growth per NOD2 genotype, 2-
proportion of events with fungal growth per genotype, 3-proportion of events with viral infections per 
genotype, 4-proportion events with unidentified organism per genotype) (proportion is a 100 of 
percentage). 
 
Fever and positive bacterial cultures Wild type; 
Total pts= 184 
Mutant; Total 
pts= 17 
Patients with only neutropenic 
events. (%). P = 0.212 
52 
(28.26%) 
4 
(23.53%) 
Patients with only non-neutropenic 
events. (%).  
P =0.082 
19 
(10.33%) 
4 
(23.53%) 
Patients with events either 
neutropenia or non-neutropenic (%).  
P =0.00 
86 
(46.74%) 
0 
Patients with events, both whilst 
neutropenic & non-neutropenic (%).   
P = 0.271 
15 
(8.15%) 
2 
(11.76%) 
 
Table 4.12.1.      
Patients with febrile 
events and positive 
bacterial cultures. FE 
in the presence or 
absence of 
neutropenia, in either 
or both, in different 
NOD2 genotypes. P 
values by Fisher exact 
test compare the wild 
type: mutant 
proportions. 
     
 
Fever with proven and probable IFD Wild type; 
Total pts= 184 
Mutant; Total 
pts= 17 
Pts with only neutropenic events. 
(%). P= 0.838 
2             
(1.09%) 
0 
Pts with only non-neutropenic 
events. (%). P =0.766 
3             
(1.63%) 
0 
Pts with total events either 
neutropenia or non-neutropenia (%).  
P = 0.640 
5 
(2.72%) 
0 
Pts with events, both whilst 
neutropenia & non-neutropenia.  
0 0 
Table 4.12.2. 
Patients with febrile 
events and proven or 
probable IFD. FE 
whilst neutropenic, 
non-neutropenic, 
either or both in 
different 
NOD2genotypes. P 
values by Fisher exact 
test compare the wild 
type :mutant 
proportions  
 
Fever and viral positive event Wild type; 
Total pts= 184 
Mutant; Total 
pts= 17 
Pts with only neutropenic events. 
(%). P= 0.215 
2          
(1.09%) 
1        (5.88%) 
Pts with only non-neutropenic 
events. (%). P = 0.915 
1 0 
Pts with total events either 
neutropenia or non-neutropenia. (%). 
P = 0.263 
3 
(1.63%) 
1 
(5.88%) 
Pts with fever, both whilst 
neutropenia & non-neutropenia 
0 0 
Table 4.12.3. 
Patients with febrile 
events due to viral 
pathogens. FE whilst 
neutropenic, non-
neutropenic, either or 
both in different NOD2 
genotypes. P values 
by Fisher exact test 
compare the wild type 
:mutant proportions  
 
 
Fever and culture -ve event Wild type; 
Total pts= 
184 
Mutant;     
Total pts=     
17 
Pts with only neutropenic events. (%) 
P= 0.249 
37 
(20.11%) 
3 
(17.65%) 
Pts with only non-neutropenic events. 
(%). P= 0.211 
27 
(14.67%) 
1 
(5.88%) 
Pts with total events either 
neutropenia or non-neutropenia. (%) 
P= 0.118 
79 
(42.93%) 
5 
(29.41%) 
Pts with fever, both whilst neutropenia 
& non-neutropenia. (%). P= 0.379 
14 
(7.61%) 
1 
(5.88%) 
Table 4.12.4.  
Patients with febrile 
events without 
identifiable organism. 
FE whilst neutropenic, 
non-neutropenic, 
either or both in 
different 
chitotriosidase 
genotypes. . P values 
by Fisher exact test 
compare the wild type 
: mutant proportions  
 
 
 
 
 
 
   
 
Table 4.13. Outcome of febrile events in relation to NOD2 gene status. (FNE: febrile 
neutropenic event, FNnE: febrile non-neutropenic event, R: treatment, HL: Hickman line, pts: 
patients, ITU: intensive treatment unit). P values calculated by Fisher exact and t-tests. 
Course & Outcome FNE= 686:102 FNnE= 103:10 
Genotype Wild type= 
184 
Mutant= 17 Wild type= 
184 
Mutant= 17 
Total febrile days/genotype 
P= 
686 
0.191 (t-test) 
102 368 
0.500 
34 
Total days of antimicrobial R 
P= 
2269 
0.294 
257 1157 
0.475 
104 
Number of febrile events 
necessitated HL removal. 
P= 
15 
8.43% of 178 
0.284 (Fisher) 
2 
11.11% of 
18 
9 
8.74% of 103 
0.061 
3 
30% of 10 
Number of febrile events with 
complete recovery. P= 
169 (94.94%) 
0.267  
16 
(88.89%) 
89 (86.41%) 
0.606 
9 (90%) 
Number of pts with recovered 
febrile events. P= 
95 (51.63%) 
0.378 
10 
(58.82%) 
59 (32.06%) 
0.212 
5 (29.41%) 
Number of febrile events ended in 
ITU. P= 
6 (3.37%) 
0.133 
2 (11.11%) 12 (11.65%) 
0.398 
1 (10%) 
Number of pts admitted to ITU 
P= 
6 (3.26%) 
0.118 
2 (11.76%) 5 (2.72%) 
0.333 
1 (5.88%) 
Number of febrile events ended in 
death. P= 
Febrile event : death 
ITU : death 
4 (2.25%) 
0.678 
 
3 
1 
0 6 (5.82%) 
0.566 
 
3 
3 
0 
Number of pts died. 
P= 
4 (2.17%) 
0.700 
0 6 (3.26%) 
0.584 
0 
Median 
Fever days per patient 
Antimicrobial R days per patient 
Antimicrobial R days/fever days 
 
1 
7 
7 
 
1 
10 
10 
 
0 
0 
0 
 
0 
0 
0 
 
4.6.8. Course and outcome of the febrile events in relation to NOD2 
gene status 
The outcome of febrile events in different genotypes was analysed, in the presence 
and absence of neutropenia. In the 17 patients carrying the mutant genotype there 
were 18 febrile neutropenic events (FNE). These events comprise 102 febrile 
neutropenic days, 257 days of antimicrobial treatment with a median of 1 and 10 
respectively. Out of the 18 FNE in the mutant genotype 2 FNE necessitate 
Hickman line removal. All of these along with the number of events and patients 
     
ended with recovery, ITU admission and death showed no statistical significant 
differences in both wild type and mutant genotypes with FNEs (table 4.13.).  
The febrile non-neutropenic events (FNnE) necessitated Hickman line removal 
were higher in the mutant NOD2 (30%) compared to wild type (8.74%). These 
differences showed a trend of significance, p=0.061. 
Otherwise as in the FNE, the febrile non-neutropenic events (FNnE) showed no 
differences in the course and outcome in relation to events or number of patients 
(table 4.13.). 
NOD2 mutation showed no effect in the duration of febrile events or treatment 
required. The outcome of such febrile events showed no significant differences in 
the presence of neutropenia.  
 The same outcome was seen in the absence of neutropenia, except with the 
number of febrile events necessitated Hickman removal as a part of management 
in the mutant NOD2.  
 
4.7.  Discussion  
The cytoplasmic localization of NOD2, provides the cellular compartment 
protection against invasive bacterial organisms by a variety of mechanisms.134 
Three major polymorphisms (L1007fsinsC, Arg702Trp and Gly908Arg) within the 
NOD2-LRR region have been identified and genetically associated with CD in both 
European and American populations.4, 5, 130, 149 
In this study the aim was to look in the three major variants of NOD2 in relation to 
sepsis. The frameshift L1007fsins (SNP13) was eventually not included due to 
technical difficulties; software designed only for missense detection not the 
frameshift mutation.  
The incidence of the NOD2 mutation had been investigated by different groups in 
relation to ethnic and geographical factors. The mutation rate was highest in 
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Belgium and Canada and lowest in Finnish populations. While it was absent in 
Japanese, Korean and Han Chinese populations.147 NOD2 mutation have been of 
interest to investigators relating frequency of mutations in general population and 
CD.130, 149  
The incidence of mutation in our study population (201 patients of multiethnic 
background), was 8.46%. The heterozygote state accounted for 3.48% and 5.47% 
for SNP8 and SNP12 respectively. Homozygote mutations accounted for (0.50%), 
and that occurrence was in SNP12. While compound heterozygosity for both SNPs 
occurred at rate of 0.99% in our study population. 
This finding falls between the frequency of NOD2 mutations found by various 
investigators.130, 146, 149, 152 the incidence of Arg702Trp (SNP8) varies between 
4.5147-2.7151 and Gly908Arg (SNP12) was 5.5203-0.6149, which is compatible with 
our finding. 
Several studies have looked into occurrence of malignancy and NOD2 mutation, 
but most looked in the frameshift L1007fsinsC variant (SNP13). Malignancies such 
as colorectal,204, 205 breast,206, 207 and NHL208 were all associated with L1007fsinsC. 
While gastric lymphoma in H pylori infected patients was associated with the three 
major polymorphisms of NOD2.209 In this study NOD2 mutation (Arg702Trp (SNP8) 
and Gly908Arg (SNP12)) showed a significant association with chronic leukaemia 
(all types of chronic leukaemia). There were 17.65% (three cases) in the NOD2 
mutation genotype compared to 4.35% in the wild type genotype in our study 
population. The chronic leukaemia patients were all mutant for SNP8, and one was 
carrying double allele for SNP8 and SNP12. This association with Arg702Trp 
(SNP8) requires verification in a larger based study.   
There was no impact on the diagnosis of haematological malignancies in relation to 
sex or age distribution. The NOD2 mutation also did not seem to affect the course 
and outcome of haematological malignancy. 
Bone marrow suppression can readily occur as a result of the haematological 
malignancy itself , as well as the myelosuppressive chemotherapeutic effect.210 
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Neutropenia, the fall of absolute neutrophil count, ANC  500 cell/mm3, is a 
frequent side effect of chemotherapy. Neutropenia as well as the duration of 
neutropenia  ( 7-10 days) are important parameters for infection severity, 
frequency, treatment  and outcome.210, 211 In this study neutropenia showed no 
significant differences in occurrence and duration according to NOD2 genotypes. 
In recent years the role of genetic factors determining the susceptibility to sepsis 
and the severity of the disease has been explored. The intracellular protein (NOD2) 
contributes to antibacterial effects through a variety of mechanisms, including 
cytokine responses, production of reactive oxygen species, upregulation of 
antimicrobial peptides, altered intracellular trafficking and enhanced killing of 
intracellular microbes.212 Mutations of genes involved in the innate immune system 
(NOD2) have been reported to be associated with an increased sepsis rate in 
adults164 and very low birth weight infants.163  
Infection and resulting fever occurs in malignancy due to defects in the neutrophil 
phagocytic bactericidal activity functions. These defects become more pronounced 
with the chemotherapy induced neutropenia rendering such patients more 
susceptible to opportunistic pathogens.213 Our hypothesis is that defects in 
macrophages function due to NOD2 mutation may become apparent during 
periods of neutropenia.  
The number of febrile events was analysed by NOD2 genotype, and also presence 
and/or absence of neutropenia. The proportion of patients with febrile events did 
not differ by NOD2 status. Our findings suggest that overall susceptibility to 
infection resulting in fever is not affected by NOD2 genotype. It may be that longer 
periods of neutropenia are required to detect this defect. 
Microbiologically documented infections with identified organisms accounted for 
only 10-20% of all episodes of fever.214 Pneumonia and pulmonary infiltrates 
accounted for 15-30% of clinically and/or radiologically documented fevers.215 The 
other 50% were considered as fever of unknown origin (FUO).216 The prevalence 
of particular classes of microorganism positively detected in febrile patients was 
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analysed with respect to NOD2 status for the total number of febrile events, total 
episodes of neutropenia and total patients. 
The analysis of febrile events in relation to positively detected organism (bacterial, 
viral and fungal), or the febrile events without microbiological identification was 
analysed. There was a statistical significant association of positive bacterial 
cultures with the mutant NOD2 genotype in the absence of neutropenia and a trend 
to an association with viral isolation regardless neutropenia. Culture negative 
febrile events showed statistically significant negative association in mutant NOD2 
genotypes in the absence of neutropenia. 
Functional studies revealed that the Arg702Trp (SNP8), Gly908Arg (SNP12) and 
L1007fsinsC (SNP13) are defective in their ability to respond to bacterial LPS and 
PGN. The frameshift L1007fsinsC variant showed a lack of responsiveness to LPS 
and PGN-induced NF-κB activation. While the Arg702Trp and Gly908Arg variants 
responded to LPS and PGN, but the response was significantly reduced because 
of diminished ability to activate NF-κB.217  
NOD2 is expressed mainly in monocytes131 and to lesser extent in other blood 
leukocytes144 This along with the diminished LPS and PGN response in the SNPs 
8 and 12 could explain our findings of increase prevalence to bacterial organisms 
in the mutant group in the presence of normal neutrophil count. 
Fever due to unidentified organisms, occurred significantly less frequently in the 
NOD2 mutant group in our study. This could be explained by the organisms 
included in this category, e.g. possible fungal and the NOD2 association with 
bacterial infections as in most studies.163, 164  
Bacterial sepsis incidence increased, while episodes of fever where no organism 
was cultures was proportionally   decreased in patients with mutant NOD2 
genotypes when neutrophil count was within the normal range. The association 
with bacterial sepsis and NOD2 polymorphisms has previously been documented 
but change in incidence of FUO not commented upon. Since this finding was in the 
absence of neurtopenia our study may suggest that monocytes of patients with 
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mutated NOD2 have a defect in function as a result of the malignancy itself rather 
than only due to chemotherapy. This findings need to be explored in a larger study. 
The frequency of the NOD2 mutation in our study was 8.46% for two SNPs only. It 
may be that this study would show more significant values if the three planned 
SNPs were identified. Other issues were the small number of documented fungal 
and viral infections in our study population. 
Overall the Arg702Trp, Gly908Arg seems not to affect the course, duration and 
antimicrobial therapy of febrile events whatever the causative organism was.  
In the absence of neutropenia there was a trend towards more HL removal in 
patients with NOD2 mutant genotype this could reflect the macrophage function. 
However other indications of outcome were not different in the NOD2 genotypes. 
The occurrence of both incidences in the absence of neutropenia; significant 
positive bacterial cultures as a cause of a febrile event and the trend of HL removal 
in the mutant NOD2 genotype could suggest the neutrophil defect in antimicrobial 
function218 and the altered response towards LPS/PGN.219 Although we might have 
hypothesized this effect would be stronger in the presence of neutropenia, this was 
not the case. Haematological malignancy and chemotherapy may not have the 
same effect on neutrophils, monocytes or other leukocytes of different genotypes 
of NOD2. Nevertheless these finding confirms other studies associating NOD2 
mutation to bacterial cultures.164 Viral isolates sepsis in relation to NOD2 mutation 
need to be examined in a larger study.  
 
4.8.  Conclusion 
4.8.1.  In relation to sepsis our study suggests 
4.8.1.1  An association between NOD2 (Arg702Trp, Gly908Arg) and: 
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Sepsis, in the NOD2 mutant genotype showed variable occurrence with different 
organisms either positive or negative isolates all in the presence of normal 
neutrophil count.  
There was a significant increase incidence of sepsis with bacteria as the causative 
organism, while sepsis due to unidentified organisms was less common in patients 
with NOD2 mutation. There was a trend towards a greater likehood of hickman line 
removal in patients with NOD2 mutations   
There was also a trend to more viral isolates from septic patients with NOD2 
mutations and this incidence occurred regardless absence or presence of 
neutropenia. 
4.8.1.2. There was no association between NOD2 (Arg702Trp, Gly908Arg) 
and incidence or duration of neutropenic episodes between the NOD2 genotypes. 
The incidence of febrile events per neutropenic episode showed no difference 
between NOD2 genotypes nor the prevalence of any particular isolates as cause of 
the febrile events per patient. 
Our findings in relation to sepsis suggest that monocytes in patients with the 
mutant NOD2 become less responsive to bacterial components. Another 
suggestion could be that in this group immune response to bacterial invasion relay 
on monocytes alone, indicating monocytes function diminishes with malignancy in 
the presence of polymorphisms.  
4.8.2.  In relation to haematological malignancy: 
NOD2 mutation, in particular Arg702Trp have a significant association with the 
diagnosis of chronic leukaemia but this may have been due to the small number if 
patients in that group. 
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Chapter 5 
 
NOD2 mutation and ALL outcome 
 
5.1.  Introduction: 
ALL is the most common malignancy in childhood,51, 52 accounting for 30% of all 
cancers and 80% of all leukaemia. It comprises 2 lineages; B-cell and T-cell 
precursor. B-cell accounts for 75% of ALL, and is generally associated with better 
outcome than T-cell linage ALL which constitutes approximately 25%.52 Complete 
remission (CR) can be achieved in 70-80% of patients but more than half are 
expected to relapse later, with only a minority sustaining a long lasting second 
remission. 10-20% die early during induction treatment, and around a further 10% 
are refractory to remission-induction programs.55  
Whilst ALL differs genetically in children and adults, common mechanisms 
underlay the documented genetic alterations and the leukemic transformation of 
hematopoietic stem cells. Mechanisms include proto-oncogene expression and 
chromosomal translocations that generate fusion genes with oncogenic potential. 
These changes affect cell processes including the capacity for self-renewal, 
proliferation, differentiation and prevention of apoptosis by promoting resistance to 
death signals.53  
Favourable chromosomal abnormalities such as high hyperdiploidy are more 
frequently found in children. While the translocation involving chromosome 9 
(9;22), the Philadelphia chromosome which is associated with poor outcome, is 
found in 25% of adults compared to only 5% of children.51  
Allogeneic stem cell transplantation (Allo-SCT) preferably from a HLA-matched 
related donor has shown superiority in prolonging initial CR in Ph(+) ALL, but not in 
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patients with other high-risk leukaemia (e.g. t(4;11)). Some studies indicate that 
hypodiploidy, near-diploidy or poor responders to initial remission-induction therapy 
may also benefit from transplantation, but the evidence is not definitive.54, 59  Other 
work indicates that disease free survival and possibly overall survival (OS) is 
prolonged after transplantation in the high-risk ALL group who failed 
chemotherapy, but success is limited compared to AML.220  
In previous studies the NOD2 gene mutation has been studied in relation to the 
outcome in Allo- SCT recipients in acute leukaemia patients with respect to, the 
impact of the mutation on graft versus host disease (GvHD), DFS, OS, and 
transplant related mortality (TRM). The relative risk varies depending whether 
either recipient, donor or both carry the NOD2/CARD15 mutation.8, 9, 221  
Holler et al., reported an increased risk of GvHD; grade (III/IV) when the recipient 
carried the NOD2 mutation, a risk which further increases if only the donor is 
positive for the mutation. A dramatic rise in GvHD occurs when both recipient and 
donor carry the NOD2 mutation.8 The cumulative incidence of 1-year TRM 
increased from 20% in wild type recipient/donor pairs to 49% if the recipient was 
NOD2 mutant, 59% with the donor gene mutation, and 83% when both donor and 
recipient are NOD2 mutant.8 Holler et al confirmed this in a multicenter study 
performed two years later.221  
Mayor et al., studied the risk of relapse and death after Allo-SCT in relation to the 
presence of the NOD2 mutation and the study showed no impact of NOD2 gene 
mutation on TRM and GvHD. However, the presence of NOD2 mutation in the 
recipient did reduce OS, and increased the incidence of disease relapse 
(significant in ALL) compared to wild type-type NOD2 group.9  
 
5.2.  Study Rationale  
NOD2 mutations result in its impaired function as an  intercellular receptor to 
bacterial LPS and peptidoglycan (PGN) and the subsequent activation of the NF-
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κB signaling cascade93, 138, 139 leading to increased infections. In this study we 
aimed to investigate the effect of the NOD2 mutation on relapse rate and overall 
survival in a group of ALL patients who only received chemotherapy and no SCT to 
assess the impact of this mutation in the outcome of this cohort. 
 
5.3.  Materials: 
Samples were collected as a part of UKALL-12 trial –MRD (minimal residual 
disease) study, in adult patients (age 15-59 years) following a diagnosis of ALL. 
Diagnosis was based on clinical parameters, blood and/or bone marrow 
morphology as defined by World Health Organisation and the inclusion criteria for 
this trial (UKALL-12; Medical Research Council UK and Eastern Co-operative 
Oncology Group trial). 
 Data of patients (date of birth, sex, date for the commencement of treatment, 
immunophenotype and cytogenetics) were collected either from CTSU (Clinical trial 
service unit and epidemiological unit) Oxford or the local (referral) hospital or 
laboratory. Philadelphia status was determined by FISH analysis at the local 
cytogenetic laboratory where samples were collected and confirmed by molecular 
technique in the Royal Free Hospital (RFH) laboratory. The clinical outcome was 
obtained mostly through the clinician from referral centres. 
The inclusion criteria of this study were; diagnosis of ALL B-cell precursor and Ph 
negative. B cell precursor was chosen as it was the commonest in ALL with less 
chances of transplant. Allogenic transplant was an exclusion criterion.  
  
5.4.  Methods: 
General Methods are described in chapter 2. 
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From stored DNA samples in the molecular biology laboratory at the RFH, 60 
samples were analyzed by following methods: PCR amplification using NOD2-WT 
and SNP fluorescently labelled primers, and genescanning. A random sample were 
amplified and sequenced after being genescanned to ensure the accuracy of the 
results. 
Analysis was performed using Microsoft office excel 2007, P value was calculated 
by Chi square contingency table analysis. The OS, DFS (relapses) and time to 
achieve complete remission (CR) were calculated by Kaplan Meier method (SPSS 
17.0). 
 
5.5.  Results: 
5.5.1.  Demographics 
Patient demographics are shown in table 3.1.  Males accounted for 55.32% aged 
between 18-49yrs, while females account for 44.68% aged between 16-55yrs. 
The median age in males was 33.5 years and in females was 35.5 years, (table 
5.1). 
 
Table 5.1. Patients’ demographics. 
Total samples 47 Male Female 
Number of samples 26 21 
Percentage  55.32% 44.68% 
Age range 18-49 16-55 
Median age 33.5 35.5 
 
Table 5.2 Causes of exclusions in the 13 samples/patients. 
Cause of exclusion Number of patients 
Allogeneic SCT 8 
T cell ALL 3 
Unknown Outcome 2 
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5.5.2.  Frequency of NOD2/CARD15 mutation: 
Out of the 60 samples only 47 met the criteria, (table 5.2.). In the 47 DNA samples 
included 31 (65.96%) showed no mutation in any of the SNPs tested and 16 
(34.04%) were mutated for any of the NOD2 SNPs. One of the DNA samples 
exhibited compound heterozygosity (SNP8 and 12), whilst only one sample was 
homozygote for SNP13, (table 5.3.). 
Frequency of mutation in relation to sex showed no statistical significance, 8 
(30.77%) out of the 26 males and 8 (38.10%) out of the 21 females showed 
mutation, (table 5.4.). 
 
 
Table 5.3. The frequency of NOD2-SNPs mutations in 47 ALL DNA samples, the only 
homozygote mutation was in SNP13 and on e sample exhibited compound heterozygosity. 
Genotype SNP8(%) SNP12 (%) SNP13 (%) 
Wild type 42 (89.36%) 37 (78.72%) 45 (95.74%) 
Heterozygote 5 (10.34%) 10 (21.28%) 1 (2.13%) 
Homozygote 0 0 1 (2.13%) 
 
 
Table 5.4. Mutation in different sexes. P value was calculated by Chi squre. 
Total samples 47 Males = 26 Females = 21 
Wild type NOD2 =31 18 (69.23%) 13 (61.90%) 
Mutant NOD2 =16 
(P value 0.598) 
8 (30.77%) 8 (38.10%) 
 
 
5.5.3.  Follow-up period: 
Follow up in all 47 samples ranged between 111-1840 days with a median of 
666.91 days until death or the completion of the study (last follow up). The earliest 
relapse occurred at 117 days, while the earliest death was at 169 days, both 
events occurred in patients with the wild type NOD2. 
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5.5.4.  Outcome of ALL patients: 
The outcome was analaysed in three groups, as time to achieve complete 
remission (TtCR), relapse and overall survival (OS). Each of the outcomes was 
analysed in relation to gender and NOD2 status separately and then combined. 
The outcome was first analysed according to gender, (table 5.5.).  The incidences 
of relapse and OS along with TtCR showed no differences between both genders. 
P value showed no significances between sexes in all outcomes (CR, relapse, 
OS).  
35 patients initially entered CR but three (two males and one female), did not 
sustain remission and later died. One male and one female death were due to 
sepsis.  
 
Table 5.5. Outcome in relation to gender. P value was calculated by Chi square & Fisher 
exact. 
Outcome Male (%) Female (%) 
47 samples 26 (55.32%) 21 (44.68%) 
35 CR  
(P value 0.668) 
20 (76.92%) 15 (71.43%) 
12 Relapse  
(P value o.668) 
6 (23.07%) 6 (28.57%) 
10 Deaths (OS) 
(P value 0.703) 
5 (19.23%) 5 (23.81%) 
 
Table 5.6. Outcome in relation to NOD2 mutation. P value was calculated by Chi square & 
Fisher exact. 
Total samples 47 Wild type NOD2 
n=31 (65.96%) 
Mutant NOD2 
n=16 (34.04%) 
35 CR  
P value 0.952 
23 
(74.19.%) 
12 
(75%) 
12 Relapse 
P value 0.952 
8 
(25.81%) 
4 
(25%) 
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Figure 5.1.1. 
Time to achieve 
complete remission in 
relation to gender. 
Male; 61.5%   
Female: 85.7 %(in 
proportion; proportion 
is a 100 of 
percentage). 
P=0.077 
 
 
Figure 5.1.2. 
Time to achieve 
complete remission in 
relation to NOD2 
status.   Wild 
type:71%  Mutant: 
75% 
(in proportion; 
proportion is a 100 of 
percentage). 
P=0.679 
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Figure 5.1.3. 
Time to achieve 
complete remission in 
relation to gender and 
NOD2 status in 
combination.        
Male wild type:66.7%, 
& mutant:50%. 
Female wild 
type:76.9%, & 
mutant:100% 
(in proportion; 
proportion is a 100 of 
percentage). 
P=0.099 
 
There were 35 CR, 74.19% and 75% in the wild type and mutant genotypes 
respectively, (table 5.6.). Only 32 sustained CR out of the total 35 (22 (70.97%) in 
the wild type NOD2 group and 10 (62.5%) in the mutant for any of the NOD2-
SNPs. The TtCR did not show statistical differences in relation to either gender, 
NOD2 status or combined, (table 5.7., figures 5.1.1., 5.1.2., 5.1.3.). 
There was no difference in the relapse rate between wild type and mutant NOD2 
patients. Out of the 47 patients, 12 relapsed; 8 (25.81%) were mutated and 4 
(25%) were wild type for NOD2, (table 5.6.). Statistically there was no significant 
differences in comparing incidence of relapse in relation to gender, NOD2 
genotypes and combined, (table 5.8., figures 5.2.1., 5.2.2., 5.2.3.) 
As noted above, three patients were initially in remission and subsequently died. 
Two of the patients initially in CR who later died were found to be mutant for the 
NOD2 gene, (table 5.9.). The cause of death in one was sepsis, and in the other 
transformation to AML. The third patient dying in the CR group was wild type for 
NOD-2 with unknown cause of death (table 5.10.).   
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There were 10 deaths in total, 3 were in CR while 7 were in relapse, (table 5.9.). 
The cause of death in the wild type NOD2 patients were all as a result of the 
relapsed disease, but in the mutant patients the causes of death varied, (table 
5.10.). Overall survival at 2 years was 80.6% and 75% in the wild type and mutant 
NOD2 respectively. Observation and follow up was stopped and deaths occurring 
later had not been notified. 
Overall survival did not show any statistical differences in all the categories, (table 
5.11, figures 5.3.1., 5.3.2., 5.3.3.) 
 
Table 5.7. Cox Regression analysis of the time to achieve complete remission (TtCR) 
Analysis P value Odd ratio CI 95% 
Univariate 
Sex 
NOD2 
 
0.09 
0.68 
 
0.33 
1.28 
 
0.09-1.21 
0.39-4.22 
Multivariate 
Sex 
NOD2 
 
0.10 
0.99 
 
0.33 
1.01 
 
0.09-0.24 
0.30-3.37 
 
Table 5.8. Cox Regression analysis of the time to relapse. 
Analysis P value Odd ratio CI 95% 
Univariate 
Sex 
NOD2 
 
0.83 
0.76 
 
1.145 
1.24 
 
0.33-3.97 
0.319-4.78 
Multivariate 
Sex 
NOD2 
 
0.79 
0.76 
 
1.18 
1.27 
 
0.323-4.97 
0.336-4.15 
 
Table 5.9. Deaths in both CR and relapse for wild type and mutant NOD2 patients. P value 
were calculated by Fisher exact. 
Deaths Wild type NOD2; n=31 Mutant NOD2; n=16 
Total deaths 
P value 0.654 
6  
(19.35%) 
4  
(25%) 
Deaths in CR 
P value 0.218 
1  
(2.23%) 
2  
(12.5%) 
Deaths in Relapse 
P value 0.741 
5  
(16.13%) 
2  
(12.5%) 
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Figure 5.2.1. 
Time to relapse in 
relation to gender. 
Male: 80.8% 
Female:76.2% 
(in proportion; 
proportion is a 100 of 
percentage). 
P=0.831 
 
Figure 5.2.2. 
Time to relapse in 
relation to NOD2 
status.   Wild 
type:77.7% 
Mutnat:81.3% 
(in proportion; 
proportion is a 100 of 
percentage). 
P=0.758 
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Figure 5.2.3. 
Time relapse in 
relation to gender 
and NOD2 status in 
combination. Male 
wild type:83.3%, 
mutant:75%.      
Female wild 
type:69.2, 
mutant:87.5% 
(in proportion; 
proportion is a 100 of 
percentage). 
P=0.697 
 
 
 
 
5.5.5.  Survival of ALL patients by NOD2 genotype 
Disease-free survival in the relapsed patients with a wild type NOD2 genotype 
ranged from 117-947 days, while for patients with the NOD-2 mutant genotype the 
range was between 193-917 days, (figure 5.2.2.). The odd ratio of disease-free 
survival in the relapse group was 1.24 and the 95% CI of ratio between o.319-4.78.  
NOD2 variants showed no propotional significance in the relapse group, p=0.76 
(table 5.8., figure 5.2.2.). 
The overall survival odd ratio 0.92 with 95% CI ranged between 0.259-3.289. Days 
of disease-free survival were in the range of 169-832 in the wild type genotype and 
217-917 in the mutant genotype. P value 0.90 showed no significance. (table 5.9., 
figure 5.3.2.).  
Neither of the compound heterozygote or the homozygote patients segregated with 
the death or relapse groups. 
Complete remission achievement in relation to NOD2 status showed no significant 
differences p=0.68 with odd ratio of 1.28 and CI 95% 0.09-4.22. (table 5.7., figure 
5.1.2.). 
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Table 5.10. Cause of death in the four NOD2 mutant patients. 
Patient-1 Patient-2 Patient-3 Patient-4 
Female 
Relapse/sepsis 
Male 
Autograft/CR/Sepsis 
Male 
AML transformation 
Female 
Post-autograft 
 
Table 5.11. Cox Regression analysis of the overall survival time (OS). 
Analysis P value Odd ratio CI 95% 
Univariate 
Sex 
NOD2 
 
0.70 
0.90 
 
1.27 
0.92 
 
0.366-4.436 
0.259-3.289 
Multivariate 
Sex 
NOD2 
 
0.72 
0.98 
 
1.27 
0.981 
 
0.349-4.610 
0.262-3.669 
 
Figure 5.3.1. 
Overall survival 
(OS) time in 
relation to gender.                  
Male: 80% 
Female:76.2% 
(in proportion; 
proportion is a 100 
of percentage). 
P=0.702 
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Figure 5.3.2. 
Overall survival 
(OS) time in 
relation to NOD2 
status. Wild 
type:80.6% 
Mutant:75% 
(in proportion; 
proportion is a 
100 of 
percentage). 
P=0.900 
 
Figure 5.3.3. 
Overall survival 
(OS) time in 
relation to gender 
and NOD2 status 
in combination. 
Male wild 
type:88.9, 
mutant:62.5%.   
Female wild 
type:69.2%, 
mutant:87.5% 
(in proportion; 
proportion is a 
100 of 
percentage). 
P=0.164 
 
 
 
 
5.6.  Discussion: 
Previous studies of mutations in NOD2 and their relation to relapse; disease free 
survival and overall survival have been performed in post-transplant patients for 
whom the indication for transplantation was leukaemia. In these studies the NOD2 
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status was investigated in recipients, donors or both to find if the mutation had a 
cumulative effect on the incidence of relapse, DFS ,OS, GvHD.8, 9, 221 Other studies 
had linked NOD2 and different types of malignancies including colorectal,204, 222 
breast,160, 161 NHL,162 and MALT.159  
The purpose of the current study was to examine the frequency of mutation in our 
ALL group and to investigate the impact of the NOD2 mutation on relapse rate and 
OS in a non-transplant group. 
The incidence of the NOD2 mutation in this study was 34.04% for any of the NOD2 
SNPs. This frequency of mutation is comparable to the study by Cuthbert  et al. in 
which the frequency of the NOD2 mutation in a selected cohort in UK was 
35.8%.149 The NOD2 mutation were slightly higher in the females than males with 
percentage of 38.10 and 30.77, respectively; but occurrence differences maybe 
need to be validated on a larger cohort of patients. 
In our study the ALL incidence was slightly higher in males (55.32%) and in 
younger age than in female (mean age of 34.85 in males). Recent studies have 
shown that, males show an increased occurrence of ALL.52, 59 Males  30years 
have a worse outcome61 but in our study relapse incidence and OS were equal in 
both sexes 50% for all groups (wild type and mutant genotype). CR was between 
42.86-57.14% (female-male) with a mean follow up period of 22.02 months and 
this could be comparable to the 5 years survival of 20-40% observed by 
Castagnola et al.55  
We observed no significant difference in CR, incidence of relapse or OS among all 
groups. Achievement of complete remission and relapse showed no differences 
between NOD2 variants. Death occurred less frequently in the mutant (40%) than 
the wild type group (60%). This contrasts with other studies which showed an 
increase  in incidence of relapse and a decrease in overall survival in the mutant 
group8, 9, 221 but is in agreement with other investigators.10  
In the group of patients who did not survive 2 (NOD2 mutant) out of the ten (20%) 
deaths were due to sepsis which may confirm the immunological effect theory of 
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this gene and which we are going to investigate it further in our study in different 
population. 
 
5.7.  Conclusion 
We detect no impact of NOD2/CARD15 mutation on OS and relapse in non-
transplanted Philadelphia negative -B cell ALL and we found no association 
between the presence of mutation and sex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Chapter 6 
 
Genetic determinant of sepsis in haematological 
malignancy 
Combined study: 
NOD2 & Chitotriosidase mutations 
 
6.1.  Introduction 
Host defence against invading microorganisms is elicited by immune cells.93, 94  
The phagocytic and antigen presenting cells such as neutrophils and macrophages 
express various receptors for detection of such microorganisms. The extracellular 
toll-like receptors (TLR) recognise pathogen associated molecular patterns 
(PAMPs)94 and intracellular NOD2 receptors bacterial derived LPS and PGN.93, 131, 
144
 Chitotriosidase synthesis by macrophages or neutrophil granules occurs in 
response to stimuli by chitin containing fungi, however its role in fungal defence is 
not completely clear.98, 99  
Mutations in the innate immunity genes (chitotriosidase and NOD2) have been 
under focus. Studies show an impaired immune response and resultant defective 
NF-κB activation initiates the inflammatory response in Crohn’s disease patients 
carrying the NOD2 mutation.4, 131 Mutation in NOD2 also was found to reduce 
phagocytosis and increases susceptibility to bacterial infections163, 175 as well to 
increase mortality in septic patients.163, 164 On the other hand chitotriosidase levels 
have been seen to rise in bacterial, fungal6, 7 and malaria falciparum infections.112 
Chitotriosidase mutations appear to render patients susceptible to gram negative 
infections96 and W. bacrofti.115  
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Recently a study was conducted to elicit the effect of TLR and NOD2 on 
chitotriosidase expression and release as part of the innate immune response. 
Results showed NOD2 activation induces chitotriosidase expression on the 
macrophages while TLR regulates its release from neutrophils in response to 
bacterial MDP.97  
In contrast in this study we have attempted to uncover the synergistic effects of 
both gene mutations in the innate immune response required for elimination of 
infections (bacterial, fungal or viral). The study was conducted in the same 
population as previous studies. Patients with a diagnosis of haematological 
malignancy in relation to the absolute neutrophil count (neutropenic or non-
neutropenic), were observed during their hospital stay. Events of fever (as defined 
previously) were investigated and treated.   
Gene mutations (chitotriosidase alone, NOD2 alone or mutation of both genes in 
an individual) in relationship to infection, sepsis and absolute neutrophil count were 
studied in this group of patients. The infectious pathogen and outcome of infection 
were analysed according to mutant status.  
 
6.2.  Hypothesis: 
Patients carrying combined mutations of both chitotriosidase and NOD2 are at 
increased risk of infection and sepsis during periods when they are neutropenic.  
 
6.3.  Objectives: 
1)  To determine the effect of mutations (chitotriosidase, NOD2 or in 
combination) on the incidence and outcome of sepsis in patients with 
haematological malignancy, including those with leukaemia, lymphoma, 
and myeloma.  
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2)  To examine the effect of mutations (chitotriosidase, NOD2 or in 
combination) on the incidence and outcome of sepsis in patients with 
haematological malignancy who are neutropenic and those who are not. 
3) To examine the effect of mutations (chitotriosidase, NOD2 or in 
combination) on the prevalence of organisms in neutropenic and non-
neutropenic patients with haematological malignancies. 
4)  To correlate neutrophil function and duration of neutropenia with the 
mutations (chitotriosidase, NOD2 or in combination). 
 
6.4.  Materials and methods: 
General material and methods are described in Chapter 2. 
Inclusion and exclusion criteria are also described in chapter 2. 
Recruitment of patients with haematological malignancy was performed in the 
Royal Free Hospital.  
The study was ethically approved and all patients gave informed consent. They 
were followed up during their in-patient stay.  Clinical data were collected daily by 
the clinical fellow. Observations were recorded including ANC, temperature, related 
investigations (microbial and imaging) to determine the source and type of sepsis, 
and antimicrobial management.  
Investigation and data of patients recruited from the out-patient department or after 
patients discharge were recorded electronically or from paper medical records.  
DNA was extracted and genotyped for chitotriosidase and NOD2, according to 
methods mentioned in chapter 2. Only two SNPs (8 and 12) were studied in 
relation to NOD2 mutation. 
 
    
6.5.  Statistics: 
The p value was calculated by the Chi square and Kruskal Wallis tests, a p value of 
0.05 considered significant.  
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The p value differences were calculated for four proportions. The wild type for any 
mutation, versus chitotriosidase only mutation, versus NOD2 only mutation, versus 
combined gene mutation.  
Basic descriptive statistics and graphs were prepared using Microsoft excel and 
SSPS 17.0. 
 
6.6.  Results: 
6.6.1.  Incidence of combined gene mutation: 
Mutation: Out of the 201 patients, 7 (3.48%) were mutant for both chitotriosidase 
and NOD2. The proportion of a solitary mutation of either gene was 37.31% for 
chitotriosidase and 4.97% for NOD2 (table 6.1.). 
 
6.6.2.  Range of Diagnoses 
The study population was 201 patients. The range of diagnosis varied. There was 
no difference in diagnosis by mutation (table 6.1.). 
 
6.6.3.  Analysis of episodes of neutropenia (EoN): 
Patients with a diagnosis of haematological malignancy and receiving 
chemotherapy become neutropenic. A fall of the absolute neutrophil count (ANC)  
0.5x109/L is referred to as neutropenia. Neutropenia was analysed according to its 
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incidence and duration. The number of patients developing neutropenia and the 
frequency of neutropenic episodes per patient was also analysed. Analysis was 
done in four proportions in the wild type for any mutation, chitotriosidase only 
mutation, NOD2 only mutation and the combination of mutation for chitotriosidase 
and NOD2.  
 
Table 6.1. Diagnosis with different haematological malignancies in our study population. The 
number of patients and frequencies (%) in: total, in wild type to any, in relation to chitotriosidase 
only mutation, NOD2 only mutation or both mutations. P value calculated by Chi square. 
Mutation status Diagnosis 
 Lymphoma Multiple 
myeloma 
Acute 
Leukaemia 
Chronic 
Leukaemia 
Other 
Total 201; (%) 106 (52.74%) 32 (15.92%) 50 (24.88%) 11 (5.47%) 2 (0.99%) 
WT for any 
mutation: 109 
(54.23%) 
59         
(54.13%) 
17   (15.60%) 25    
(22.94%) 
6        
(5.50%) 
2    
(1.83%) 
Chitotriosidase: 75 
(37.31%) 
38         
(50.67%) 
13   (17.33%) 22    
(29.33%) 
2        
(2.67%) 
0  
NOD2: 10 (4.97%) 7 (70%) 0  1 (10%) 2 (20%) 0 
Both: 7 (3.48%) 2 (28.57%) 2 (28.57%) 2 (28.57%) 1 (14.29%) 0 
P= 0.384 0.415 0.522 0.099 0.636 
 
6.6.3.1. Number of patients with neutropenic episode per genotype: 
The total proportion of patients developed episodes of neutropenia (wild type for 
any mutation chitotriosidase and NOD2) was 93 (85.32%) out of 109. For 
chitotriosidase mutant group 60 out of 75 (80%) and the NOD2 mutant group 7 out 
of the 10 patients (70%) became neutropenic during their treatment. 5 out of 7 
(71.43%) of the individuals carrying both mutations became neutropenic. There 
were no statistically significant differences between the four proportions (table 
6.2.). 
6.6.3.2. Number of neutropenic episodes per genotype: 
There were 450 episodes of neutropenia in total, 261 episodes out of the 450 
occurred in patients wild type for any of the mutations, in the 158 chitotriosidase 
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only mutation genotypes and 18 in the NOD2 only mutation patients. 13 out of the 
450 episodes occurred in the patients group carrying both mutations (table 6.3.) 
 
Table 6.2. Total number of patients (Pts) with episodes of neutropenia (EoN) in each group 
(wild type for any mutation, chitotriosidase only mutation, NOD2 only mutation and combined genes 
mutation).  % of neutropenic patients within each genotype. P value calculation by Chi square.  
Total patients in 
the study =201 
WT for any of the 
mutations 
Chitotriosidase 
only mutation  
NOD2 only 
mutation  
Combined 
mutations 
Total patients (%) 109 (54.23%) 75 (37.31%) 10 (4.97) 7 (3.48%) 
Pts with EoN in 
each genotype 
(P= 0.470) 
93 
(85.32%) 
60 
(80%) 
7 
(70%) 
5 
(71.43%) 
 
Table 6.3. Episodes of neutropenia (EoN) analysed for wild type for any mutation, 
chitotriosidase only mutation, NOD2 only mutation and combined mutation proportions.  
Total episodes of 
neutropenia  
=450 
WT for any of 
the mutations 
EoN=261 
Chitotriosidase 
only  mutation 
EoN=158 
NOD2 only 
mutation 
EoN=18 
Combined 
mutations 
EoN=13 
Total pts / genotype 109 75 10 7 
Total neutropenic episodes  261 158 18 13 
Total neutropenic days 2496 1510 174 88 
Range  
Episodes of neutropenia / 
patient 
Neutropenic days per patient 
 
0-11 
 
0-80 
 
0-13 
 
0-50 
 
0-4 
 
0-33 
 
0-6 
 
0-23 
Median 
Episodes of 
neutropenia/patient 
Neutropenic days/patient 
Day/episode 
 
 
2 
11.5 
5.75 
 
 
2 
10 
5 
 
 
1.5 
14.5 
9.67 
 
 
2 
9 
4.5 
 
6.6.3.3. Duration of neutropenic episode: 
The duration of neutropenic episodes in the four groups was calculated, in order to 
evaluate the effect of single or combined mutation on neutrophil regeneration. 
The total number of neutropenic days were 2496, 1510, 174 and 88 in the wild type 
for any mutation, chitotriosidase only mutation, NOD2 only mutation and combined 
gene mutations genotypes respectively (table 6.3.). 
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The median number of neutropenic days per patient (14.4) and neutropenic days 
per episode (9.67) were higher in the NOD2 only mutation group. Again, although 
suggestive, there were no statistically significant differences between the groups 
(table 6.3.). 
Overall we found no statistically significant differences between the different 
groups in the occurrence of neutropenic episodes per genotype (table 6.2.).  
 
6.6.4.  Analysis of febrile events: 
Analysis was performed to determine if the type of mutation affect the frequency of 
fevers. We analysed the incidence of febrile events in the four groups (wild type for 
any, chitotriosidase alone, NOD2 alone or in combination) in relation to presence 
and/or absence of neutropenia.  
6.6.4.1. Febrile neutropenic events (FNE):   
There was a total of 307 febrile events. 195 (63.52%) febrile events occurred in the 
presence of neutopenia while 112 (36.48%) occurred in the absence of 
neutropenia (table 6.5., 6.6.). 
There were no statistical differences in the proportion of patients developing febrile 
events with neutropenia only, without neutropenia, either neutropenic or non-
neutropenic events or both events (neutropenic and non-neutropenic events) for all 
genotype groups (table 6.4.). 
The number of febrile neutropenic events per patient, per episode of neutropenia 
and per days of neutropenia was almost the same in the NOD2 and combined 
mutation groups. There were no statistical differences in the occurrence of febrile 
neutropenic events in the three groups (table 6.5.). 
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Table 6.4. Porportions of patients (Pts) out of each group with febrile events whilst 
neutropenic (FNE), non-neutropenic (FNnE), either (FNE or FNnE) or both (FNE and FNnE) febrile 
events. The p value calculated by the Chi square test compares the wild type for any mutation: 
chitotriosidase only mutation: NOD2 only mutation: combined mutation proportions.  
Total WT for any of 
the mutations 
Chitotriosidase 
only mutation  
NOD2 only 
mutation 
Combined 
mutations 
Total pt 201 (%) 109 (54.23%) 75 (37.31%) 10 (4.98%) 7 (3.48%) 
Pts with FNE (% pts of FNE/ 
genotype).  
P = 0.492 
64 
(58.71%) 
37 
(49.33%) 
6 
(60%) 
5  
(71.43%) 
Pts with FNnE (% pts of 
FNnE/ genotype).  
P = 0.860 
43 
(39.45%) 
26     
(34.67%) 
3 
(30%) 
3     
(42.86%) 
Pts with either febrile events 
P = 0.815 
49 
(44.95%) 
35  
(46.67%) 
5 
(50%) 
2    
(28.57%) 
Pts with both febrile events. 
P = 0.346 
30 
(27.52%) 
14  
(18.67%) 
2 
(20%) 
3  
(42.86%) 
 
Table 6.5. Number of febrile neutopenic events (FNE) in the wild type for any, chitotriosidase 
only mutation, NOD2 only mutation and combined mutation proportions.  
Total febrile neutropenic 
events = 195 
WT for any of 
the mutations 
Chitotriosidase 
only mutation  
NOD2 only 
mutation 
Combined 
mutations 
Number of FNE 112 66 7 10 
Range per patient 0-5 0-7 0-2 0-4 
Median  
Number of events/patient 
Event/episode of 
neutropenia 
Event/neutropenic days 
 
1 
0.5 
0.087 
 
0 
0 
0 
 
1 
0.67 
0.069 
 
1 
0.5 
0.11 
 
Table 6.6. Number of febrile non-neutropenic events (FNnE) analysed in the wild type for any, 
chitotriosidase only mutation, NOD2 only mutation and combined mutation proportions.  
Total febrile non-neutropenic 
events=112 
WT for any of 
the mutations 
Chitotriosidase 
only mutation 
NOD2 only 
mutation  
Combined 
mutations 
Number of FNnE 66 36 5 5 
Range per pt 0-6 0-4 0-2 0-2 
Median;  
number of events per pt 
 
0 
 
0 
 
0 
 
0 
 
6.6.4.2. Febrile non-neutropenic events (FNnE):  
112 events of non-neutropenic fever occurred.  The number of patients with febrile 
events not associated with neutropenia were 43 out of the 109 patients wild type 
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for any mutation (39.45%), 26 out of the 75 in the chitotriosidase mutant genotype 
(34.67%), 3 out of the 10 in the NOD2 mutant genotype (30%) and 3 out of 7 in 
patients with both gene mutation (table 6.4. & 6.6.).  
6.6.4.3. Analysis of patients developing either febrile (neutropenic or non-
neutropenic) event:  
There was no statistical significance in the proportion of patients who developed 
any febrile event either in the presence or absence of neutropenia. 
There were 49 (44.95%) in the wild type for any mutation, 35 (46.67%) patients in 
the chitotriosidase only mutation, 5 (50%) in the NOD2 only mutation and 2 
(28.57%) in the combined gene mutation group (table 6.4.).  
6.6.4.4. Analysis of patients developing both febrile (neutropenic and non-
neutropenic) events:  
The number of patients developing febrile events both while they are neutropenic 
and non-neutropenic during their course of therapy was 30 (27.52%) in the wild 
type for any mutation, 14 (18.67%) in the chitotriosidase only mutant, 2 (20 %) in 
the NOD2 only mutant and 3 (42.86%) in the combined mutation genotypes 
(chitotriosidase & NOD2 mutant). There were no statistical differences between the 
four proportions (table 6.4.). 
 
6.6.5. Analysis of the types of organism cultured  
The likelihood of having positive cultures with a particular organism (bacteria, virus 
or fungus) was analysed according to the number of febrile events, the number of 
episodes of neutropenia and the number of patients within the four proportions. 
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Table 6.7.1. Total febrile events regardless neutropenia in the four groups and the type of 
identifiable organism if present. P value by Chi square test. 
Total febrile events 
 
= 307 
WT for any of 
the mutations 
=178 
Chitotriosidase 
only mutation 
=102 
NOD2 only 
mutation     
 =12 
Combined 
mutations    
=15 
Total bacterial +ve events 
Bacterial +ve/febrile event % 
P= 0.123 
86 
48.31% 
61 
59.80% 
9 
75% 
8 
53.33% 
Total fungal +ve events 
Fungal+ve/febrile event % 
P =0.298 
5 
2.81% 
0 
 
0 0 
 
Total viral +ve events 
Viral +ve/febrile event % 
P = 0.116 
1 
0.56% 
2 
1.96% 
1 
8.33% 
0 
Total culture -ve events 
Culture –ve / febrile event % 
P = 0.094 
86 
48.31% 
39 
38.24% 
2 
16.67% 
7 
46.67% 
 
 
Table 6.7.2 Total febrile neutropenic events in the four groups and the type of identifiable 
organism if present. P value by Chi square test. 
Total febrile neutropenic 
events 
(FNE) =195 
WT for any of 
the mutations  
FNE=112 
Chitotriosidase 
only mutation 
FNE=66 
NOD2 only 
mutation 
FNE=7 
Combined 
mutation 
FNE=10 
Number of bacterial FNE 
Bacterial rate/FNE, % 
P =0.485 
63 
56.25% 
41 
62.12% 
 
5 
71.43% 
4 
40% 
 
Number of fungal FNE 
Fungal rate / FNE,% 
P= 0.683 
2 
1.79% 
0 0 0 
 
Number of viral FNE 
Viral +ve / FNE, % 
P =  0.016 
0 2 
3.03% 
 
1 
14.29% 
0 
 
 
Number of culture -ve FNE 
Culture -ve rate / FNE, % 
P = 0.212 
47 
41.96% 
23 
34.85% 
 
1 
14.29% 
6 
60% 
 
 
6.6.5.1. Analysis of organism cultured per febrile events in the presence 
and/or absence of neutropenia. 
Here the number of febrile events in relation to the organism isolated was 
calculated in order to evaluate organism prevalence, in the four different genotypes 
in the presence and/or absence of neutropenia. 
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Analysis of the number of febrile events with identified organism (bacterial, fungal 
or viral) showed no statistical differences regardless neutropenia in all four 
genotypes. Analysis of the number of febrile events and unidentified organism 
showed a trend towards significance with the highest (48.31%) occurrence in the 
wild type for any proportion and lowest (16.67%) in the NOD2 only mutation (table 
6.7.1.). 
Analysis of febrile events in the presence of neutropenia in relation to organism 
showed a statistical significance when viruses were the isolate. The diagnosis of 
positive viral isolate was higher in the NOD2 only mutation and none in the 
combined gene mutation and wild type for any genotypes, however the clinical 
significance in unclear as only a very small number of viral isolates were identified 
(table 6.7.2.).  
Analysis of febrile events in the absence of neutropenia showed statistical 
significance with positive bacterial cultures, lowest in the wild type group. Cultures 
negative fever for were highest in the wild type group and lowest in patients with 
mutations. 
 
Table 6.7.3. Total febrile non-neutropenic events in the four groups and the type of identifiable 
organism if present. P value by Chi square test. 
Total febrile non-neutropenic 
events  
(FNnE) =112 
WT for any of 
the mutations  
FNnE=66 
Chitotriosidase 
only mutation 
FNnE=36 
NOD2 only 
mutation 
FNnE=5 
Combined 
mutations 
FNnE=5 
Number of bacterial FNnE 
Bacterial rate/FNnE% 
P = 0.017 
22 
33.33% 
 
20 
55.56% 
 
4 
80% 
4 
80% 
 
Number of fungal FNnE 
Fungal rate / FNnE% 
P =0.542 
3 
4.54% 
0 0 0 
 
Number of viral FNnE 
Viral +ve / FNnE% 
P =0.872 
1 
1.52% 
0 
 
0 0 
 
Number of culture negative 
FNnE 
Culture -ve rate / FNnE% 
P = 0.076 
40 
60.61%% 
 
16 
44.44% 
 
1 
20% 
1 
20% 
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6.6.5.2. Analysis of organism cultured per episode of neutropenia 
Patients who develop neutropenia are prone to develop infections and become 
febrile. However not all patients develop fever whilst neutropenic. The reason for 
this is likely to be multifactorial with involvement of innate and adaptive immunity 
compensating for neutropenia. In this section the proportion of episodes of 
neutropenia during which patients became febrile for each genotype was 
calculated. 
There was statistical difference in the number of neutropenic episodes with fever 
due to unidentified organism (FUO) in the four groups. Neutropenic episodes which 
were culture negative were higher when both genes were mutant in combination 
(table 6.8.). Episodes of neutropenia and viral isolate were evident with either 
mutation. 
There was no significant difference between the total episodes of neutropenia due 
to bacteria or proven and probable IFD in the four groups (table 6.8.). 
 
Table 6.8. Total episodes of neutropenia associated with febrile events in the four groups and 
the type of identifiable organism if present. P value by Chi square test. 
 
Episodes of neutropenia with 
febrile events. 
WT for any of 
the mutations; 
Total EoN 
=261 
Chitotriosidase 
only mutation; 
Total EoN 
=158 
NOD2 only 
mutation; 
Total EoN 
=18 
Combined 
mutations; 
Total EoN 
=13 
EoN with bacterial event. 
FNE (%). 
P = 0.696 
56 
(21.46%) 
37 
(23.42%) 
6 
(33.33%) 
3 
(23.08%) 
EoN with probable/ proven 
fungal event. FNE. (%). 
P =0.693 
2          
(0.77%) 
 
0 
 
0 0 
 
EoN with viral event.  
FNE (%). 
P = 0.027 
0 
 
2 
(1.27%) 
1 
(5.56%) 
0 
 
EoN with culture negative 
event.  FNE. (%). 
P = 0.017 
42 
(16.09%) 
 
24 
(15.19%) 
 
1 
(5.56%) 
6 
(46.15%) 
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6.6.5.3. Analysis of organism cultured per patient 
In this section all patients developing febrile events were categorised according to 
the organism grown in their cultures. This analysis was carried out in the presence 
and/or absence of neutropenia. 
There were no statistically significant differences in the proportions of patients have 
positive cultures to bacteria or fungal isolates either when neutropenic or not 
neutropenic (table 6.9.1 & 6.9.2). 
There was a trend towards significance in the prevalence of viral isolates with the 
presence of neutropenia in the NOD2 mutant patients but numbers were low. 
Another trend towards significance occurred in patients with febrile events 
regardless neutropenia (FNE, FNnE or both) and the diagnosis of FUO due to 
negative culture and isolates. This finding was higher in the wild type for any 
mutation group (table 6.9.3 & 6.9.4).  
Patients with combined mutation seemed not to exhibit any organism more than 
the solitary mutation. 
 
Table 6.9.1. Patients with febrile events and positive bacterial cultures. FNEs only, FNnEs only, 
any event either FNE or FNnE, and both FNE & FNnE. in the four groups. P value by Chi square 
test. 
Fever and positive bacterial 
cultures 
WT for any of 
the mutations; 
Total pts=109 
Chitotriosidase 
only mutation; 
Total pts=75 
NOD2 only 
mutation;      
Total pts=10 
Combined 
mutations;  
Total pts=7 
Patients with only FNE.  
(%). P = 0.871 
30 
(27.52%) 
19 
(25.33%) 
3 
(30%) 
1 
(14.29%) 
Patients with only FNnE. 
 (%). P =0.393 
11 
(10.09%) 
8 
(10.67%) 
2 
(20%) 
2 
(28.57%) 
Patients with any events, 
either FNE or FNnE.  
(%). P =0.755 
49 
(44.95%) 
 
34 
(45.33%) 
 
6 
(60%) 
 
4 
(57.14%) 
 
Patients with events, both 
whilst neutropenic & non- 
neutropenic.  
(%). P = 0.899 
8 
(7.34%) 
 
7 
(9.33%) 
 
1 
(10%) 
 
1 
(14.29%) 
 
 
  
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Table 6.9.2. Patients with febrile events and proven or probable IFD. FNEs only, FNnEs only, 
any event either FNE or FNnE, and both FNE & FNnE. in the four groups. P value by Chi square 
test. 
Fever with proven and 
probable IFD 
WT for any of 
the mutations; 
Total pts=109 
Chitotriosidase 
only mutation; 
Total pts=75 
NOD2 only 
mutation;      
Total pts=10 
Combined 
mutations;  
Total pts=7 
Pts with only FNE.  
(%) . P= 0.636 
2 
(1.83%) 
0 0 0 
Pts with only FNnE.  
(%).  P= 0.463 
3 
(2.75%) 
0 0 0 
Pts with total events either 
FNE or FNnE.  
(%). P =0.228 
5 
(4.59%) 
0 0 0 
Pts with events, both whilst 
neutropenia and non-
neutropenia.  
(%). P =0.838 
1 
(0.92%) 
 
0 
 
0 
 
0 
 
 
 
Table 6.9.3. Patients with febrile events due to viral pathogens. FNEs only, FNnEs only, any 
event either FNE or FNnE, and both FNE & FNnE. in the four groups. P value by Chi square test. 
Fever and viral positive 
event 
WT for any of 
the mutations; 
Total pts=109 
Chitotriosidase 
only mutation; 
Total pts=75 
NOD2 only 
mutation;      
Total pts=10 
Combined 
mutations;  
Total pts=7 
Pts with only FNE. (%).  
P= 0.061 
0 
 
2 
(2.67%) 
1 
(10%) 
0 
Pts with only FNnE. (%) 
P= 0.838 
1 
(0.92%) 
0 0 0 
Pts with total events either 
FNE or FNnE. (%).  
P = 0.236 
1 
(0.92%) 
 
2 
(2.67%) 
 
1 
(10%) 
 
0 
 
Pts with fever, both whilst 
neutropenia and non-
neutropenia. (%) 
P =0.636 
2 
(1.83%) 
 
0 
 
0 
 
0 
 
 
 
 
6.6.6. Course and outcome of the febrile events  
The outcome of febrile events in the different groups was analysed, in the 
presence and absence of neutropenia.  
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There were 112, 66, 7 and 10 febrile neutropenic events in the wild type for any 
mutation, chitotriosidase only mutation, NOD2 only mutation and combine mutation 
groups respectively. Total febrile days (neutropenic or non-neutropenic) and total 
days of antimicrobial treatment per group showed no statistical differences 
between the four groups. Number of febrile events ended in recovery, ITU 
admission or death showed no significance between all groups (table 6.10.). 
Combined gene mutation showed no effect in the duration of febrile events or 
treatment required.  
The outcomes of such febrile events in the presence or absence of neutropenia 
showed no significant differences. Although a trend towards significance was 
observed in the febrile non-neutropenic patients with combined mutation and the 
necessity of Hickman line removal as a part of management. 
 
 
Table 6.9.4. Patients with febrile events without identifiable organism. FNEs only, FNnEs only, 
any event either FNE or FNnE, and both FNE & FNnE. in the four groups. P value by Chi square 
test. 
Fever and culture -ve event WT for any of 
the mutations; 
Total pts=109 
Chitotriosidase 
only mutation; 
Total pts=75 
NOD2 only 
mutation;      
Total pts=10 
Combined 
mutations;  
Total pts=7 
Pts with only neutropenic 
events. (%) 
P= 0.578 
24 
(22.02%) 
12 
(16%) 
1 
(10%) 
2 
(28.57%) 
Pts with only non-
neutropenic events. (%). P= 
0.550 
19 
(17.43%) 
10 
(13.33%) 
1 
(10%) 
0 
Pts with total events either 
neutropenia or non-
neutropenia. (%).  
P= 0.055 
54 
(49.54%) 
24 
(32%) 
2 
(10%) 
3 
(42.86%) 
Pts with fever, both whilst 
neutropenia and non-
neutropenia. (%).  
P= 0.164 
11 
(10.09%) 
2 
(2.67%) 
0 1 
(14.29%) 
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Table 6.10. Outcome of febrile events in the four proportions. (FNE: febrile neutropenic event, 
FNnE: febrile non-neutropenic event, R: treatment, HL: Hickman line, pts: patients, ITU: intensive 
treatment unit). P values calculated by Chi square and Kruskal Wallis (Kw) tests. 
Course & Outcome FNE= 112:66:7:10 FNnE= 66:36:5:5 
Pts per group WT; 
109 
Chito; 
75 
NOD2;  
10 
Comb; 
7 
WT; 
109 
Chito; 
75 
NOD2; 
10 
Comb; 
7 
Total febrile 
days/genotype 
P= 
460 
 (Kw) 
2.988  
226 
 
49 53 221 
 
0.085 
147 
 
 
22 12 
Total days of 
antimicrobial R 
P= 
1477   
Kw 
1.830 
792 
 
136 121 733 
 
0.111 
424 
 
65 39 
Number of FE 
necessitated HL 
removal. 
P= 
10 
8.93% 
 
0.959 
7 
10.61
% 
    
1 
16.67
% 
1 
10% 
4 
6.06% 
 
0.078 
5 
13.89
% 
 
1 
20% 
2 
40% 
Number of FE with 
complete recovery.  
 
P = 
105 
93.75
% 
0.625 
64 
96.97
% 
7 
100% 
9 
90% 
60 
90.91
% 
0.353 
29 
80.56
% 
 
5  
100% 
4          
80% 
Number of pts with 
recovered febrile 
events.  
P= 
60 
55.05
% 
 0.507   
35 
46.67
%  
5 
50% 
5 
71.43
% 
38 
34.86
% 
0.797 
21 
28% 
3 
30% 
2 
28.57
% 
Number of febrile 
events ended in ITU.  
P= 
5 
4.46% 
0.274 
1 
1.51% 
 
1 
14.29
% 
1 
10% 
4 
6.06% 
0.391 
5 
13.89
% 
0 1 
20% 
Number of pts 
admitted to ITU 
P= 
5 
4.59% 
0.224 
1 
1.33% 
 
1 
10% 
1 
14.29
% 
3 
2.75% 
0.847 
3 
4% 
 
0 0 
Number of FE ended 
in death.  
P= 
2 
1.79 
0.871 
2 
3.03% 
 
0 0 2 
1.79% 
0.305 
4 
11.11
% 
0 0 
Number of pts died. 
 
P= 
2 
1.83% 
0.871 
2 
2.67% 
 
0 0 2 
1.83% 
0.305 
4 
5.33% 
 
0 0 
Median 
-Fever days per 
patient 
-Antimicrobial R days 
per patient 
-Antimicrobial R 
days/fever days 
 
2 
 
9 
 
4.5 
 
0 
 
0 
 
0 
 
1 
 
7.5 
 
7.5 
 
7 
 
15 
 
2.14 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
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6.7.  Discussion  
In this study, we investigated the association between functional polymorphisms in 
selected genes involved in innate immunity and the risk of infections. The NOD2, a 
general sensor of PG from negative and gram positive bacteria223 and 
chitotriosidase with the chitolytic activity towards fungal pathogens.224 
The incidence of double mutation of both genes (chitotriosidase & NOD2) in our 
study population was 3.48%. This section of the study was done to determine the 
effect of combined gene mutation in innate immunity (chitotriosidase & NOD2) 
compared to single gene mutation or no mutation on the incidence and outcome of 
sepsis in the presence or absence of neutropenia compared to single mutation of 
each gene.  
The presence of combined mutations (chitotriosidase & NOD2) showed no 
statistical differences in the incidence and duration of neutropenia as well as the 
number of neutropenic days per patient. Neutropenic days per patient and per 
episode of neutropenia were higher in the NOD2 mutation compared to the other 
three groups. 
The number of febrile events was analysed per group, and in the presence and/or 
absence of neutropenia. The proportion of patients with febrile events did not differ 
statistically between the four groups. Also there were no statistical differences in 
the number of febrile events per episode of neutropenia. This section showed no 
impact differences between the four groups whether one gene or both gene were 
mutant on the number of febrile events per patient in the presence or absence of 
neutropenia or the in number of febrile events per episode of neutropenia. 
The prevalence of certain pathogens were analysed in relation to number of 
events, patients and organisms.  
Unidentified organisms causing fever in relation to episode of neutropenia was 
significantly higher in the combined gene mutation group.  
  
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Wild type for any mutation group seemed to have a tendency for unidentified cause 
of febrile events regardless or without neutropenia. In all comparisons NOD2 only 
mutation group was repeatedly the lowest in FUO occurrence. 
Episodes of neutropenia and fever due to viral isolate were significantly higher in 
the NOD2 only mutation. This significance was carried along when febrile events 
associated with neutropenia were analysed.  
It is worth mentioning that documented viral infections were very few in our study. 
Viruses are still difficult to isolate technically. The availability of viral RNA-PCR is 
still limited and not all viruses could be identified. For these reasons it could be that 
viral infection, reactivation or co-infection were missed and the diagnosis of FUO is 
eminent. As it is shown from our study usually patients are neutropenic and may be 
unable to elicit any immune response. Patients could deteriorate so fast prior to a 
diagnosis or occurrence of fever. 
Fever due to viral isolates, especially in the presence of neutropenia and in relation 
to NOD2 mutation may need to be investigated in larger scale in the future. 
In the absence of neutropenia both the combined gene mutant and NOD2 only 
mutant groups showed statistical significance of positive bacterial cultures as a 
cause of sepsis.   
Fungal infections were so small in number to give a good picture in our study. 
Combined genes mutation seems to have no effect in overall course and outcome 
of febrile events in comparison to only gene mutation. Although a trend of Hickman 
line removal was observed in the combined gene mutant group this could be due to 
increase defect in macrophages function. 
In our study population the incidence of combined gene mutation was only 3.48%.  
 
 
    
6.8  Conclusions 
In this comparative study the following were significant associations: 
 Positive bacterial cultures and fever with normal count of neutrophils were higher 
in patients with NOD2 only mutation or combined gene mutations.  
Positive viral isolate in fever accompanied with neuropenia in the group of NOD2 
only mutation. 
Culture negative and fever with neutropenia in the combined gene mutation group. 
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Chapter  7 
 
General discussion 
 
7.1. Genetic determinants of sepsis in haematological 
malignancy: 
Studies are ongoing to determine the role of genetic background in various 
malignancies, infections, immunity and inflammatory syndromes, since some 
genes have been shown to be linked to incidence, course and outcome of such 
conditions either directly or indirectly.   
Patients diagnosed with haematological malignancy are at risk of sepsis due to 
bone marrow involvement and the subsequent neutropenia. Studying the impact of 
genetic determinants may improve our understanding of the pathogenesis and 
ultimately may allow identification of patients who would benefit from specific 
preventive or therapeutic measures. 
In our study we focused on two genes, which have been implicated in the immune 
response. Mutations in such genes have been shown to alter the immune cascade 
through recognition, presentation and elimination of pathogen by macrophages and 
neutrophils. The aim of our study was to determine if mutation in either of these 
genes increases the incidence of sepsis, prevalence to specific organism or alters 
the outcome of infection. This was examined in all states of neutrophil count.  
We have selected to study two genes involved in innate immunity. The first gene is 
the human phagocyte-specific chitotriosidase. Increased enzyme activity has been 
demonstrated in patients with Gaucher disease,100 and also reported in other 
lysosomal diseases.118 Elevated activity was associated with gram-negative 
infection in children undergoing therapy for acute myeloid leukaemia suggesting 
    
pleiotropic effects96 and in neonates with fungal infection.6 Other associations have 
been observed in malaria,112 sarcoidosis,121, 225 leprosy226 visceral Leishmaniasis112 
and tuberculous pleural effusions.227  
The second gene, NOD2 ,encodes the intracellular NOD2 receptor, expressed in 
the monocytes,131 macrophages, dendritic cells,144  intestinal epithelial140 and 
Paneth cells.145 which binds to MDP of bacterial cell wall and leading to 
inflammatory response.93, 138, 139 Three alleles of NOD2 have been linked mainly to 
CD4, 130 but also an association has been described with sepsis,164, 175  sepsis 
related mortality in GvHD (hematopoietic stem cell transplant),8, 9 small intestine 
allograft rejection228 and more recently with spontaneous bacterial peritonitis in 
patients with cirrhosis.229  
Chitotriosidase and NOD2 genes are both involved in the immune response by 
common recognition of pathogen molecules.97 Molecules such as PGN which 
initiate the response by stimulating the neutrophils. Ejik et al even studied the 
effect of NOD2 activation on chitotriosidase expression by phagocytes.97 After 
studying the effect of mutations in each gene separately we tried to find out if the 
combined mutation of both genes have a synergic effect on incidence of sepsis, 
prevalence to specific organism or alters the outcome of infection.The presence of 
mutations and the impact on the immune response in patients with haematological 
malignancy were the basis of our study. This impact was investigated in three 
different sub studies. The first sub study was carried out comparing the 
chitotriosidase genotypes (wild type, heterozygote and homozygote for the 
mutation). Secondly we compared NOD2 genotypes the wild type, the NOD2-
SNP8; Arg702Trp and the NOD2-SNP12; Gly908Arg. The third sub study was 
comparative, carried out between four groups wild type for any mutation, 
chitotriosidase only mutation, NOD2 only mutation (SNP8 and SNP12) and 
combined chitotriosidase and NOD2 mutation. 
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7.1.1.  Incidence and duration of neutropenia: 
A reduction in neutrophil count is a usual finding in haematological malignancies 
and due to chemotherapy. The effect of neutropenia and duration of neutropenia 
on sepsis incidence, outcome and organism prevalence were studied in relation to 
gene status.  
Analysis was carried out separately in the three sub studies. We compared the 
number of episodes of neutropenia per genotype and per patients. The incidence 
of neutropenia showed no statistical differences between the chitotriosidase or 
NOD2 genotypes. The finding was the same when mutation of either gene 
genotypes was studied or when the mutation of each gene was compared with the 
absence of mutation or the combined chitotriosidase NOD2 mutation.  
There was no significant difference in the number of neutropenic episodes but 
there was a suggestion, which did not meet statistical significance, of an increase 
in duration of neutropenia with the homozygote chitotriosidase mutation. NOD2 
genotypes did not appear to influence incidence or duration of neutropenia. 
From the above findings we can conclude the absence of any relationship between 
innate immune genes, chitotriosidase and NOD2 (SNP8 & SNP12)) and 
neutrophils response to chemotherapy. There was no effect on the neutrophils fall 
or duration of regeneration in our study population of haematological malignancy 
patients regardless of genotype of chitotriosidase or NOD2.  
 
7.1.2.  Incidence of infective episodes: 
Next we evaluated the incidence of sepsis in patients with haematological 
malignancy who were either neutropenic or not. To determine if mutation of two 
genes involved in innate immunity have any effect on neutrophil function we 
analysed the incidence of febrile events (infections) in relation to neutrophil 
according to genotype in each patient.  
  
 
A febrile event was considered if temperature of 38.5°C or greater occurred once 
or 38°C in more than one occasion.We observed that the incidence of infection did 
not differ between chitotriosidase genotypes whatever the neutrophil count was. In 
contrast other studies have demonstrated a relationship between chitotriosidase 
and sepsis such as a study in children with the mutation undergoing AML 
chemotherapy.96 Another study showed improved survival with the introduction of 
recombinant human chitotriosidase to neutropenic mice with Aspergillosis.7 
Explanations of our findings could be the wider variety of haematological 
malignancies, the patients’ age (adults) and the species in which our study was 
conducted on (human vs mice).  
The overall incidence of sepsis was the same for all three NOD2 genotypes (wild 
type NOD2, NOD2-SNP8; Arg702Trp or NOD2-SNP12; Gly908Arg). Although 
NOD2 response leads to NF-κB activation the degree of response to LPS and 
PGN differ between genotypes, due to selective defects in leukocyte function with 
NOD2 mutation.230 The response in NOD2-SNP8; Arg702Trp and the NOD2-
SNP12; Gly908Arg is diminished compared to the absence of response230 in the 
more prevalent frameshift SNP13; L1007fsinsC.4, 130 We could not examine this 
mutation due to technical difficulties (software and primer design). 
The innate immune response in the low birth weight infants163 and adults164 has 
also been examined, in different studies and an increase incidence of sepsis was 
found in the mutant genotypes a finding we could not replicate in our study with 
adult patients.  
NOD2 and the incidence of sepsis have been studied widely but not in relation to 
neutropenia. In our study the incidence of sepsis in NOD2 genotypes showed no 
significant association to neutrophil count. Similar studies are in post transplant 
(SCT) patients which showed increase TRM due to intestinal and pulmonary 
complications.8, 9  
The incidence of sepsis was also not affected by combinations of the mutations of 
the innate immune genes (chitotriosidase and NOD2 (SNP8 & SNP12)). 
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From the above findings we can conclude the absence of any association between 
the incidence of sepsis whatever the neutrophil count was and any of the genes we 
looked at (NOD2 and chitotriosidase genotypes) in isolation or combination. 
 
7.1.3.  Organism prevalence: 
The final section of this study was to evaluate the relationship between mutations 
of (chitotriosidase and NOD2 (SNP8 & SNP12)) genes and prevalence of various 
organisms in patients with infective events. Organisms were divided into four 
groups; bacterial, fungal (proven and probable IFD), viral and unidentified (culture 
negative and possible IFD). Possible IFD is the term used when the radiology 
histopathalogy, cytology or fluid and body material direct examination are not 
suggestive of fungal infection despite the clinical picture.183  We felt that the 
evidence for fungal infection in these cases was so limited that it would be 
inappropriate to include these events in any group other than the culture negative. 
Studies have shown increased chitotriosidase activity during bacterial infections in 
neonates6 and immune compromised children due to AML and chemotherapy.96  
Although we did not include measurements of chitotriosidase activity in our study, 
nevertheless we did find a positive association between bacterial cultures and 
heterozygote chitotriosidase mutations regardless of neutropenia. 
This association arose in the presence of neutropenia for heterozygote 
chitotriosidase mutation. NOD2 mutations have also been observed in association 
with increased incidence of sepsis due to bacterial pathogens in both adults and 
neonates by different investigators.163, 164 Although we did not identify the 
SNP13;L1007fsinsC which is considered to lack bacterial PGN/LPS response230 
and only identified  the SNP8;Arg702Trp and SNP12;Gly908Arg, SNPs with 
decreased response to the same bacterial components230 the NOD2 mutations 
showed significant association with bacterial infections in febrile events occurring in 
non-neutropenic patients. This finding was confirmed when the NOD2 mutation 
was considered in combination with the chitotriosidase.  
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Documented fungal infections (proven and probable) were so few in our study and 
we could not obtain a result in all the three sub studies. The diagnosis of fungal 
infection requires host factor, clinical and mycological criterion. Definite 
identification of fungal infection requires histological, cytopathalogical or direct 
microscopic examination of body material and fluids.183 The absence of such 
mycological criterion even with the strong suspicions based on host-clinical factors 
make the category of diagnosis of fungal infection ‘possible’. In our study we 
analysed the ‘possible IFD’ with the other culture negative events. 
Documented viral isolates causing febrile events in neutropenic patients showed a 
statistical association with NOD2 mutations but with uncertain relevance since so 
few viral infections were confirmed. This may be because these organisms are 
difficult to identify technically (PCR not available for every virus), or loss of some 
patients from the study before samples were taken. We believe viral infections can 
be easily missed and miss-classified as culture negative. A larger study specifically 
of viral and fungal events would be necessary to confirm this finding.  
The proportion of febrile events with negative cultures and so unidentified cause of 
infection was significantly higher in the chitotriosidase homozygote mutation 
genotypes. This significance was more pronounced with the presence of 
neutropenia. 
As mentioned earlier the culture negative category includes possible fungal 
infections. Could this be the cause of more febrile events with unidentified cause of 
infections in the homozygote chitotriosidase mutation in our study? Keeping in 
mind the studies7, 106, 182 mentioning the association of chitotriosidase and fungal 
infections. 
Combining gene mutations showed significant association with FUO in relation to 
episodes of neutropenia, although none of the genes showed this association 
when studied separately.  It looks from our comparative sub study that there is 
synergistic effect of combined mutations on susceptibility to bacterial infections 
even when there are adequate number of neutrophils. The synergistic effect is 
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more pronounced when the patient is neutropenic, as during episodes of 
neutropenia there were increase occurrences of FUO.  
In conclusion it would appear that there were more bacterial isolates from patients 
with chitotriosidase mutations when neutropenic and more in patients with NOD2 
genotypes or combined chitotriosidase and NOD-2 mutation when not neutropenic.  
Culture negative infections were associated with both chitotriosidase genotypes 
and the combination of chitotriosidase and NOD2 during neutropenia. This 
association could be due to the synergistic effect of combined mutation on top of 
neutropenia. The question here is, does combined NOD2/chitotriosidase mutation 
predispose individuals in the set of immunosupression to infections with unusual 
organisms or does the patient immunological response alter the picture of clinical 
presentation! 
Another question is how accurate is the diagnosis of culture negative fever is? Are 
we obtaining enough specimens or is technology here to blame?  
The number of patients with combined mutations in our study was only 3.48% (7 
out of 201 patients). The incidence of infections in the set of combined mutations 
involved in immune response may need to be investigated in wider scale of 
patients.  
The outcome of sepsis was not significantly affected by any of the genes involved 
in our study. Severe infections and death has been investigated by various 
researchers and found to be increased in relation to NOD2 polymorphisms.164, 175, 
229
 
The findings in our study could be of clinical significance in patients becoming 
immunocompromised in the course of their life due to disease or therapy 
(chemotherapy or SCT). As the innate immune mechanism is affected by 
mutations of chitotriosidase and NOD2, it might be possible to prevent or decrease 
the incidence of morbidity infections by taking extra prophylactic measures in 
patients known to have the relevant genotypes. Measures could be targeted 
according to mutation and Neutrophils status. 
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7.2.  NOD2 mutation and ALL outcome 
Several studies8, 9, 221 observed the effect of NOD2 polymorphisms on the outcome 
of SCT  in immunocompromised patients and concluded an increase incidence in 
relapse and decrease overall survival. The incidence was higher when both 
recipient and donor carried the mutation. Contrary to this study Sairafi et al10 
showed no impact of NOD2 mutation in outcome post transplant. Similarly our 
study in ALL patients undergoing chemotherapy also showed no statistical 
significance of NOD2 polymorphisms and the outcome (CR, relapse or OS). Death 
was due to sepsis in 40% of our ALL population.  
 
7.3.  Mutations: 
7.3.1.  Chitotriosidase: 
The frequency of chitotriosidase mutation was around 40.20%. The heterozygote 
gene mutation was 34.80% in our study population almost as same as the 
Portuguese population 30-40%,107 and in the Netherlands among Ashkenazim106 
(37%). In both studies the homozygote mutation was about 6%,106, 107 again close 
to 5.39% homozygote mutation  seen in our study.  
 
7.3.2.  NOD2: 
There was a noticeable variation in NOD2 mutation frequencies in our two studies. 
This could be contributed to the different ethnic background and/or diagnosis. The 
NOD2 mutation frequency in our studies population was 13.31% (variation 
between the two studies; 8.46-34.04%). The Gly908Arg (SNP12) was the more 
frequent mutation. 
The compound heterogeneity (SNP8 and SNP 12) mutation was 1.21% (variation; 
1.0-2.13). 
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In the NOD2 mutation and ALL outcome study population, the three SNPs 
polymorphisms were successfully identified. The incidence of heterozygosity was 
10.64%, 21.28% and 2.13% for Arg702Trp (SNP8), Gly908Arg (SNP12) and 
frameshift L1007fsins (SNP13) respectively. Homozygosity for the mutation was 
2.13% and occurred only in the L1007fsins. The compound (Arg702Trp and 
Gly908Arg) allele mutation incidence was 2.13%.   
In the genetic determinants of sepsis study the frequency of the heterozygote 
mutation was 3.48% and 5.57% for Arg702Trp (SNP8) and Gly908Arg (SNP12) 
respectively. Homozygosity for the mutation was 0.50% for Gly908Arg and 
compound heterozygosity for both SNPs was 1.0%. The Gly908Arg mutation 
occurred more frequently, while L1007fsins was the least identified mutation in this 
study. The frameshift L1007fsins identification was unsuccessful in this arm of the 
study. The initial genescanning technique failed as well as Anthony Nolan 
protocol231 and even the pyrosequencing method used for detection of the two 
missense variants (Arg702Trp and Gly908Arg) did not work. Eventually we had to 
terminate our study exempting the frameshift mutation.   
The three major NOD2 polymorphisms Arg702Trp (SNP8), Gly908Arg (SNP12) 
and the frameshift L1007fsins (SNP13) have demonstrated remarkable 
heterogeneity across ethnicities and populations with regional differences. The 
variations in the mutation frequency in our studies could be contributed to by the 
ethnic differences or the diagnoses. In the NOD2 mutation and ALL outcome study, 
patients were only diagnosed with ALL and the study was multicentre, raising the 
possibilities of differences in ethnicity eg variation in predominance of Caucasians 
in some parts of the UK 146. In the genetic determinants of sepsis study, patients 
were diagnosed with various haematological malignancies (including AML, ALL, 
CLL, CML, MM... etc). An explanation for the low incidence of NOD2 mutation in 
this study population could be the mixture of diagnosis and ethnic background. For 
example Multiple myeloma incidence is as twice as common in patients of African 
descent compared to cauacasions190 while NOD2 mutation is low in this group147. 
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This study was only conducted in the RFH in central London with wide background 
ethnicities. 
 
7.4.  Limitations: 
Recruitment took place in the RFH between June 2006 - March 2008. Initially 310 
patients with haematological malignancy were approached but only 257 consented. 
Out of the consented patients only 204 met the inclusion criteria. 
The aim was to recruit 200-250 patients from in-patient haematological wards but 
later out-patient department was included due accelerate the recruitment process. 
Blood samples were planned to be drawn with the routine investigations while in-
patient admission. Later blood was collected from the haematology laboratory due 
to loss of in patient samples and convenience for patients 2-3 samples for each 
patient were required to reach the desired DNA concentration (200ng/µl), more 
samples were necessary when patients were neutropenic. Difficulties in obtaining 
enough blood were another obstacle in patients who had undergone allogenic 
transplant or patients who had died. 
NOD2 identification was initially successful by gene scanning and results were 
obtained and checked randomly for accuracy by DNA sequencing. But this method 
was tricky and at a point stopped working although measures were taken to try and 
find out what went wrong. Measures such as; change of the primer set and 
annealing temperature (gradient temperature). Other methods such as NOD2 
genotyping adopted by Anthony Nolan231 was also tried but with no success. It took 
months – year to find a team to give us assistance and alternatively 
pyrosequencing was started with the help of Hammersmith haematology 
laboratory. 
By pyrosequencing, SNP8 and SNP12 missense mutations were easily determined 
and distinguished from the wild type but this was different with SNP13 frameshift 
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mutation. Technical support advice was sought with no success. Unfortunately time 
limitations meant the laboratory work had to be completed without SNP13.  
Identification of NOD2 SNPs 8 and 12 by genescanning and pyrosequencing were 
compared for the same 50 DNA samples. The results obtained were identical, 
confirming the equality and accuracy of both methods used. 
 
7.5.  Conclusions: 
Polymorphisms in genes involved in innate immunity appear to be associated with 
bacterial infections. Chitotriosidase mutations were associated with bacterial 
infections in the neutropenic patients while NOD2 and combinations of mutations 
were similarly associated in the non-neutropenic patients. 
Innate immune gene polymorphisms also seem to predispose to infections with 
unidentified pathogens in the presence of neutropenia. This association was seen 
in patients with the homozygote mutation of chitotriosidase and the combination of 
NOD2 and chitotriosidase mutations. 
Documented viral infection was associated with NOD2 mutations in the presence 
of neutropenia, but in a very small number of patients. 
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Appendix-1 
 
A.1. Recruitment forms 



A.1.1.  Invitation letter 
 
 
Study title: 
Genetic determinants of sepsis and gasterointestinal pathology in haematological 
malignancy 
 
 
 
Dear Patient 
 
You are invited to join our study of genetic determinants of sepsis and 
gasterointestinal pathology in haematological malignancy, as you did fulfill our 
inclusion criteria. If you do wish to participate please read the information leaflet 
and sign the consent form attached. Should you want to discuss any aspect of the 
study we will be happy to explain it. 
 
 
 
Thank you 
 
Research Fellow 
Lamya Saeed 
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Study Number: 
Patient Identification Number for this study: 
 
A.1.2. CONSENT FORM 
 
Title of Project: 
Genetic determinants of sepsis and gastrointestinal pathology in haematological malignancy 
 
Name of Researcher: 
Dr Satish Keshav MBBCh DPhil FRCP, Consultant Physician & Gastroenterologist 
Dr Lamya Saeed 
Dr Derralynn Hughes 
Professor S MacKinnon 
Professor Alejandro Madrigal 
         Please initial box 
1. I confirm that I have read and understand the information sheet dated .................         
for the above study. I have had the opportunity to consider the information,  
ask questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw ........  
  at any time, without giving any reason, without my medical care or legal rights  
 being affected. 
 
3. I understand that relevant sections of any of my medical notes and data collected ..   
 during  the study, may be looked at by researchers involved in the study.  
 I give permission for these individuals to have access to my records.                             
                                                                                                                                            
 
4. I agree to my GP being informed of my participation in the study.                        
 
 
5.   I agree to take part in the above study.       
 
________________________ ___________________________________ 
Name of Patient Date Signature 
 
 
 
_________________________ ____________________________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ___________________________________ 
Researcher Date  Signature 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes 
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A.1.3.         Patient Information Sheet 
 
Part 1. 
 
Study title: Genetic determinants of sepsis and gastrointestinal pathology in 
haematological malignancy. 
 
 
This information sheet is written to help to answer questions you might have about 
this study, which we have invited you to participate in. In addition to reading this, 
you will have the opportunity to ask questions from the researchers in person, and 
you should participate only if you fully understand what we are proposing.  
 
 
What is the purpose of the study? 
To find out what influences the chances of developing an infection as a 
consequence of having leukaemia, lymphoma, or a number of other blood 
disorders, particularly after treatment with anti-cancer drugs. Specifically, we want 
to understand the influence of inherited genes, such as the NOD2, Chitotriosidase, 
and Dectin genes, on the susceptibility to and severity of infections. Also there is 
some evidence of NOD2 involvement in other conditions.  
 
Why have I been chosen? 
Patients suffering from blood cancers are prone to severe infections, and as you 
are in this category, we want to study if you have any of the genes that we think 
may make patients with blood cancers prone to severe infections.  
 
Do I have to take part? 
Participation is completely voluntary, and if you do not feel able to participate this 
will not effect your treatment or care in any way. 
 
What will happen to me if I take part? 
A small tube of blood (approximately x tablespoon/10mls) will be taken in addition 
to your usual blood tests, and during your stay in hospital, we will keep a check on 
your blood count, and whether you develop a fever or infection. We will take blood 
when most convenient for you e.g. at the time when other bloods are taken as part 
of your standard hospital care. 
 
The blood sample will be used to test your DNA for the presence of particular 
genes.  
You will not be required to do anything else, and your medical treatment will not be 
influenced in any way.  
If you leave hospital while still on antibiotics, we will check on your condition when 
you come back to clinic.  
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What do I have to do? 
All you need to do is to give a blood sample, for DNA extraction and analysis. If 
you wish to take part in this study you will be given a copy of this information sheet 
and a signed consent form to keep. 
 
 
What are the risks of taking part? 
There are no risks to you. 
 
What are the benefits of taking part? 
By finding out the relation between infections and NOD2, Chitotriosidase, and 
Dectin genes status, we might be able to prevent fever and infections in certain 
patients in the future, and thus improve treatment. However, it is unlikely that this 
research will benefit you personally. 
 
What if relevant information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the area that is being studied. If this happens, we will tell you about 
it and discuss whether you wish to participate. 
 
What happens when the research study stops?  
The information will be analysed and stored. Your name and identity will remain 
anonymous.  
 
What if there is a problem? 
You will be able to contact any of the study staff, and they will liaise with your 
regular medical carers.  
 
If you have a concern about any aspect of this study, you should ask to speak with 
the researchers who will do their best to answer your questions (Dr Lamya Saeed, 
32887; Dr Satish Keshav, ext 32882; Derralynn Hughes, bleep 71-1720). If you 
remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital. 
 
In the event that something does go wrong and you are harmed as a result of 
taking part in this research study there are arrangements for non-negligent 
harm/no-fault compensation. If you are harmed and this is due to someone’s 
negligence then you may have grounds for a legal action for compensation but you 
may have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you.  
 
Will information about me be kept confidential? 
Yes. All the information collected about you during the course of the study will be 
strictly confidential. Any published report or research will not identify you. 
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This completes Part 1 of the information sheet. 
If the information in Part 1 has interested you and you are considering participation, 
please continue to read the additional information in Part 2 before making any 
decision. 
 
 
Part 2 
 
What will happen if I do not want to carry on with the study? 
Participation in the study is entirely voluntary, withdrawal from the study will not 
affect your medical care and your data and samples can be destroyed if you 
request this. 
 
 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of research will 
be confidential. Name, address and records identification will be removed and data 
will have a number and stored in excel sheet.  
 
What will happen to any sample I give? 
Blood will be extracted only once in the beginning of the participation and used for 
DNA extraction and genotyping.  
 
Will any genetic tests be done? 
Yes. We will look for the presence of particular genes such as the NOD2, 
Chitotriosidase, and Dectin on the susceptibility to and severity of infections. 
 
 
What will happen to the results of the research study? 
The research results will be reported in the scientific and medical literature. You 
will not be identified in any report/publication. If you wish to be informed of the 
study’s finding, please inform Dr Keshav or Dr Saeed. 
 
Who is organizing and funding the research? 
This study is the initiative of researchers in the departments of Gastroenterology 
and Haematology, and the funding is from various sources. If the study results are 
positive, further funding from public bodies will be sought. University College 
London (UCL) is the Research Governance sponsor for this study 
 
Who has reviewed the study? 
The study has been reviewed by scientific and medical colleagues who are not 
connected with the study, and by the Ethics committee of the Royal Free Hospital.  
 
Contacts: Dr Lamya Saeed, ext. 32887, Dr Satish Keshav, ext. 32882, Derralynn Hughes, bleep 71-1720 
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A.1.4. GP letter 
 
 
      Date 
Dr General Practioner 
Community Health Centre 
Street 
Suburb 
City 
Postcode 
Country 
 
 
Dear Dr 
 
RE: Name 
DOB 
Hosp. no 
 
Your patient has kindly agreed to participate in our study “Genetic determinants of sepsis 
in haematological malignancy”.  
The study will involve drawing 10ml of blood during routine venepuncture for DNA 
extraction and subsequent genotyping. During the patient’s stay in hospital a data sheet 
will be maintained charting their WBC count and details of any septic episodes. Patients 
will be followed in their in-patient stay and the outcome of their stay will be recorded.  
Longer follow up may be needed in a few patients, who are discharged whilst still on 
antimicrobial therapy. 
We do not anticipate that participation will have any effect on their treatment or its 
outcome. If you have any questions relating to this study, please contact us. 
 
Yours sincerely 
 
 
Dr Satish Keshav      Dr L. Saeed 
Senior lecturer & Consultant Physician   Clinical research fellow 
Gastroenterology      Gastroenterology 
 
cc: Dr Derralyn Hughes, Lecturer in haematology 
cc: Professor Stephen MacKinnon, … 
cc: Professor Jose Alejandro Madrigal, ... 
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Appendix-2 
 
A.2. Follow up forms 
 
A.2.1.    NOD-2 and Sepsis project 
Back ground haematology history 
 
Name:     
DOB:      Hosp Number:   
Date admitted:     Date assessed: 
 
 
Diagnosis on admission:  
Date first diagnosed:   
Place of diagnosis:   
 
Referring GP & address:  
 
1st line therapy:  
Response:    
Date of 1st CR: 
Duration of CR: 
Date of 1st relapse: 
 
2nd line therapy: 
Response: 
Date of 2nd CR: 
Duration 2nd CR: 
Date of  2nd relapse: 
 
Background & follw up: 
 
 
Summary: 
Admission  
 
Neutropenia (/7) 
 
Neutropenic episode= 
Neutropenic sepsis= 
 
Status on D/C Neutopenia 
   Antibiotics 
   Prophylactic regimen 
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A.2.2.  Data collection sheet page 1 
Study: Genetic determinants of sepsis in haematological malignancy 
Table 1 – Basic data 
Case number: 
 
 
 Hospital 
number: 
 Date of birth: 
 
 Sex: 
 
M or F 
Diagnosis: 
 
 BMT? 
N or A or R 
 Date of admission:  Date of 
discharge: 
Neutropenia: 
 
Y or N 
 Sepsis: 
N or Y 
? clinical or 
proven  
 Discharge status: 
 
 
  
DNA sample  NOD2  Chitotriosidase  Dectin 
Table 2 – Daily data during admission 
Day No.  1 2 3 4 5 6 7 
Date         
WCC (109/ml)         
PMN (109/ml)         
Max temp (°C)         
Min temp (°C)         
Not septic         
?Septic         
Clinical sepsis         
Proven sepsis         
Culture result         
Site of sepsis         
Antibiotics         
Antifungals         
Other:         
Day No.  8 9 19 11 12 13 14 
Date         
WCC (109/ml)         
PMN (109/ml)         
Max temp (°C)         
Min temp (°C)         
Not septic         
?Septic         
Clinical sepsis         
Proven sepsis         
Culture result         
Site of sepsis         
Antibiotics         
Antifungals         
Other:         
Continue notes on back of sheet if necessary.   For hospital stay >14 days, use continuation sheets.  
   
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Table 3 – Notes (with dates): 
Sepsis:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Culture:  
 
Antimicrobial treatment: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging/radiology:  
 
 
Relevant haematology/comorbidity:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other:  
 
G-CSF? 
 
GM-CSF? 
For hospital stay >14 days, use continuation sheets.  
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Data collection sheet page 2 
Study: Genetic determinants of sepsis in haematological malignancy 
Table 1 – Basic data 
Case number: 
 
 
 Hospital 
number: 
 Date of birth: 
 
 Sex: 
 
M or F 
Diagnosis: 
 
 BMT? 
N or A or R 
 Date of admission:  Date of 
discharge: 
Neutropenia: 
 
Y or N 
 Sepsis: 
N or Y 
? clinical or 
proven  
 Discharge status: 
 
 
  
DNA sample  NOD2  Chitotriosidase  Dectin 
Table 2 – Daily data during admission 
Day No.  15 16 17 18 19 20 21 
Date         
WCC (109/ml)         
PMN (109/ml)         
Max temp (°C)         
Min temp (°C)         
Not septic         
?Septic         
Clinical sepsis         
Proven sepsis         
Culture result         
Site of sepsis         
Antibiotics         
Antifungals         
Other:         
Day No.  22 23 24 25 26 27 28 
Date         
WCC (109/ml)         
PMN (109/ml)         
Max temp (°C)         
Min temp (°C)         
Not septic         
?Septic         
Clinical sepsis         
Proven sepsis         
Culture result         
Site of sepsis         
Antibiotics         
Antifungals         
Other:         
Continue notes on back of sheet if necessary.   For hospital stay >28 days, use continuation sheets.  
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Table 3 – Notes (with dates): 
Sepsis:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Culture:  
 
Antimicrobial treatment: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging/radiology:  
 
 
Relevant haematology/co-morbidity:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other:  
 
G-CSF? 
 
GM-CSF? 
 
For hospital stay >14 days, use continuation sheets.  
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Data collection sheet page __ 
Study: Genetic determinants of sepsis in haematological malignancy 
Table 1 – Basic data 
Case number: 
 
 
 Hospital 
number: 
 Date of birth: 
 
 Sex: 
 
M or F 
Diagnosis: 
 
 BMT? 
N or A or R 
 Date of admission:  Date of 
discharge: 
Neutropenia: 
 
Y or N 
 Sepsis: 
N or Y 
? clinical or 
proven  
 Discharge status: 
 
 
  
DNA sample  NOD2  Chitotriosidase  Dectin 
Table 2 – Daily data during admission 
Day No.  __ __ __ __ __ __ __ 
Date         
WCC (109/ml)         
PMN (109/ml)         
Max temp (°C)         
Min temp (°C)         
Not septic         
?Septic         
Clinical sepsis         
Proven sepsis         
Culture result         
Site of sepsis         
Antibiotics         
Antifungals         
Other:         
Day No.  __ __ __ __ __ __ __ 
Date         
WCC (109/ml)         
PMN (109/ml)         
Max temp (°C)         
Min temp (°C)         
Not septic         
?Septic         
Clinical sepsis         
Proven sepsis         
Culture result         
Site of sepsis         
Antibiotics         
Antifungals         
Other:         
Continue notes on back of sheet if necessary.   For longer hospital stay, use continuation sheets.  
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Table 3 – Notes (with dates): 
Sepsis:  
 
 
 
 
 
 
 
 
 
 
 
 
 
Culture:  
 
Antimicrobial treatment: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging/radiology:  
 
 
Relevant haematology/co-morbidity:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other:  
 
G-CSF? 
 
GM-CSF? 
For hospital longer hospital stay, use continuation sheets.  
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Appendix-3 
 
A.3. 
 
WHO Classification of neoplastic diseases of the haematopoietic 
and lymphoid tissues 
 
 
I. Proposed WHO classification of myeloid neoplasms 
 
1- Chronic Myeloproliferative Diseases (MDP)*   
Ch myelogenous leukaemia, Philadelphia chromosome positive (t(9;22)(qq34;q11), 
BCR/ABL) 
 Ch neutrophilic leukaemia 
 Ch eosinophilic leukaemia/hypereosinophilic syndrome 
   Male : Female-9:1 
 Ch idiopathic myelofibrosis 
 Ch myeloproliferative disease, unclassified 
 Polycythemia vera 
 Essential thrombocythemia 
 
2-  Myelodysplastic / Myeloproliferative Diseases* 
 Ch myelomonocytic leukaemia (CMML) 
 Atypical ch myeloid leukaemia (aCML) 
 Juvenile myelomonocytic leukaemia (JMML) 
 Myelodysplastic/myeloproliferative diseases, unclassifiable 
    
3- Myelodysplastic Syndromes* 
 Refractory anaemia (RA) 
  -with ringed sideroblasts (RARS) 
  -without ringed sideroblasts 
 Refractory anaemia with excess blasts (RAEB) 
Refractory cytopenia with multilineage dysplasia (RCMD) 
 Myelodysplastic syndrome 
-associated with isolated del (5q) chromosome abnormality 
-unclassifiable 
 
4- Acute Myeloid Leukaemia* 
 AML with recurrent cytogenic abnormalities 
  -AML with t(8;21)(q22;q22), AML1(CBF  )/ETO) 
-AML with abnormal bone marrow eosinophils (inv(16)(p13q22)) or 
t(16;16)(p13;q22), (CBF  /MYH11) 
-Acute promyelocytic leukaemia (AML with t(15;17)(q22;q11-12), (PML/RAR  ) and 
variants) 
-AML with 11q23 (MLL) abnormalities 
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 AML with multilineage dysplasia 
  -with prior myelodysplastic syndrome 
  -without prior myelodysplastic syndrome 
 
 AML and myelodysplastic syndromes, therapy related 
  -Alkylating agent rlated 
  -Topoisomerase II inhibitor-related (epipodophyllotoxins, etoposide) 
  -Other types 
 
 AML not otherwise categorized 
  -AML minimally differentiated 
  -AML without maturation 
  -AML with maturation 
-Acute mylemonocytic leukaemia 
-Acute monoblastic and monocytic leukaemia 
-Acute erythroid leukaemia 
-Acute megakaryoblastic leukaemia 
-Acute basophilic leukaemia 
-Acute panmyleosis with myelofibrosis 
-Myloid sarcoma 
 
 Acute leukaemia of ambiguous lineage 
  -Acute biphenotypic leukaemias 
 
 
II. Proposed WHO classification of lymphoid neoplasms 
 
1- B-Cell Neoplasms 
 Precursor B-cell neoplasm* 
  -Preccursor B lymphoblastic leukaemia/lymphoma 
 
 Mature (peripheral) B-cell neoplasms* 
  -Ch lymhocytic leukaemia/small lymphocytic lymphoma 
  -B-cell prolymphocytic leukaemia 
  -Lymphoplasmacytic lymphoma 
  -Splenic marginal zone lymphoma (+/- villous lymphocytes) 
  -Hairy cell leukaemia 
  -Plasma cell myeloma / plasmacytoma 
  -Solitary plasmacytoma of bone 
  -Extraosseous plasmacytoma 
-Extanodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 
(MALT-lymphoma) 
-Nodal marginal zone B-cell lymphoma (+/- monocytoid B cells) 
-Follicular lymphoma 
-Mantle cell lymphoma 
-Diffuse large B-cell lymphoma 
-Mediastinal (thymic) large B-cell lymphoma 
-Intravascular large B-cell lymphoma 
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-Primary effusion lymphoma 
-Burkitt lymphoma/Burkitt’s cell leukaemia 
 
 B-cell proliferations of uncertain malignant potential** 
  -Lymphoid granulomatosis 
  -Post-transplant lymphoproliferative disorder, polymorphic 
 
2- T-Cell And NK-Cell Neoplasms 
 
 Precursor T-cell neoplasms* 
  -Precursor T lymphoblastic leukaemia/lymphoma 
  -Blastic NK cell lymphoma*** 
 
 Mature T-cell and NK-cell neoplasms* 
  -T-cell prolymphocytic leukaemia 
  -T-cell large granular lymphocytic leukaemia 
  -Aggressive NK cell leukaemia 
  -Adult T-cell leukaemia/lymphoma (HTLV1+) 
  -Extranodal NK/T-cell lymphoma, nasal type 
  -Enteropathy-type    T-cell lymphoma 
  -Hepatosplenic T-cell lymphoma 
  -Subcutaneous panniculitis-like T-cell lymphoma 
  -Mycosis fungoides 
  -Sezary syndrome 
  -Primary cutaneous anaplastic large cell lymphoma (T/null cell) 
  -Peripheral T-cell lymphoma, unspecified 
  -Angioimmunoblastic T-cell lymphoma 
  -Anaplastic large cell lymphoma (T/null cell, primary systemic) 
 
 T-cell proliferation of uncertain malignant potential** 
  -Lymphoid papulosis 
    
3- Hodgkin Lymphoma* 
 Nodular lymphocyte predominant HL 
 Classical HL 
 Nodular sclerosis classical HL 
 Lymphocyte-rich classical HL 
 Mixed cellularity classical HL 
 Lymphocyte-depleted classical HL 
 
 
III. Histiocytic And Dendritic-Cell Neoplasms 
 
1- Macrophage/histiocytic neoplasm* 
 Histocytic sarcoma 
   
2- Dendritic cell neoplasms 
 Langerhans cell histocytosis** 
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 Langerhans cell sarcoma* 
 Interdigitating dendritic cell sarcoma*/tumour** 
 Follicular dendritic cell sarcoma*/tumour** 
 Dentritic cell sarcoma, not otherwise specified* 
 
 
1V. Mastocytosis; Mast Cell Diseases 
 
Cutaneous mastocytosis 
Indolent systemic mastocytosis** 
Systemic mastocytosis with associated 
 clonal, haematological non-mast cell lineage disease* 
Aggressive systemic mastocytosis* 
Mast cell leukaemia* 
Mast cell sarcoma* 
Extracutaneous mastocytoma** 
  
 
 
Behave as malignant tumours, * 
Lesions of low or uncertain malignant potential, ** 
Neoplasms of uncertain lineage and stage of differentiation, *** 
 
 
 
 
 
1. NL Harris, ES Jaffe, J Diebold, G Flandrin, HK Muller-Hermelink, J Vardiman, TA Lister & CD 
Bloomfield. The world Health Organizaton classification of neoplastic diseases of the haematopoietic 
and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, 
November 1997. Histopathalogy. 2000, 36, 69-86. 
2. ES Jaffe, NL Harris, H Stein, JW Vardiman. World Health Organization Classification of Tumours. 
Pathalogy & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon2001. 
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A.4. RFH Policy 
 
A.4.1. 
 
Anti – Infective Therapy Guidelines 
For Patients with  
Haematological Disease. 
 
ADULT EDITION  
 
Updated and Amended in 2008  
 
by: 
Dr Archie Prentice, Prof Chris Kibbler,  
Prof Paul Griffiths, Dr Ron Chakraverty, Hannah Kershaw, 
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INTRODUCTION 
 
 
There are two sets of anti-infective therapy guidelines for patients with a haematological 
disease, this one for adults and another one for paediatrics (Supportive care protocols 
paediatric haematology and oncology – found in the guidelines section on Freenet). 
 
The aims of the guidelines are to ensure that anti-infective treatment with an appropriate 
spectrum of activity is given and to avoid over prescribing. As with all protocols, specific 
clinical situations may dictate modifications, and we have attempted to include some 
general principles to help in these situations. The majority of the recommendations are for 
empirical treatment of infections. If a specific microbiological diagnosis is made, treatment 
may require modification. 
 
These guidelines are specially tailored to the requirements of a particular group of 
patients, i.e. haematological oncology patients.  They are, therefore, not directly applicable 
to other patients on cytotoxic regimens or with neutropenia. 
Patients eligible for ongoing clinical trials should, wherever possible, be entered into trials 
rather than following this protocol. 
 
Further details of drugs and doses are included in Section 4. 
 
If you are not experienced in the management of neutropenic and HSCT patients, 
the management of febrile patients should always be discussed. 
 
Advice may be sought from: - 
• Haematology Consultants and SpRs 
• Microbiology Registrar - Bleep 1907 or Ext. 33973 
• Virology Registrar - Bleep 1669 or Ext. 34089 
• Haematology Pharmacists – Bleep 1873, 1341 and 2054 
• On-call Pharmacist via switchboard out of hours 
• Out of hours the microbiology registrar on call can be contacted via bleep 1710 or 
via switchboard 
 
Royal Free Hospital: 020 7794 0500 
   
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1. NEUTROPENIC AND HSCT PATIENTS 
 
 
1.1. PROPHYLAXIS 
 
1.1.1 Standard Regimen (NB Note HSCT amendments) 
 
Prophylaxis should be given to all patients receiving myelosuppressive therapy, i.e. any 
block of chemotherapy that will produce a prolonged period (>7 days) of profound 
neutropenia (neutrophils < 0.5 x 109/l). 
Patients who had prolonged (>7 days) periods of neutropenia (< 0.1 x 109/l) on previous 
courses of chemotherapy normally considered non-myelosuppressive, should receive 
standard prophylaxis for subsequent courses e.g. CHOP, CODOX-M. 
 
Standard Regimen: 
 
• Chlorhexidine (0.2%) mouthwash - 5ml four times a day 
 
• Aciclovir – HSCT patients only; for those who are HSV IgG antibody positive, give 400 
mg po tds for seven days or until engraftment 
 
• Also see fungal protocol 
 
 
Commencing prophylaxis: 
Standard prophylaxis should be commenced on the first day of chemotherapy. Antifungal 
prophylaxis should, where possible, be commenced the day before chemotherapy. 
However, itraconazole must not be given until 24 hrs after cylophosphamide 
conditioning has been administered. Itraconazole must not be used at all in patients 
on vincristine – see antifungal policy. 
If the patient is neutropenic on presentation (neutrophils <0.5 x 109/l) prophylaxis should 
be commenced immediately. 
 
Stopping prophylaxis: 
Prophylaxis can be stopped when neutrophils are > 0.5 x 109/l on 2 consecutive readings 
within 3 to 4 days. 
 
 
1.1.2. Specific Prophylaxis 
 
CMV Prophylaxis 
Prophylaxis is no longer used to prevent CMV infections after HSCT, instead pre-emptive 
therapy is used (see next section). Patients receiving highly immunosuppressive 
chemotherapy, such as Fludarabine, 2cDA or CAMPATH may also be considered for CMV 
pre-emptive therapy. 
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Endocarditis prophylaxis 
Please see below. In almost every situation prophylaxis is not indicated. 
Please discuss with microbiology if there are any queries. 
 
NICE guidance 
Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing 
interventional procedures (March 2008) 
Antibacterial prophylaxis and chlorhexidine mouthwash are not recommended for the 
prevention of endocarditis in patients undergoing dental procedures. 
Antibacterial prophylaxis is not recommended for the prevention of endocarditis in patients 
undergoing procedures of the: 
– upper and lower respiratory tract (including ear, nose, and throat procedures and 
bronchoscopy); 
– genito-urinary tract (including urological, gynaecological, and obstetric procedures); 
– upper and lower gastro-intestinal tract. 
 
Whilst these procedures can cause bacteraemia, there is no clear association with the 
development of infective endocarditis. Prophylaxis may expose patients to the adverse 
effects of antimicrobials when the evidence of benefit has not been proven. 
 
Any infection in patients at risk of endocarditis should be investigated promptly and treated 
appropriately to reduce the risk of endocarditis. 
 
If patients at risk of endocarditis are undergoing a gastro-intestinal or genito-urinary tract 
procedure at a site where infection is suspected, they should receive appropriate 
antibacterial therapy that includes cover against organisms that cause endocarditis. 
 
Patients at risk of endocarditis should be: 
– advised to maintain good oral hygiene; 
– told how to recognise signs of infective endocarditis, and advised when to seek 
expert advice. 
 
GVHD or Hyposplenism 
Penicillin V 500mg bd po (if not on co-trimoxazole). If penicillin allergic, use Erythromycin 
250mg bd po. Continue lifelong. Vaccinate with Pneumovax,Hib vaccine, and 
Meningococcal C vaccine  at least two weeks before an elective splenectomy or as soon 
as possible before an emergency procedure. 
 
Herpes simplex virus prophylaxis 
Chemotherapy patients with IgG antibodies to HSV present should be prescribed Aciclovir 
po 400 mg tds while neutropenic. Patients who are negative for HSV antibody should stop 
taking aciclovir. HSCT patients with IgG antibodies to HSV presenting pre-transplant 
should be prescribed aciclovir po 400mg tds for 100 days from transplant. If the patient is 
unable to tolerate the oral route, give aciclovir iv 5mg/kg tds. 
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Pneumocystis jiroveci (PCP) 
The following groups of patients should receive prophylaxis with co-trimoxazole 960mg 
3x a week (Mon, Wed, Fri)1. 
 
• Allogeneic HSCT patients (see below) 
• Patients receiving fludarabine or cladribine (continue for 6 months post last dose) 
• Patients receiving > 40 mg prednisolone po daily for > 2 weeks2 
• Patients with ALL for 120 weeks in continuous complete remission or at least 1 extra 
year after any extramedullary relapse3 
• Hodgkins Disease 
 
Allogeneic HSCT Patients:- 
During the week prior to BMT, give co-trimoxazole 960mg bd po daily until day -1 of the 
conditioning regimen. In the immediate post transplant period give nebulised pentamidine 
150mg every two weeks (after nebulised or inhaled salbutamol) or 300mg monthly until 
engraftment. In the first three months post transplant, co-trimoxazole is especially 
associated with marrow toxicity. Restart co-trimoxazole at a dose of 960mg bd po on 2 
consecutive days per week when counts have recovered (neutrophil count > 1.0 x 109/l) 
and continue for at least six months post transplant, or until CD4 count is > 200. 
Autologous HSCT patients only require co-trimoxazole if previously treated with a purine 
antagonist as above 
 
If allergic to co-trimoxazole: prescribe dapsone po 100mg once daily (check G6PD where 
appropriate). 
 
1 Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) 
in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007 Jul 
18;(3) 
2 Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired 
immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo 
Clin Proc. 1996 Jan;71(1):5-13. 
3 Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent 
chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987 Jun 
25;316(26):1627-32. 
 
 
Toxoplasmosis 
If the stem cell donor or recipient has evidence of a recent clinical infection (IgM ELISA 
positive) give the following for 6 weeks; 
– Pyrimethamine 100 mg po twelve hourly on day 1 as a loading dose, then 25 mg 
po tds  
– Sulfadiazine 3g po as loading dose then 2g po tds, and calcium folinate 15mg po 
od 
 
Tuberculosis 
Give prophylaxis if past history of TB or suspicious CXR, irrespective of geographical 
background. Otherwise see Trust Guidelines for TB prophylaxis in immunocompromised 
patients. Usual regimen = isoniazid 300mg po od and pyridoxine 25mg po od for 6 months 
after HSCT or for duration of neutropenia. Remember to monitor LFT's closely and to 
discontinue treatment if significant deterioration occurs. 
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Viral Contact  
– Chickenpox or zoster: Check IgG status to VZV. If negative, give Zoster 
Immunoglobulin (ZIG) and consider oral Valaciclovir 1g tds from day 7-14 (where 
day of first contact is day 0)  
 
– Measles: Normal immunoglobulin, one dose for an adult is 750mg im. If patient is 
thrombocytopenic give a stat dose of Immunoglobulin iv 400mg/kg and repeat if 
further exposure occurs after 3 weeks 
 
– Parvovirus and other exanthemata: discuss with Virology Department. 
 
  
 
1.2 PRE-EMPTIVE TREATMENT 
 
 
1. Pseudomonas aeruginosa in neutropenic patients  
(isolated from mucosal sites e.g. stool, mouth) 
Discuss with microbiology, options include ciprofloxacin, aztreonam, ceftazidime, 
piptazobactam and meropenem. 
 
2. Staphylococcus aureus in neutropenic patients 
If present on nasal swab use topical Mupirocin intranasally tds for 5 days. MRSA 
eradication should be carried out using the standard protocol (infection control policies 
available on Freenet) 
 
3. Galactomannan in High Risk Patients 
Patients at increased risk of invasive fungal infection should be screened twice a week for 
invasive aspergillosis with serum galactomannan. Empiric therapy may be commenced if 
two consecutive samples are positive (after discussion with microbiology). Patients at 
increased risk of invasive fungal infection include adults on therapy for ALL, AML, 
allogenic transplant patients, patients on high dose cytarabine (ara-c) and those with 
severe GVHD (see antifungal protocol for details). 
 
4. CMV surveillance in HSCT patients 
Quantitative CMV PCR should be requested on a regular basis in HSCT patients (send a 
citrated blood sample on Tuesdays and Thursdays).  
For patients with matched unrelated donors who are CMV seronegative (and so will not 
have adoptively transferred some immunity to the recipient), pre-emptive treatment is 
warranted if a single CMV PCR result is positive. For the remaining patients,pre-emptive 
treatment is warranted if the viral load is 3000 genomes/ml or greater in a single sample.  
A number of ongoing clinical trials are performed at the Royal Free Hospital in relation to 
pre-emptive therapy for CMV. Please consult with the virology team and, where 
appropriate, the relevant trial protocol. 
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Pre-emptive therapy consists of ONE of the following along with G-CSF (lenograstim) 263 
microgram subcut / iv once daily, to be initiated if neutrophils <1.0 x 109/l and continued 
according to response.  
 
First Line therapy: 
Ganciclovir 5 mg/kg iv bd (reduced with renal impairment) 
 
Other therapeutic options include: 
 
– Foscarnet 90mg/kg iv bd (reduced with renal impairment - see appendix for dosing 
guidelines and discuss with specialist pharmacist). This is to be used in preference 
to ganciclovir if the patient is neutropaenic 
– Ganciclovir 5 mg/kg iv od PLUS Foscarnet 90mg/kg iv od 
– Valganciclovir 900mg po bd (reduced with renal impairment)  Valganciclovir is 
usually well-absorbed, even in patients who have GvHD affecting the gut, but 
monitor twice-weekly PCR results carefully and consider swopping to iv ganciclovir 
if there is any doubt about absorption. Valganciclovir may be used in low-risk 
patients with low CMV loads after discussion with the attending haematology 
consultant, and a member of the virology team. 
 
Patients with >3000 genomes/ml stop treatment when two consecutive viral load results 
are negative or according to trial protocol as appropriate. 
Patients treated because their viral load is below 3000 on two consecutive samples should 
stop treatment when two consecutive negative PCR values have been obtained.   
 
 
5. HHV- 6  in HSCT patients 
HHV-6 PCR should be performed on both donor and recipient pre-transplant to detect 
individuals with integrated DNA. 
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1.3 EMPIRICAL TREATMENT OF FEVER IN NEUTROPENIC 
PATIENTS  
 
Patients with fever of 38.5oC on one occasion should receive prompt empirical antibiotic 
therapy. Patients with a temperature of 38oC should be checked again in 1 hour and if still 
38oC, or above, should receive prompt empirical antibiotic therapy. Use of antipyretic 
therapies (e.g. steroids) should be taken into account as should the normal temperature or 
even hypothermia in a septic patient. Conversely, other non-infective causes of fever must 
be considered (e.g. blood and drugs). 
Initial Investigations: at least two sets of blood cultures from two separate sites, 
CXR, urine, as well as specimens from clinically suspicious sites. 
 
If patient is on oral itraconazole prophylaxis then an itraconazole level should be 
measured. Obtain a trough level by taking a blood sample immediately prior to the next 
dose of itraconazole after starting the antibiotics. It can take up to 3 days for results to 
become available and this will be used to guide the empirical anti fungal therapy after 
96hrs. Galactomannan can also be requested on this sample. 
 
Examination of febrile neutropenic patients must include: 
Specific questions as to the presence of; 
• respiratory tract symptoms – nasal congestion, sore throat, cough, pleuritic chest 
pain, shortness of breath 
• painful ulcers/lesions in the groin/perineum 
• new rash, or new onset of diarrhoea 
 
Full examination including the skin and mucous membranes, as well as the perineum and 
peri-anal area. Fundoscopy can reveal systemic infection (eg candida endophthalmitis). 
This must be repeated daily whilst the fever is ongoing  
 
Repeat blood cultures every 24 hours while febrile (>38oC). 
Arrange CT scanning of the chest if fever persists >96 hours 
 
If pulmonary infiltrates are present on plain chest radiography with a non-productive 
cough, an early BAL should be arranged in addition to the described schedule. (See 
section 1.4.4 for HSCT patients with pneumonitis). The algorithm below presumes the 
patient is receiving antifungal prophylaxis. 
 
Note there is no evidence for the addition of teicoplanin in the absence of clinical 
signs of line infection or positive cultures, nor is the empiric addition of amikacin 
warranted in patients with continuing fever unresponsive to meropenem.  
If the patient remains hypotensive and shocked despite aggressive fluid 
resuscitation and oxygen therapy, the addition of amikacin should be discussed 
with the consultant haematologist on call and microbiology.
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Algorithm for the Antibiotic Management of Febrile Neutropenia in 
Haematology Oncology Patients  
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1.4 INFECTIONS IN NEUTROPENIC PATIENTS  
 
1.4.1 Notes On Therapy 
 
1.  Definite Bacteraemia. 
(Two or more sets of blood cultures positive for the same organism.) 
When a definite bacteraemia has been diagnosed, antibiotic therapy should be rationalised 
(which may include continuation of broad spectrum cover). When a Gram positive infection 
is diagnosed Gram negative cover with non-aminoglycoside monotherapy should be 
continued for five days.  Methicillin resistant coagulase negative staphylococcal 
bacteraemia requires treatment with teicoplanin. 
 
2.  Persistent Fever. 
If a definite infection fails to respond to appropriate therapy the most likely causes are: 
– Fungal infection - consult the anti-fungal policy. 
– An undetected focus of infection (including line sepsis). 
– In the absence of a source of infection, consider removal of the Hickman line. 
 
3.  Allergy. 
If ANAPHYLAXIS has occurred with one class of beta-lactam antibiotic, the use of others 
is contra-indicated. Use teicoplanin, amikacin, and initiate ciprofloxacin intravenously. 
With beta-lactam allergy (e.g. rash), use meropenem (there is a low risk of cross reactivity 
of carbapenems with other beta-lactams) 
 
4.  Duration. 
– Antibiotic treatment should be given for at least seven days with an apparently 
effective antibiotic, with at least four days without fever.  Patients whose neutrophil 
counts have recovered should be individually assessed. 
– If fever has responded to empirical anti-fungal therapy, this should be continued at 
least until the neutrophil count is ≥0.5 x 109/l. Refer to the anti fungal policy for 
details. 
– No one antibiotic should be used for greater than 10 days. The options are to stop, 
change and/or discuss with microbiology. 
  
5.  Granulocyte Transfusions.  
Granulocyte transfusions are occasionally indicated in adults. Problems with these 
transfusions can include difficulty in achieving a large enough increment and worsening of 
pulmonary disease.  However, when severe infections (e.g. invasive aspergillosis), or focal 
lesions (e.g. perianal sepsis), do not respond to appropriate antibiotic therapy and/or 
neutropenia is expected to be prolonged, granulocyte transfusions may be useful. The use 
of G-CSF mobilised neutrophils from relatives should be considered on an individual basis 
(e.g. invasive aspergillosis). These must be irradiated. Remember to consider any 
ongoing trials.  
 
 
1.4.2 Specific Infections In Neutropenic Patients 
 
Intravenous Catheter-Related Infection 
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• Presumed catheter related bacteraemia / fungaemia 
– Initial empirical antibiotic therapy and then modify antibiotics according to 
isolates. 
– Treat for at least 10 to 14 days (longer if neutropenic). 
– Remove catheter if cultures remain positive after 48 hours of therapy or if 
proven catheter related infection with fungi, Staphylococcus aureus, 
Pseudomonas spp or Mycobacterium spp 
 
• Exit site infection or tunnel infection 
– Initial empirical therapy with teicoplanin. 
– Treat for at least 10 to 14 days or longer until infection resolved. 
– Modify antibiotic therapy according to isolates. 
– Remove catheter if progression or tunnel infection or if blood cultures positive 
for fungi, Staphylococcus aureus, Pseudomonas spp or Mycobacterium spp 
 
Cytomegalovirus (CMV) 
In addition to the standard treatment options for CMV discussed on page 8, 
Immunoglobulin IV could be given in the presence of end-organ CMV disease (especially 
pneumonitis) at a dose of 400 mg/kg on day 1, 4, 8, 12, and 16.  Discuss with Virology. 
 
Varicella Zoster Virus (VZV)* 
Use aciclovir (10mg/kg tds) as initial IV therapy (discuss any dose reductions for renal 
impairment with the pharmacist). You can consider the use of valaciclovir (1g tds) when 
the patients condition is stable 
 
Diarrhoea* 
This should not be treated with antibiotics unless bloody diarrhoea with increased stool 
volume and abdominal pain are present.  Then metronidazole (400mg tds) oral should be 
given while awaiting the results of faecal Clostridium difficile toxin investigations. Standard 
therapy is for 10 days but can be increased to a maximum of 14 days depending on 
symptoms. Severe C.difficile should be treated with metronidazole + oral vancomycin 
(500mg qds) - as per trust protocol (Nb vancomycin levels should be monitored, especially 
if renal impairment) 
 
Clostridium difficile disease; 
Mild = Stool 3-5 x/day and WCC <12 
Severe = WCC >20 or Temp >38.5 or Creatinine >50% baseline or complications (e.g. 
surgical abdomen). 
 
If an infectious cause for diarrhoea is not likely and both stool cultures and C. diffile toxin 
testing (at least one) are negative then the use of loperamide could be considered.  
 
 
Enteric Virus Infection* 
Rotavirus, Adenovirus, Calicivirus (small round structured viruses), Astrovirus. 
     
Send stool sample for Electron microscopy (EM) and for viral culture (VC) in universal 
container. 
 
Haemorrhagic Cystitis 
Polyomavirus (BK), Adenovirus. 
Send urine specimen for Electron microscopy (EM) and for PCR in universal container.  
 
Respiratory Virus Infection* 
(RSV, Influenza A/B, Parainfluenza 1,2,3, Adenovirus). 
 
All inpatients and attending transplant outpatients with acute respiratory symptoms should 
be screened by NPA to screen for viral infection prior to their admission to a general 
haematology/ oncology ward or day assessment area. 
– The NPA should be performed by someone who has been trained by an 
experienced operator. 
– The initial screen will be performed by direct immunofluorescence (IFT) and by 
PCR. 
– All subsequent screening tests will be performed by IFT only.  Once a patient is 
free of symptoms and has had 2 consecutive negatives by IFT, then they will be 
considered negative. 
 
Inpatients 
– Haematology inpatients testing positive in the first screening test will need to be 
moved to a negative pressure room.  
– Return to the Haematology ward will be contigent upon absence of symptoms 
and 2 consecutive negative NPA by direct IFT. 
– This policy is the same as previously with the exception that the initial 
screening test will include PCR.  
 
Outpatients 
– All transplant outpatients with respiratory symptoms will be encouraged to 
contact the BMT CNS before they attend the hospital.  In outpatients known to 
be positive, the transplant team will discuss measures to minimize outpatient 
visits.   
– All transplant outpatients with respiratory symptoms (even without a positive 
NPA) should attend ward 4 West B where one sideroom has been designated 
for respiratory isolation. This room will contain only essential equipment (couch, 
bedside table, stethoscope). Curtains and any other non-essential equipment 
will be removed. 
– The Transplant team will liase with the ward 4 West B staff and ensure the 
room is available before a patient attends. Screening of patients by NPA will be 
as for inpatients. 
– All staff dealing with the patient should wear gown, masks and gloves. The 
appropriate 'Isolation' sign should be posted on the door. 
– After the patient has been seen and has left ward 4 West B, the member of 
staff dealing with the patient should perform a wipedown of horizontal surfaces 
(sink, couch, bedside table) with Milton disinfectant. Gowns, gloves and apron 
should be discarded in the room and the staff member should then wash 
his/her hands. 
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– The following day, this room will be the first to be cleaned and then other 
patients will be free to use this room. 
– Isolation of such patient will continue until they are free of symptoms and have 
2 consecutive negative NPA by direct IFT. 
 
If Virology tests positive; 
 
• RSV* 
     Discuss with Virology. There is no treatment with proven efficacy. 
Nebulised Ribavirin, 6g (in 100ml water for injection) per day. 
Administered as follows: Nebulise either over 12 to 16 hours or nebulise for 2 hours 
then stop for 6, repeat for a total of three times in a day. 
Please liaise with pharmacist about the nebuliser equipment needed for this. 
 Plus 
 If patient hypoxic or abnormal chest X-ray/CT, consider intravenous  ribavirin. 
      Discuss with virology.  
      Repeat NPA at day 3. 
 
• Influenza* 
Start treatment with zanamivir or oseltamivir after discussion with virology. 
The zamamivir dose is 10mg inhaled twice a day. The dose of oseltamivir is 75mg 
bd orally. Treatment is for at least five days, but may continue for longer. 
In cases where a patient appears to have developed influenza while an inpatient, 
prophylactic zanamivir or oseltamivir treatment of other neutropenic or 
immunocompromised patients in the same ward area may be considered. This 
should be done in consultation with virology and infection control. 
 
• Parainfluenza* 
Discuss treatment with Virology. 
 
• Adenovirus* 
Discuss treatment with Virology. Consider cidofovir and discuss doses with 
Pharmacy and virology. 
Staphylococcus aureus (Methicillin sensitive) 
In proven line associated S.aureus bacteraemia intravenous treatment with flucloxacillin 
should be given for at least 14 days.  If the heart valves are abnormal, the fever is slow to 
settle or no focal lesion is seen, a bone scan and echocardiogram are indicated.  
Indwelling vascular devices must be removed unless there are pressing clinical or 
comorbidity reasons to retain it. 
 
Methicillin Resistant Staphyloccocus aureus (MRSA)* 
In proven line-associated bacteraemia, intravenous teicoplanin should be given for at least 
14 days. Intravenous catheters must be removed.  There is a potential for 
dissemination and this should be investigated as for methicillin sensitive S. aureus (as 
above). 
 
* Infection control procedures and protocols in place. Please see trust 
protocol on Freenet (clinical policies) or contact the Infection Control team 
(x35216) 
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1.4.3 Fever With Pulmonary Infiltrates  
 
• Any drop in oxygen saturation or objective evidence of dyspnoea is an emergency. 
Immediate CXR and therapy must be initiated without delay.  Patients with a normal CXR 
should proceed to a thoracic CT scan. 
• At least two sets of blood cultures should be taken: one from central line and one from a 
peripheral vein  
• If a significant pathogen is isolated, treat appropriately. 
• An early bronchoscopy is important in all HSCT patients. Samples should be taken by 
hand by medical staff to microbiology, virology and cytology. Please discuss all 
bronchoscopies with micro staff to ensure all the relevant tests are done. 
• Pleural effusions should be tapped early (diagnostically) where possible. 
• Focal lesions should raise the possibility of fungal infection or of an abscess. CT 
scanning can be very helpful. 
• Serum for Legionella and atypical pathogens should be collected.  Urine should be sent 
for Legionella and pneumoccocal antigens. 
 
PCP 
– High dose co-trimoxazole for a total of 21 days: 120mg/kg/day in 2-4 divided doses 
intravenously for 10 days followed by the same dose orally for 11 days. 
– Calcium folinate (folinic acid - 15mg po/iv once daily) should always be given with high 
dose co-trimoxazole. 
– In proven episodes where the patient is hypoxic, give steroids AT THE START of 
therapy: Prednisolone 40 mg po bd for 5 days, 40 mg od for 5 days, 20 mg od for the 
remainder of therapy.  (40mg Prednisolone is equivalent to 160mg Hydrocortisone). 
Remember to tail down the dose of steroids gradually. 
 
 
1.4.4 Fever with pulmonary infiltrates in HSCT patients (after bone marrow 
recovery)   - not in respiratory failure 
 
1.4.5 Empirical Therapy Of Acute Respiratory Failure. 
 
Requirement of FiO2 35% or active consideration for ventilation. Consider involving the 
Patient At Risk and Resuscitation Team (PARRT). 
For all the following patient types also consult the antifungal guidelines for the appropriate 
treatment option. 
 
 
Neutropenic 
 
General 
Meropenem + Azithromycin + Amikacin + Caspofungin. 
(For adults with lymphoproliferative disease, ALL, or on steroids consider high dose Co-
trimoxazole and CMV treatment). 
 
HSCT patients or chemotherapy with prior Fludarabine / Cladribine  
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Meropenem + aminoglycoside + Azithromycin + High-Dose Co-trimoxazole + Caspofungin 
Consider CMV treatment (check PCR status).  
Caution: this regimen may represent a large fluid load. 
 
Non-neutropenic 
 
HSCT (within 6 months) or Heavy immunosuppression (e.g. long term high dose steroids 
or chronic GVHD) or prior Fludarabine / Cladribine 
High-Dose Co-trimoxazole + consider Azithromycin + consider CMV treatment. 
 
 
See page 8/9 for notes on CMV therapy and page 16 regarding the use of steroids for 
PCP. 
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2. THE FEBRILE NON-NEUTROPENIC PATIENT 
 
These patients should be treated as any other patients*. Their infections and the 
antibiotics they need are different from those of neutropenic patients. Many of the pyrexial 
episodes may be due to mild viral illness for which antibiotics are not indicated. 
 
*Except prior HSCT (within 6 months), chronic GvHD, or fludarabine / cladribine patients in whom 
CMV and PCP will need to be excluded. 
 
General Notes  
 
– All febrile patients should have 2 sets of blood cultures, and an MSU or CSU 
before antibiotics are given. Itraconazole trough levels should be measured if 
patient is on itraconazole prophylaxis. Other samples such as sputum and pus are 
invaluable. 
– These are empirical guidelines and may need modification in the light of 
subsequent isolation of an organism. 
– Further detail including options for Beta-lactam allergy can be found on Freenet or 
in the Adult Antibiotic Prescribing Aid 
 
Candidosis 
Vaginal: Fluconazole po 150mg single dose. 
Oral: Amphotericin B suspension 500mg qds (+/- lozenges). 
Oesophageal or failure to respond: Fluconazole po 100mg od for 7 days. 
 
Cellulitis       
Minor infections: Oral flucloxacillin. 
Otherwise: Intravenous flucloxacillin and benzylpenicillin 
 
Chest Infection 
Non-severe; Amoxicillin +/- clarithromycin 
Severe; Co-amoxiclav + clarithromycin 
Hospital acquired pneumonia; Co-amoxiclav. 
 
Haematuria 
Send urine specimen to Virology (EM and VC) and Microbiology. 
 
Herpes Zoster* 
Cases may be admitted to designated non positive pressure side rooms if no other 
immunocompromised patients are on the ward. Otherwise or for patients with 
disseminated disease discuss with the Infectious Diseases team / ward for admission to a 
negative pressure side room.unless their clinical condition precludes this. Ensure that both 
the Virology department and Occupational Health Unit are notified. Ask Virology 
department to take viral scrape for DIF, PCR and EM. 
 
For non-disseminated infection treat with Aciclovir 10mg/kg tds iv or Valaciclovir 1g tds po 
(if patient stable) at least until all vesicles have scabbed and the patient has been afebrile 
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for 48 hours (in HSCT patients this is rarely less than one week). If disseminated use iv 
Aciclovir 10mgs/kg 8 hourly.  
 
For eye involvement, add Aciclovir 3% eye ointment (topically 5 times daily and continuing 
for at least 3 days after complete healing) and consider a formal ophthalmic assessment. 
Topical 5% cream is also available for facial lesions. 
 
Outpatients who are well and have no evidence of dissemination and can reliably report 
progress daily by telephone, may be treated with acyclovir 800mg 5x a day or valaciclovir 
1 g 3x a day for 7 days – both oral.  
 
Intravenous Catheter-related Infection (See 1.4.2 above) 
Fever in such patients should not automatically be attributed to the line. If the line is 
infected, coagulase negative staphylococci are the most likely organisms. It is essential 
that two sets of blood cultures (from separate sites) are taken before treatment. In the 
absence of strong clinical evidence, therapy with glycopeptides should not be initiated. If 
immediate treatment for a line infection with another focus is required, Teicoplanin plus 
therapy directed at that focus should be used. 
 
Severe Staphylococcus aureus soft tissue infection may be treated with flucloxacillin plus 
oral fusidate sodium. 
 
Meningitis* 
Treatment should be discussed with the Microbiology Department in the light of results of 
investigations. If immediate treatment is needed for suspected meningitis, Ceftriaxone 
should be given (other agents may be more appropriate after LP results are available). 
Vancomycin does not cross the blood brain barrier and penetrates poorly into joints.  
 
Osteomyelitis and Septic Arthritis 
First line; Flucloxacillin 1-2g qds IV (+ sodium fuscidate PO if osteomyelitis) 
 
Septic Shock 
Febrile, hypotensive patients with clinical sepsis and no apparent focus of infection: 
Amikacin and Meropenem (which will include cover for Yersinia, Listeria and Enterococci). 
In patients without lines Teicoplanin is not indicated unless known to be MRSA colonised.  
 
Sickle Crisis 
Intravenous ceftriaxone to cover infections with Haemophilus influenzae, Streptoccocus 
pneumoniae and Salmonella species. Likely sepsis in adults should be treated with co-
amoxiclav.  
 
Superficial mycosis 
After taking scrapings use clotrimazole 1% cream to affected areas bd or tds. Treat for at 
least 14 days after lesions have healed. In persistent or relapsing cases or for cases of 
onychomycosis please discuss with the Microbiology Department. 
 
Toxoplasmosis 
Pyrimethamine 100mg po twelve hourly on day 1 as a loading dose, then 25mg po tds 
Sulfadiazine 3g po/iv as a loading dose, then 2g tds.  
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Calcium floinate 15mg po once daily. 
Treatment is likely to continue for at least 6 weeks. Discuss with microbiology. 
 
Tuberculosis* 
Start patient on quadruple therapy (with Isoniazid, Rifampicin, Ethambutol and 
Pyrazinamide) and contact Dr Lipman’s team for further advice. They will also be able to 
trace contacts, etc, as required. NB: TB is a notifiable disease. 
 
Atypical Mycobacteria 
Antibiotic susceptibility varies and all cases should be discussed with micro. Initial 
treatment usually consists of a combination of amikacin, clarithromycin and ciprofloxacin. 
Treatment can be modified in light of species and sensitivity results but treatment is 
usually up to 6 months in duration. 
 
Urinary Tract Infection 
– Uncomplicated : Nitrofurantoin (contraindicated in G6PD deficiency, in this instance 
use trimethoprim) po for 3-5 days in women (not in 3rd trimester of pregnancy), 5-7 
days plus urological investigation in men. 
– Pyelonephritis: Gentamicin iv initially, then be guided by culture results. 
 
 
* Infection control procedures and protocols in place. Please see trust 
protocol on Freenet (clinical policies) or contact the Infection Control team 
(x35216) 
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3. GUIDELINES ON VACCINATION 
 
(a) Haematological Malignancy and Haematopoetic Stem Cell 
Transplantation. 
 
Inactivated vaccines do not represent a danger to immunocompromised persons.  These 
vaccines comprise DTP, Inactivated Polio vaccine (Salk vaccine), Hib, Hep B, Hep A, 
human papillomavirus, influenza, Pneumococcal, Meningococcal C (A/C/Y/W135 
quadrivalent vaccine is required if participating in the Haj or if visiting endemic areas 
i.e. Middle East, Africa and Asian subcontinent), as well as Cholera and inactivated 
Typhoid vaccine (NB: NOT the new oral vaccine). The inactivated polio vaccine is only 
available in combination with diptheria (low dose) and tetanus (‘Revaxis’).  
 
The immune response of an immunocompromised person to the vaccine antigens may not 
be as good as that of a healthy individual, so that higher doses and more frequent 
boosters may be required.   
 
If vaccination with an inactivated vaccine is needed in a patient about to undergo 
chemotherapy or radiotherapy, it should precede the treatment by at least two weeks.  The 
antibody response may be sub-optimal if vaccination is carried out closer to, or during 
treatment. 
 
Live vaccines (e.g. BCG, MMR, oral Sabin polio vaccine, Live Attenuated Typhoid, Yellow 
fever, Vaccinia,  Chickenpox or Zoster [note that the zoster vaccine contains a higher dose 
of virus than does the chickenpox vaccine]  vaccines) are contraindicated in this group of 
patients but those with leukaemia in remission who have not received chemotherapy for at 
least 12 months may receive live vaccines safely. Maintenance treatment for ALL in 
remission should be considered to be immunosuppressive chemotherapy. 
Live vaccines should not be administered until 2 years after HSCT. This period may 
be prolonged indefinitely for patients receiving continuous immunosuppression for GVHD. 
 
Oral polio vaccine should NOT be administered to household contacts of 
immunocompromised patients.  Inactivated polio vaccine should be used instead. (note 
inactivated polio vaccine is now only available in combination with diphtheria (low dose) 
and tetanus). 
 
Offer influenza vaccine to family members who will visit the HSCT patient during October- 
April. 
 
If family members do not have a history of chickenpox, test them for VZV IgG and give live 
attenuated chickenpox vaccine if seronegative. If they develop a rash (uncommon) they 
should avoid contact with immunocompromised patients. 
 
Recipients of BCG should avoid contact with immunocompromised patients for 1 month 
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Immunisation Programme for HSCT Patients (ALLO OR AUTO) 
 
One Year Post HSCT 
 
Check functional antibody titres (pneumococcal, haemophilus influenza B, tetanus) pre-
vaccination. Then give; 
• Revaxis (combined diphtheria [low dose], tetanus and inactivated polio vaccine) 3 
doses 4 weeks apart. 
• Hib vaccine (combined with meningococcal C vaccine at Royal Free – see below) 
• Meningococcal C vaccine. If participating in the Haj give A/C/Y/W135 quadrivalent 
vaccine. As meningococcal A/C vaccine is no longer available, patients living in a 
country with a high prevalence of serotypes A and C may also require the 
quadrivalent vaccine 
• Influenza vaccine. 
• Hepatitis B vaccine – best results are achieved with a 0, 1month, 6 month regime 
• Pneumococcal (23 valent) Vaccine. If the patient has chronic GvHD/hyposplenic 
state or is undergoing continuing immunosuppression, Penicillin V prophylaxis 
(500mg po bd) should also be given. 
 
3 months following vaccination, re-check titres for functional antibodies. Aim for tetanus 
toxoid >1IU/ml, haemophilus influenza B >1mg/l and pneumococcal antibody >50mg/l. 
 
2 Years Post HSCT 
 
• MMR II vaccine, 2 injections 6-12 months apart. No clear evidence for benefit of 
second dose so this can be omitted if desired 
 
Note MMR is contraindicated in the presence of immunosuppression or GVHD. HSC 
transplant recipients are presumed immunocompetant at >24 months post-transplant if 
they are off all immunosuppressive therapy and have no evidence of GVHD. 
 
Every Year Thereafter 
 
• Give Influenza vaccine to patients with chronic GVHD or who are undergoing 
continuing immunosuppression. 
• Check Pneumococcal antibodies if the patient has chronic GVHD / hyposplenic 
state or is undergoing continuing immunosuppression. Re-vaccinate at 5 year 
intervals if the antibody level is less than 50mg/l. 
 
 
(b) Vaccinations Pre-splenectomy Or In Patients With Functional 
Hyposplenism 
 
One month to fourteen days before splenectomy, or as early as possible before operation 
or when functional hyposplenism is diagnosed: 
 
• Give Pneumococcal vaccine.  Antibody levels should be monitored every year and re-
vaccination considered at five years if antibody level less than 50mg/l. 
• Give Hib vaccine (single dose) 
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• Give Meningococcal C vaccine. Other meningococcal vaccines are only necessary if 
patients are travelling to an area of increased risk of infection, or those for whom it is 
specifically recommended i.e. contacts of cases, Haj pilgrims (see above). 
• These patients also require Penicillin V prophylaxis (500mg po bd) for life. If penicillin 
allergic, use Erythromycin 250mg bd po 
• Patients should also be given advice regarding travel to malarious areas. Please liase 
with a travel clinic or the ID team. 
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4. THERAPEUTIC DOSES OF ANTI-INFECTIVE DRUGS 
 AND ADMINISTRATION DETAILS 
 
• The following are general guidelines for therapeutic doses of anti-infective drugs for 
haematology patients.  Specific clinical situations may dictate modifications. 
• For further advice about dosage modifications in renal/liver impairment or drug 
administration, contact the Specialist Haematology Pharmacists (Bleep 1873, 1960, 
2054) or Medicines Information (Extension: 33114). Out of hours you can access the 
pharmacist via switchboard. 
• In G6PD deficiency avoid Nitrofurantoin, Quinolones (eg ciprofloxacin), Sulphonamides 
(including co-trimoxazole)and Dapsone. 
• For further information on reconstitution and administration of intravenous doses, refer 
to the ‘Guidelines for Intravenous Drug Administration’ and the individual products 
summary of product characteristics. 
 
ACICLOVIR 
 
Dose Check indication, immune status, renal function and age before prescribing. Use 
ideal body weight. 
For VZV treatment:  10 mg/kg iv tds  
 (or Valaciclovir 1gm tds as out patients) 
For HSV treatment: 5mg/kg iv tds or 400mg po 5 times a day 
For HSV prophylaxis:  400mg po tds 
 
 
Dose Reduction in Renal Impairment  
- For Intravenous Doses 
Creatinine Clearance (ml/min) Dose Frequency 
26 - 50 Unit dose 5-10 mg/kg Every 12 hours 
10 - 25 Unit dose 5-10 mg/kg Every 24 hours 
<10 Half unit dose 2.5-5 mg/kg Every 24 hours 
 
- For Oral Doses  
Creatinine Clearance (ml/min) Dose Frequency 
26 - 50 Dose as normal Dose as normal 
10 - 25 Simplex: 200mg 
Zoster: 800mg 
3-4 times a day 
Every 8 – 12 hours 
<10 Simplex: 200mg 
Zoster: 400mg – 800mg 
Every 12 hours 
Every 12 hours 
 
- For Valaciclovir Doses 
Creatinine Clearance (ml/min) Dose Frequency 
30-50 Zoster  
Dose as normal renal function 
 
15-30 Zoster 1g Every 12 hours 
<15 Herpes Zoster: 1g Every 24 hours 
 
Dose Adjustment In Liver Impairment; Dose adjustment not required. 
   
 
AMIKACIN 
 
Courses exceeding 15g in total must be discussed with Microbiology/Infectious Diseases 
due to very high risk of ototoxicity.  Regular audiometry should be performed. Discuss 
need for regimen adjustment and frequency of level monitoring with Microbiology – 
patients with normal levels and stable renal function should have levels monitored twice 
weekly. 
 
Dosing:  
Standard dose is 15mg/kg amikacin IV od. Use ideal body weight (IBW) 
These regimens should be used in all patients unless the following contraindications 
apply: 
1. The dose is being given prophylactically (see Surgical Prophylaxis/Urinary Catheter 
Policies) 
2. CrCl <40ml/min* 
3. Age over 80y 
4. Pregnancy 
5. Burns 
6. Ascites, severe liver disease, jaundice 
7. Cystic Fibrosis 
 
If CrCl >40 but contraindications to once daily dosing apply, give 7.5mg/kg iv bd. Take both 
peak and trough levels across the third dose and wait for results before giving the fourth. 
Keep trough < 10mg/L and peak 20-30 mg/L. 
 
For the full guidance refer to the once daily guidelines for gentamicin and amikacin on 
Freenet. 
 
Therapeutic Monitoring 
Take first trough level before the 3rd dose. Await result before giving the 4th – re-dose 
15mg/kg if trough level <5 mg/L Monitor trough levels (22-23 hours post-dose) twice 
weekly if stable renal function. 
 
Dose Adjustment In Renal Impairment 
Discuss with Microbiology and Pharmacy.  
When initiating therapy the following dose alterations are necessary: 
– CrCl 30-39ml/min give 15mg/kg every 36h. Trough level before 2nd dose. Await 
result before giving 2nd dose. Only give 2nd dose if level <5 mg/L. 
– CrCl 20-29ml/min give 15mg/kg every 48h. Trough level before 2nd dose. Await 
result before giving 2nd dose. Only give 2nd dose if level <5 mg/L. 
– CrCl <20ml/min give 7.5mg/kg stat. Trough level 22-23h later. Await result before 
giving next dose. Only give dose if level <5 mg/L. This process is repeated daily. 
  
Levels must be monitored to allow determination of dose and dosage intervals. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required, but use with caution in patients with ascites. 
 
 
 
     
 
AMOXICILLIN 
 
Dose 
Oral: 250-500 mg tds 
Intravenous: 500 -1g tds 
 
Dose Adjustment In Renal Impairment 
If CrCl >10ml/min, dose as normal. 
If CrCl <10ml/min, give 250mg po/iv tds. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
 
 
LIPOSOMAL AMPHOTERICIN (AMBISOME) 
 
Refer to antifungal policy for all antifungal information. 
 
 
 
AZTREONAM 
 
Dose 2g iv tds 
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose Frequency 
30 – 50 Dose as normal Dose as normal 
10 – 30 1-2g loading dose, then 50% of 
normal dose 
Every 8 hours 
<10 1-2g loading dose, then 
maintenance of 25% of 
appropriate normal dose 
Every 8 hours 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
 
 
AZITHROMYCIN 
 
Dose 
Oral: 500mg od    
Intravenous: 500g od 
 
Duration of treatment = 3 days    
For severe infections, use IV for at least 2 days followed by an oral dose to complete 7-10 
days. 
     
Dose Adjustment In Renal Impairment 
Dose adjustment not required but in severe renal impairment contact pharmacist for 
specialist advice. 
 
Dose Adjustment In Liver Impairment 
Use in hepatic failure contraindicated – jaundice reported 
 
 
 
BENZYLPENICILLIN 
 
Dose 1.2g iv qds   
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose & Frequency 
20 – 50 Dose as normal 
10 – 20 600mg-2.4g every 6 hours  
depending on severity of infection. 
<10 600mg-1.2g every 6 hours  
depending on severity of infection. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required, but monitor LFT’s for cholestatic jaundice. 
 
 
CEFOTAXIME 
 
Dose 2g iv tds up to 12g daily, given in 3-4  
 divided doses, in very severe infections. 
 
Dose Adjustment In Renal Impairment 
It is only necessary to reduce the dose in severe renal impairment.   
If CrCl <10ml/min: give 1g every 8-12 hours. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
 
 
CEFTAZIDIME 
 
Dose Usually 2g iv tds 
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose Frequency 
31 – 50 1–2g Twelve hourly 
16 – 30 1–2g Every 24 hours 
6 – 15 500mg-1g Every 24 hours 
< 5 500mg-1g Every 48 hours 
    
 
Dose Adjustment In Liver Impairment   
Dose adjustment not required. 
 
 
CEFTRIAXONE 
 
Dose 1g to 2g iv every 24 hours 
 
Dose Adjustment In Renal Impairment 
If CrCl < 10ml/min, reduce the dose to 1-2g daily.  
 
Dose Adjustment In Liver Impairment 
Avoid in patients with liver disease (ceftriaxone has been associated with pseudo-lithiasis 
in some patients). 
If the patient already has renal has a further dose reduction may be necessary 
 
 
CIPROFLOXACIN  
 
Dose Oral: 500mg bd   
            Intravenous: 400mg bd 
 
Dose Adjustment In Renal Impairment 
If CrCl < 20ml/min, give 50% of normal dose (i.e. unit dose od or half unit dose bd). 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
Avoid in G6PD deficiency 
 
 
CLARITHROMYCIN 
 
Dose 
Oral: 250mg - 500 mg twice a day;   
Intravenous: 500 mg twice a day. 
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose & Frequency 
30 – 50 Dose as in normal renal function 
10 – 30 IV: 250 - 500mg every 12 hours 
Oral: 250 - 500mg every 12 – 24 hours 
<10 IV: 250mg every 12 hours 
Oral: 250mg every 12 – 24 hours 
 
Dose Adjustment In Liver Impairment 
Use with caution as hepatic dysfunction, including jaundice, has been reported. 
 
Note: Potent inhibitor of cytochrome P450 enzymes 
     
CO-AMOXICLAV (AUGMENTIN) 
 
Dose 
Oral: 375mg - 625mg tds 
Intravenous: 1.2g tds 
   
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose & Frequency 
30 – 50 Dose as in normal renal function 
10 – 30 IV: 1.2g every 12 hours 
Oral: dose as normal 
<10 IV: 1.2g stat followed by 600mg –1.2g every 12 hours 
Oral:  375mg three times a day 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required, but monitor LFT’s for cholestatic jaundice. 
 
 
CO-TRIMOXAZOLE 
 
Dose 
Prophylaxis:  960mg po bd on 2 consecutive days (Tuesday and Wednesday). 
High dose:  120mg/kg/day in 2-4 divided doses po or iv. 
With high dose treatment, Folinic Acid 15mg po daily should be 
given. 
Standard dose:  60mg/kg/day in 2-4 divided doses  
 
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required for prophylaxis treatment. 
Dose adjustment only required for patients on high dose co-trimoxazole treatment. Levels 
must be monitored. 
 
Creatinine Clearance (ml/min) Dose 
> 30  Normal dose 
15 – 30 60mg/kg for 3 days bd, then 30mg/kg/day bd 
<15 Contra-indicated unless patient on haemodialysis 
Seek specialist advice 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not necessary but co-trimoxazole can induce increases in liver enzymes.  
 
Avoid in G6PD deficiency 
 
 
ERYTHROMYCIN 
 
Dose 
Oral: 500mg qds;    
     
Intravenous: 1g qds.  
 
Dose Adjustment In Renal Impairment 
A dose reducuction is required in severe renal impairment (due to the risk of irreversible 
deafness).  
If CrCl >10ml/min, dose as normal 
If CrCl <10ml/min, give 50-75% of normal dose (maximum 1.5g daily). 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required, but use with caution and monitor LFT’s for cholestatic 
jaundice. 
 
Note: Potent inhibitor of cytochrome P450 enzymes 
 
 
ETHAMBUTOL 
 
Dose 
15mg/kg oral once daily. (Monitor visual acuity) 
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose 
10 - 50 7.5 - 15 mg/kg/day 
<10 7.5 - 10 mg/kg /day 
 
Dose Adjustment In Liver Impairment ; Dose adjustment not required. 
 
 
FLUCLOXACILLIN 
 
Dose 250mg - 500mg po QDS 
 500mg-2g iv QDS  
 Consult Microbiology for dosing guidance 
 
Dose Adjustment In Renal Impairment 
<10ml/min CrCl a maximum dose of 4g per 4 hours in divided doses can be used. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required but monitor LFT’s for cholestatic jaundice. 
 
 
FLUCONAZOLE 
 
Consult the antifungal policy for all dosing information 
 
 
FOSCARNET 
 
Dose 90mg/kg bd iv bd OR 60mg/kg iv tds  
. 
     
Dose Adjustment In Renal Impairment 
The following is a guideline only.  Contact the Specialist Pharmacists for more tailored 
dosing. 
Doses can be tailored to twice daily administration. All reductions MUST be discussed with 
the pharmacist 
 
Creatinine Clearance (ml/min) Dose Frequency 
20 - 50 28mg/kg Every 8 hours 
10 - 20 15mg/kg Every 8 hours 
< 10 6mg/kg Every 8 hours 
 
Dose Adjustment In Liver Impairment; 
Dose adjustment not required. 
 
 
 
FUSIDATE SODIUM 
 
Dose Oral and intravenous: 500mg tds.   
If patient < 50kg body weight :  6-7mg/kg 8 hourly, all routes. 
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required. 
 
Dose Adjustment In Liver Impairment 
Consider dose adjustment in moderate to severe liver impairment. 
 
 
GANCICLOVIR 
 
Dose 
For pre-emptive treatment: 5 mg/kg bd iv. G-CSF should be given concurrently. 
 
Dose Adjustment In Renal Impairment 
 
Creatinine Clearance (ml/min) Dose Frequency 
> 70 5mg/kg Twelve hourly 
50 – 69 2.5mg/kg Twelve hourly 
25 – 50 2.5mg/kg Every 24 hours 
10 –25 1.25mg/kg Every 24 hours 
<10 Consult specialist advice form 
Pharmacy 
 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required 
 
 
 
     
GENTAMICIN 
 
This must be prescribed on the approved label which is specific to Gentamicin 
 
Dose 
Once daily dosing : Initial dose 7mg/kg iv in 100ml glucose 5% over 1 hour. 
Nb – use ideal body weight = [males 50kg, females 45kg] + 2.3 kg per inch over 5ft 
 
Levels must be taken 6 -14 hours post dose. A Microbiologist must interpret the first level, 
before the second dose is prescribed. Levels need to be monitored regularly and dose and 
dosing interval modified accordingly.  Refer to the once daily guidelines on Freenet.  
Potential dosing intervals can be predicted as follows: 
 
Creatinine Clearance (ml/min) Dosing Interval 
>60     24 hrs 
40 – 59    36 hrs 
20 – 39    48 hrs 
 
Dose In Renal Impairment 
If CrCl 20 – 60, give 2mg/kg iv bd. Take both peak and trough levels at the third dose and 
wait for results before giving the fourth. 
If CrCl < 20ml/min, give 2 mg/kg od iv.  Do a trough level at 24 hours, and wait for a trough 
level of <2mg/litre before giving next dose. 
 
Dose In Liver Impairment 
Dose adjustment not required, but use with caution if patient has ascites. 
 
 
 
INTRAVENOUS IMMUNOGLOBULINS  
 
Dose 
Intravenous: 400mg/kg/day.  Regime varies.  
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
 
ISONIAZID 
 
Dose 
Oral and intravenous: 5mg/kg once daily (10mg/kg/day for tuberculous meningitis).  Usual 
adult dose is 300mg once daily. 
 
   
 
Dose Adjustment In Renal Impairment  
In severe renal impairment (CrCl <10ml/min), give a maximum dose of 200mg once daily.  
If liver function normal, can give 300mg once daily 
Dose Adjustment In Liver Impairment  
Avoid in liver dysfunction as increase in idiosyncratic hepatotoxicity.  Only initiate therapy if 
expected benefits exceed risk of further hepatic injury. 
 
 
ITRACONAZOLE 
 
Refer to antifungal policy for all antifungal information. 
 
 
LENOGRASTIM GCSF 
 
Normal dose 263mcg daily 
Dose reduction not required in renal failure 
 
 
MEROPENEM 
 
Dose 
1g iv tds 
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose Frequency 
26 - 50 500mg - 2g 12 hourly (bd) 
10 - 25 500mg - 1g 12 hourly (bd) 
< 10 500mg - 1g Every 24 hours (od) 
  
Dose Adjustment In Liver Impairment 
Dose adjustment not required but monitor transaminase and bilirubin. 
 
 
METRONIDAZOLE 
 
Dose 
Oral:  400mg tds (max 2 weeks therapy) 
Intravenous: 500mg tds 
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required unless severe renal impairment.  
If CrCl < 10ml/min, give normal dose every 12 hours. 
 
     
Dose Adjustment In Liver Impairment 
In severe liver dysfunction, there is impaired metronidazole clearance.  Monitor patients 
closely. 
 
 
NITROFURANTOIN 
 
Dose 
Acute uncomplicated infection 50mg every 6 hours 
Severe recurrent infection 100mg 6 hourly 
 
Dose Adjustment In Renal Impairment 
Contraindicated in renal failure 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
Avoid in G6PD deficiency 
 
 
PENTAMIDINE 
 
Dose 
Intravenous: For patients who are allergic or intolerant to high dose co-trimoxazole 
treatment: 4mg/kg once daily for at least 14 days.. 
Nebulised:       Treatment:  600mg nebulised daily (treatment dose), after test dose of 
150mg. (Rarely used). 
Prophylaxis: 300mg nebulised every 4 weeks or 150mg every 2 weeks. 
NB:  Give inhaled terbutaline before each nebulised pentamidine dose. 
  
Dose Adjustment In Renal Impairment 
Dose adjustment not required for nebulised therapy. 
For intravenous pentamidine therapy, if CrCl <10ml/min: consider a dose reduction to 
4mg/kg for 7-10 days then alternate day to a total of 14 days or doses. Seek specialist 
advice from Microbiology and Pharmacy. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required for nebulised therapy. 
For intravenous pentamidine therapy, use with caution in patients with liver impairment, 
and monitor LFT’s and blood glucose. 
 
 
PIPERACILLIN / TAZOBACTAM (TAZOCIN®) 
 
Dose 
IV 4.5g four times a day 
   
 
Dose Adjustment In Renal Impairment 
If CrCl 20-35ml/min, give 4.5g tds 
If CrCl <20ml/min, give 4.5g twelve hourly (bd) 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
 
PYRAZINAMIDE 
 
Dose 
Adults <50kg: 1.5g po once daily ;    
Adults >50kg: 2g po once daily. 
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required. 
 
Dose adjustment In Liver Impairment 
Avoid in liver dysfunction as idiosyncratic hepatotoxicity more common.  Only initiate 
therapy if expected benefits exceed risk of further hepatic injury. 
 
 
PYRIMETHAMINE 
 
Dose 
50mg -75mg po od  or  25mg  po tds 
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required. 
 
Dose adjustment In Liver Impairment 
Dose adjustment not required, but use with caution. 
 
 
RIBAVIRIN 
 
Dose 
Nebulised for RSV (see below).  Treatment is for 3 days.  Discuss longer treatment with 
Virology.  The need for iv ribavirin should also be discussed with Virology. 
Dose Adjustment In Renal Impairment 
Dose adjustment not required for nebulised treatment. 
Dose adjustment required for intravenous ribavirin.  Discuss with the Specialist 
pharmacists. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
     
 
Administration Of Ribavirin Aerosol Dose 
Reconstitute 6g in 100ml WFI. This is nebulised via a small particle aerosol generator 
(SPAG) as follows: 
Nebulise for 2 hours then stop for 6 hours, then nebulise for a further 2 hours then stop for 
6 hours, and then nebulise for a final 2 hours then stop. 
Discard any unused preparation after 24 hours. 
Ribavirin 6g in 300ml has also been nebulised continuously over 12 to 18 hours. 
NB: Any member of staff who is, or could possibly be pregnant, should not enter the room 
whilst the nebulisation is taking place.  It is safe to enter the room when nebulisation has 
stopped. 
 
 
 
TEICOPLANIN 
 
Dose 
400mg iv 12 hourly for 3 doses then 400mg iv once daily. 
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose & Frequency 
20-50 Dose as usual for the first three dose, then give 100% 
dose every 48 hours. Or 
Give 50% every 24 hours 
10-20 Give 100% of the dose every third day (i.e. every 72 
hours). Or 
Give 30%  of dose every 24 hours 
<10 Give 100% of the dose every third day (i.e. every 72 
hours). Or 
Give 30%  of dose every 24 hours 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
 
RIFAMPICIN 
 
Dose 
Adults <50kg:  450mg po / iv once daily (if giving orally, ideally before breakfast) 
Adults >50kg  600mg po / iv once daily (if giving orally, ideally before breakfast) 
 
Use Rifinah (an oral combination of rifampicin and isoniazid) for the treatment of TB. 
 
     
Dose Adjustment In Renal Impairment 
<10ml/min CrCl 50-100% dose, consider a dose reduction.  
Consult Microbiology and Pharmacy. 
 
Dose Adjustment In Liver Impairment 
Avoid in liver impairment, or do not exceed maximum of 8mg/kg per day. Only initiate 
therapy if expected benefits exceed risk of further hepatic injury. 
 
Note: Potent inducer of cytochrome P450 enzymes 
 
 
TRIMETHOPRIM 
 
Dose   200mg po bd for 7 days 
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required. 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required. 
 
 
VALGANCICLOVR 
 
Dose: 
Pre-emptive therapy:  900mg bd until CMV PCR becomes negative on two occasions (or is 
less than 3000 genomes/ml; see current trial). 
 
 
 
Dose adjustment in Renal impairment: 
Creatinine Clearance 
(ml/min) 
Treatment dose (mg) 
40-59 450mg BD 
25-39 450mg OD 
10-24 450mg every 48hours 
<10 Seek Specialist advice 
 
Dose adjustment in liver impairment: 
Dose adjustment not required 
 
 
VALACICLOVIR 
 
Dose 
For treatment of chickenpox or zoster: 1g po tds   
     
 
Dose Adjustment In Renal Impairment 
Creatinine Clearance (ml/min) Dose  Frequency 
15-30     1g  bd 
<15     1g  od 
 
Dose Adjustment In Liver Impairment 
Dose adjustment not required 
 
 
VANCOMYCIN 
 
Dose 
Oral:  125mg qds for 7-10 days for antibiotic associated colitis 
Intravenous: 1g bd. (NB: Infusion over at least 100 minutes) 
 
Dose Adjustment In Renal Impairment 
Dose adjustment not required for oral administration, only intravenous administration. 
Dose adjust in renal impairment according to blood levels. As a guide: 
 
Creatinine Clearance (ml/min) Dose & Frequency 
20 - 50 500mg every 12 hours 
10 - 20 500mg every 24 - 48 hours 
< 10 500mg every 48 - 96 hours 
 
Dose Adjustment In Liver Impairment; Dose adjustment not required. 
 
Therapeutic Monitoring; Levels must be monitored regularly. 
Peak levels should be 18-26mg/l, and trough levels should be 10 -15mg/l. 
 
 
 
 
 
 
 
     
 
 
A.4.2. 
 
 
 
 Antifungal Strategy for Patients with 
Haematological Malignancies 
 
 
 
 
 
Issued November 2003 Amended May 2005 
Re-issued September 2005 Amended October 2005 
Revised February 2007 
A joint collaboration between The Royal Free Hospital, University College 
Hospital and the North London Cancer Network (NLCN)  
 
     
 Introduction  
This collection of guidelines for prophylaxis, investigation, treatment and audit has been 
agreed by the Leukaemia and Lymphoma Board and forms the policy for management of 
all fungal infections in patients with haematological malignancy.  
 
 
 Prophylaxis   
Patients receive prophylaxis according to risk category and this in turn influences their 
empirical therapy. Not all neutropenic patients require prophylaxis and some non-
neutropenic ones with other significant risk factors (such as severe graft-versus-host 
disease) do. Risk is most easily categorised by therapeutic regimen, which allows the 
majority of associated risk factors to be taken account of. Patients receiving itraconazole 
should be considered early for the IV formulation if they are intolerant. 
Prophylaxis should be continued until recovery of the neutrophil count (>0.5 x 109/l) with 
no evidence of fungal infection. 
For cyclophosphamide-containing regimens, prophylaxis should start on the day of HSCT 
transplant, at least 48 hours after the end of chemotherapy and continued until the 
neutrophil count is ≥ 0.5 x 109/L. 
 
Regimen Risk Category Prophylaxis 
Auto PBSC Low No 
Lymphoma chemotherapy* Low No 
Adult ALL chemotherapy** High - Int For vincristine containing blocks: 
Ambisome 3mg/kg three times per week 
for outpatients), followed by itraconazole 
at least 1 week after last vincristine dose. 
Otherwise use itraconazole and oral 
Amphotericin B 
AML chemotherapy High - Int Itraconazole and oral Amphotericin B 
Allogeneic transplantation High Itraconazole and oral Amphotericin B 
 
  
High-dose Cytarabine (ara-C) 
or fludarabine regimens 
High Itraconazole and oral Amphotericin B 
 
* HIV positive patients may require prophylaxis according to HIV risk 
** avoid using itraconazole and voriconazole with vincristine containing regimens. 
Vincristine cannot be given within 5 days of the last itraconazole or voriconazole dose. 
 
Risk factors which may 
change risk category  
  
Colonised at > 1 site High - Int Itraconazole and oral Amphotericin B 
Neutropenia > 5 weeks High Itraconazole and oral Amphotericin B 
Corticosteroids > 1 mg/kg and 
neutrophils < 1 for > 1 week 
High Itraconazole and oral Amphotericin B 
GVHD requiring steroids High Itraconazole and oral Amphotericin B 
 
 
     
Graft-versus-host disease and graft rejection/failure 
Patients with chronic graft-versus-host disease and those who become neutropenic again 
as a result of graft rejection/failure are at significant risk of invasive aspergillosis and 
should receive oral itraconazole prophylaxis. Those with significant gut involvement should 
have levels measured weekly. 
 
Secondary prophylaxis 
Patients with previously documented fungal infection (proven or probable invasive 
aspergillosis or other mould infections, or fungaemia) must receive secondary prophylaxis 
during subsequent neutropenia and graft-versus-host disease. This should be oral 
itraconazole (unless the previous infection broke through itraconazole prophylaxis or was 
unresponsive to itraconazole). AmBisome 3mg/kg/day three times per week may be given 
as an alternative. In cases where patients required voriconazole for treatment of the initial 
infection, this would also be a suitable secondary prophylactic agent. 
 
Abnormal Liver Function Tests 
Pre-existing abnormal liver function tests are not a contra-indication to azole prophylaxis, 
but patients should be monitored carefully and azoles discontinued if there is associated 
progressive hepatotoxicity. 
 
 
 Management of Neutropenic Fever - Investigations  
 
At onset of fever:  
• Trough itraconazole level 
High-risk patients receiving oral itraconazole prophylaxis who become febrile are 
commenced on broad spectrum antibiotic therapy and should have itraconazole levels 
taken. Levels should be taken prior to the next itraconazole dose following the onset of 
fever.  The time of the dose AND the time of the level must be recorded. Assays for 
itraconazole levels are performed twice weekly, therefore a result should be available at 96 
hours to guide subsequent management. If patients have been intolerant of the oral 
preparation and are receiving IV itraconazole, the level can be assumed to be therapeutic 
and no assay need be performed. 
 
At 96 hrs of fever:  
• HRCT chest 
If the fever persists despite 96 hours of broad spectrum empirical antibiotic therapy, a high 
resolution chest CT scan should be performed. If the HRCT is negative and trough 
itraconazole levels are greater than 500ng/ml or the patient is receiving IV itraconazole 
then additional antifungal agents are not required. If the HRCT is negative and the trough 
intraconazole levels are subtherapeutic, then the patient should be switched to IV 
itraconazole prophylaxis (200mg BD for 48hrs, then 200mg OD). 
If there is a delay in performing the HRCT (beyond 120 hours), then patients should be 
treated with targeted therapy pending the CT. If the CT has features suggestive of fungal 
infection, then the patient should received targeted therapy. 
     
  
Ongoing investigations:  
• Serum galactomannan levels twice weekly in high risk patients in centres 
where available 
High-risk patients should be screened twice weekly for serum galactomannan and the 
antigen should be assayed in bronchoalveolar lavage samples, when available.   
Any new respiratory clinical feature should be investigated by CT scanning. All patients 
developing a new fever which persists despite 96 hours of broad spectrum antibiotic 
therapy at the end of neutropenia should have an upper abdominal CT scan (to exclude 
chronic disseminated candidosis).  
Two sets of blood cultures should be taken from different sites (including central lines) in 
patients remaining febrile. An MSU (for fungal culture) should be sent prior to 
commencement of antifungal therapy and in symptomatic patients. 
All patients with blood cultures positive for Candida species should have an upper 
abdominal HR CT scan and an ophthalmological examination of their fundi (for the 
detection of choroidoretinitis/endophthalmitis). 
 
Other:  
Low/low intermediate-risk patients should be managed on clinical or microbiological 
grounds. Consideration should be given to performing a chest HRCT at 96 hours of fever. 
 
 
 
Targeted Therapy 
Targeted therapy is given where evidence exists to suggest invasive fungal infection (CT, 
galactomannan PCR, blood culture), as outlined in the algorithm. This sets out the therapy 
to be given for the different categories of infection and causative organism and subsequent 
modification (if necessary) in the case of toxicity or failure of response. All cases should be 
discussed with the Microbiology Department. Completion of therapy will depend upon the 
causative organism, the extent of the infection and the response to therapy. It may be 
possible to switch to an oral azole to complete therapy, in which case the intravenous 
antifungal should be continued during the 24 hour loading period for the azole. 
 
 Modification of Therapy 
Therapy should be modified as detailed in the algorithm. It should be noted that there is 
currently no evidence for combining antifungal agents in the management of invasive 
aspergillosis and this should not, therefore, be done.  
 
Failure of treatment is defined as progression of clinical features (fever, respiratory 
function, hypotension, haemoptysis or chest pain) after at least 7days of adequate 
antifungal treatment. 
 
Renal toxicity is defined as a creatinine clearance < 50mls/min (this can be calculated 
rather than directly measured). 
 
   
 
Liver toxicity is defined as an elevation of transaminases and/or bilirubin to at least 3 
times the upper limit of normal. 
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Antifungal Agents: Doses 
 
LIPOSOMAL AMPHOTERICIN (AMBISOME) 
 
Dose in Adults & Children 
Intravenous: 3mg/kg three times per week for prophylaxis (see text and algorithm) 
  3mg/kg/day for treatment 
Give a test dose of 1mg on the first day of treatment. 
N.B. Liposomal amphotericin must be infused in glucose 5% with a pre and post flush 
of glucose 5%. 
 
Dose Adjustment in Renal Impairment 
Monitor renal function closely. If renal toxicity supervenes swap to caspofungin or 
voriconazole, taking the potential for drug interactions into consideration 
Dose Adjustment in Liver Impairment 
Dose adjustment not required. 
 
ORAL AMPHOTERICIN B 
 
Dose in adults 
500mg four times a day, total of 2grams. 
Tablets: 5 x 100mg four times a day  
or  Suspension: 5ml four times a day 
Dose in children 
Dose is dependant on age and weight, consult Paediatric Pharmacist for specialist 
advice. 
 
CASPOFUNGIN 
 
Dose in Adults 
Intravenous: Loading dose of 70mg, then 50mg od 
thereafter.   
 NB: If patient weight >80kg: loading dose of 70mg, then 70mg od thereafter. 
N.B. Caspofungin must have a pre and post flush with sodium chloride 0.9% and be 
infused in sodium chloride 0.9% 
Dose in Children 
Clinical experience limited.  Seek specialist advice. 
 
Dose Adjustment in Renal Impairment 
Dose adjustment not required. 
 
Dose Adjustment in Liver Impairment 
For mild hepatic insufficiency (Child-Pugh score 5 - 6): no dose adjustment required. 
For moderate hepatic insufficiency (Child-Pugh score 7 - 9): loading dose of 70mg, 
then 35mg od thereafter. 
For severe hepatic insufficiency (Child-Pugh score > 9): there is no clinical experience 
but a higher exposure than in moderate hepatic impairment is expected, so use with 
caution in these patients.  
 
FLUCONAZOLE 
 
Dose in Adults 
Oral:  100mg od for prophylaxis.   
Otherwise 400mg OD for systemic  candidosis or cryptococcosis 
   
Intravenous: Loading dose of 800mg, then 400mg od. 
Dose in Children 
Mucosal candidiasis:  iv/oral: 3mg/kg daily 
Systemic candidiasis:  iv/oral: 6-12mg/kg daily 
 
Dose Adjustment in Renal Impairment 
For adults: If CrCl <10ml/min, give a maximum daily adult dose of 150mg. 
For children: 
CrCl  11-40ml/min/1.73m2   
Dosage interval: 48 hours (or half the normal daily dose) 
CrCl <10ml/min/1.73m2   
Dosage interval: 72 hours (or third of the normal daily dose) 
 
N.B. If patient established on effective haemofiltration specialist advice should be 
sought. 
 
Dose Adjustment in Liver Impairment 
Dose adjustment not required. 
 
ITRACONAZOLE 
 
Dose in Adults 
Oral solution: 200mg bd (if tolerance is a problem od dosing may be appropriate). If 
still intolerant, give itraconazole IV. 
 When switching therapy from IV antifungal therapy load with 400mg bd for 24 hours. 
Intravenous: 200mg bd for 48 hours then 200mg od 
 
Dose In Children 
Oral:  2.5mg/kg bd (max 200mg bd) 
Intravenous: 2.5mg/kg od (max 200mg od) 
 
Dose Adjustment in Renal Impairment  
Dose adjustment not required. 
If CrCl < 30ml/min, intravenous itraconazole should not be used as accumulation of the 
intravenous vehicle (cyclodextran) occurs and can result in potential toxicity.   
 
Dose Adjustment in Liver Impairment 
Itraconazole is predominantly metabolised in the liver.  Therefore, in moderate to 
severe liver dysfunction (Child-Pugh score > 7), consider dose adjustment and only 
initiate therapy if expected benefits exceed risk of further hepatic injury. 
 
VORICONAZOLE 
 
Voriconazole can cause serious visual disturbances, these affect colour, focus and 
concentration. These are reversible on discontinuation of the drug.    
 
Dose in Adults 
Oral:  Patients >40kg: 400mg bd for first 24 hours, then 200mg bd 
thereafter 
  Patients <40kg: 200mg bd for first 24 hours, then 100mg bd 
thereafter 
   
 
Intravenous: 6mg/kg every 12 hours for first 24 hours, then 4mg/kg bd 
 
Dose in Children 
In children aged 2 to 12 years: 
Oral:  200mg BD 
Intravenous: 7mg/kg every 12 hours  
 
In children 12-16 years: dose as adults 
 
Dose Adjustment in Renal Impairment  
Dose adjustment is not required, for the oral formulation. 
If CrCl <50ml/min, accumulation of the intravenous vehicle (SBECD) occurs, and the 
oral route should be used, unless the benefits outweighs the risks of intravenous 
treatment. 
 
Dose Adjustment in Liver Impairment 
No dose adjustment necessary in patients with acute hepatic injury, manifested by 
elevated liver function tests, but continued monitoring is required. 
In patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B, or score 5 - 9), 
the standard loading dose should be used, but the maintenance dose should be 
halved.   
Voriconazole has not been studied in severe chronic cirrhosis (Child-Pugh C, or score 
>10). 
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Appendix-5 
Materials  
 
A.5.1. Equipments: 
Capillary electrophoresis analyzer  (Applied Biosystems 31130;California;USA) 
50ml falcon tubes    (Greiner;Bio-one;North America) 
Gel Doc 2000    (BioRad;California, USA) 
G-Storm thermal cycler   (Biotage;Virginia;USA) 
Microcentrifuge    (MSE;London;UK) 
Microcentrifuge (0.25, 0.5 & 1.5 ml) tubes   
(BioSc;Utah;USA) 
Micropipettes tips (1-20µl and 20-200µl)  
(Starlab ;USA) 
Nanodrop-ND1000   (Labtech;UK) 
PCR (polymerase chain reaction) machine / thermal cyclerThermal seal   
     (WebScientific;Cheshire;UK) 
PCR microplate (PCR-96-AB-C)  (Axygen Scientific;California;USA) 
PCR plate (96 well thin wall)  (Webscientfic;Cheshire;UK) 
Pipetman (20 & 200-µl)   (Gilson;France)  
PyroMark Q24 (Pyrosequencing) (Biotage;Virginia;USA) 
Tetrad & Dyad blocks   (MJ Research;Aberdeen;UK) 
Vortex mixer     (Scientific ind;Bohemia NY;USA) 
14ml yellow top (centrifuge) tubes  (TPP;Switzerland) 
 
   
A.5.2. Reagents: 
A.5.2.1.  DNA extraction & Red cell lysis 
RBC lysis solution    (Gendera Puregene;Wales;UK) 
Cell lysis solution    (Gentra Puregene;Wales;UK) 
DNA hydration solution   (Gentra Puregene;Wales;UK) 
70% Ethanol 
Isopropanol 
PBS (Phosphate buffered saline)  (Oxoid;Basingstoke;UK) 
Protein precipitant solution for DNA  (Gentra Puregene;Wales;UK) 
RBC lysis solution    (Gendera Puregene;Wales;UK) 
 
A.5.2.2.  Electrophoresis reagents: 
Agrose multiple-purpose   (Bioline ltd;London;UK) 
DNA Lader Low 1000bp   (Bioline ltd;London;UK) 
Syber safe DNA gel stain  (Invitrogen;Oregon;USA) 
TBE x10 buffer solution   (Flowgen;Nottingham;UK) 
Tracing dye     (Bioline ltd;London;UK) 
 
A.5.2.3.  Genescanning reagents: 
- Gene ScanTM-500 LIZTM Size standard  
(AB applied Biosystems;California;USA) 
-Hi-dye formamide   (AB applied Biosystems;California;USA) 
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A.5.2.4.  Pyrosequencing reagents: 
Annealing buffer   (Biotage;Virginia;USA) 
Binding buffer    (Biotage;Virginia;USA) 
SNP primer S1 
Streptavidin sepherose  (GE healthcare;Sweden) 
  
A.5.2.5.  PCR reagents: 
BioTaqTM DNA polymerase  (Bioline ltd;London;UK) 
100mM dNTP set (Deoxynucleotide Triphosphates) dNTPs  
dATP, dGTP, dCTP, dTTP (invitrogen;CA;USA) 
     (Bioline ltd;London;UK) 
Magnesium chloride    (Bioline ltd;London;UK) 
10x polymerase buffer   (Bioline ltd;London;UK) 
Sterile water (dd H2O) 
 
A.5.3. Primers: 
A.5.3.1.  Chitotriosidase primers for genotyping: 
Oligonucletoid primers   (Sigma Genoys;Texas;USA) 
 
Primer Name   Primer sequence (5’-3’) 
Chito-F’   AGCTATCTGAAGCAGAAG 
Chito-R’   GGACAAGCCGGCAAAGTC 
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A.5.3.2.  NOD2  primers for genescanning & sequencing: 
Oligonucletoid primers   (vh bio;Edinburgh;UK) 
 
Primer Name   Primer sequence  
Exon 4 WT   5’ FAM CAT CTG AGA AGG CCC TGC TCC  
Exon 4 SNP8   5’ HEX CAT CTG AGA AGG CCC TGC TCT-3’ 
Exon 4 Common Antisense 5’-CTG CCC AAC ATT CAG GCC AC-3’ 
 
Exon 8 WT   5’ FAM TCG TCA CCC ACT CTG TTG CC-3’ 
Exon 8 SNP12  5’ HEX TCG TCA CCC ACT CTG TTG CG-3’ 
Exon 8 Common Sense 5’-GAT GGA GGC AGG TCC ACT TTG C-3’ 
 
Exon 11 WT   5’ FAM ATG GCT TCA TTC CTT TCA AGG GC 
Exon 11 SNP13  5’HEX ATG GCT TCA TTC CTT TCA AGG GG 
Exon 11 Common Sense 5'TGG TAC TGA GCC TTT GTT GAT GAG CTC 
 
A.5.3.3.  NOD2 primers for pyrosequencing: 
Oligonucletoid primers   (vh bio;Edinburgh;UK) 
Exon 4: F1  5’-Biotin-GGG GCC TGC TGG CTG AGT-3’ 
  R1  5’-GGA AGT GCT TGC GGA GGC T-3’ 
Exon 8: F1  5’-GCA GAG GGA GGA GGA CTG TT-3’ 
  R1  5’-Biotin-CCC TCG TCA CCC ACT CTG TT-3’ 
Exon 11: F1  5’-Biotin-ACC AGA ACC AGG ATG A-3’ 
  R1  5’-AAA CTG AGG TTC GGA GAG CTA A-3’ 
  
 
A.5.4. Solutions: 
A.5.4.1.  Agrose gel (1.5%): 
Agrose powder (0.75g) was mixed with TBEx5 (50ml) and heated in the microwave for 
one minute, then ethidium promide, or sybersafe (2.5 l) was added to the mixture and 
stirred. The mixture was poured in the electopherosis plate and was left for 15-20 
minutes in order for the gel to form. 
A.5.4.2.  dNTP stock: 
2mM dNTPs (Invitrogen) was prepared by mixing equal volumes of each dNTP (dATP, 
dGTP, dCTP, dTTP) to give a concentration of 25mM. This was diluted 1:12.5 in ddH2O 
(10µl dNTP mix + 115µl ddH2O) to give a final 2mM working solution, and stored at -
20ºC. 
A.5.4.3.  Ethidium bromide: 
Ethidium bromide used for staining DNA in gels was prepared as a stock solution of 
10mg/ml in ddH2O. It was stored at room temperature in a bottle wrapped in an 
aluminium foil. 
A.5.4.4.  MgCL2 stock: 
Magnesium chloride (BioLine) 50mM was diluted at proportion of 15:35 in ddH2O to 
give a final concentration 15mM of working solution, and stored at -20ºC. 
A.5.4.5.  PBS buffer x1: 
10 PBS tablet (Oxoid) was dissolved in a liter of ddH2O to make a final 1xPBS. 
A.5.4.6.  TBE x10:    
10xTBE (Flowgen) was diluted with ddH2O to 0.5 stored at room temperature. 
A.5.4.7.  Tracking dye: 
The tracking dye was prepared by dissolving 0.25% Bromophenol blue, 0.25% Xylene 
Cyanol FF, 15% Ficoll (Type 400; Pharmacia) in water and stored at room temperature. 
It was used to load DNA in the wells of agros gel. 
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Appendix-6 
CHITOTRIOSIDASE as genetic determinant of sepsis in  
haematological malignancy 
 
 
Table A.6.1. Total febrile events in each genotype.  Porportions of patients (Pts) out of each 
chitotriosidase genotype with febrile events whilst neutropenic (FNE) or non-neutropenic 
(FNnE). (P value: 1st column wild type:hete:homo, 3rd column wild type :mutant, 4th column wild 
type:hete, 5th wild type:homo). P value calculation by Chi square, figures    10 Fisher exact was 
used. 
Total Wild  type Mutant Heterozygote Homozygote 
Total pt 204 (%) 122 (59.80%) 82 (40.20%) 71 (34.80%) 11 (5.39%) 
Total Febrile events 317 
(%; total events/genotype 
event) 
200 
(63.09) 
117 
(36.91) 
101 
(31.86) 
16 
(5.05) 
Total 203 FNE (%;genotype 
total events/genotype events) 
127   
(62.56%) 
76     
(37.44%) 
63    
(31.04%) 
13      
(6.40%) 
Total 114 FNnE (% genotype 
total events/genotype events) 
73     
(64.04%) 
41     
(35.96%) 
38    
(33.33%) 
3        
(2.63%) 
Pts with FNE (% pts of FNE/ 
genotype pts) 
P = 0.399 
74     
(60.66%) 
42     
(51.22%) 
                   
Wt:Mut 0.182 
36    
(50.70%) 
                 
Wt:Het 0.178 
6      
(54.55%) 
               
Wt:Hom 
0.484 
Pts with FNnE (% pts of 
FNnE/ genotype pts)                              
P = 0.754 
47     
(38.52%) 
29     
(35.37%) 
                   
Wt:Mut 0.642 
26    
(36.62%) 
                  
Wt:Het 0.792 
3      
(27.27%) 
               
Wt:Hom 
0.205 
Pts with either febrile events 
P = 0.413 
56 (45.90%) 37 (45.12%) 
Wt:Mut 0.913 
30 (64.79%) 
Wt:Het 0.623 
7 (63.64%) 
Wt:Hom 
0.208 
Pts with both febrile events. 
P = 0.370 
33    
(27.05%) 
17    
(20.73%) 
Wt:Mut 0.304 
16     
(22.54%) 
Wt:Het 0.487 
1        
(9.09%) 
Wt:Hom 
0.140 
 
Table A.6.2. Non-neutropenic events in relation to chemotherapy in different chitotriosidase 
genotypes. Percentage calculation: FNnE in chemo relation x 100 / total FNnE in each 
genotype. 
Febrile non 
neutropenic 
events=114 
Wild type=73 Heterozygote=38 Homozygote=3 
Chemo related 
Mean; FNnE/pt 
% 
71 
0.58 
97.26 
38 
0.54 
100 
3 
0.27 
100 
Chemo unrelated 
Mean; FNnE/pt 
% 
2 
0.02 
2.74 
0 
 
0 
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Table A.6.3. Chemo-related FNnE in relation to chemo-induced neutropenia in the 
chitotriosidase genotypes. 
FNnE=114  Wild type=73 Heterozygote=38 Homozygote=3 
Pre-neutropenia (%) 
Mean; FNnE/pt 
31 (42.47%) 
0.25 
18 (47.37%) 
0.25 
2 (66.67%) 
0.18 
Post-neutropenia (%) 
Mean; FNnE/pt 
24 (32.88%) 
0.20 
10 (26.32%) 
0.14 
1 (33.33%) 
0.09 
Unrelated to EoN (%) 
Mean; FNnE/pt 
16 (21.92%) 
0.13 
10 (26.32%) 
0.14 
0 
 
Table A.6.4. Febrile events with positive bacterial cultures. (Neutopenic and/or non-
neutropenic) in different chitotriosidase genotypes. (P value: 1st column wild type:hete:homo, 3rd 
column wild type :mutant, 4th column wild type:hete, 5th wild type:homo). P value calculation by 
Chi square, figures    10 Fisher exact was used. 
Fever and positive bacterial cultures Wild type 
Total=122 
Mutant 
Total=82 
Heterozygote 
Total=71 
Homozygote 
Total =11 
Pts with only neutropenic events.  
(%).  
Pvalue 0.564 
38 
(31.15%) 
 
20 
(24.39%) 
0.294 
18 
(25.35%) 
0.392 
2 
(18.18%) 
0.199 
Pts with only non-neutropenic events 
(%).  
P value 0.662 
22 
(10.66%) 
10 
(12.20%) 
0.733 
8 
(11.27%) 
0.078 
2 
(18.18%) 
0.312 
Pts with total events either 
neutropenia or non-neutropenia (%).  
P value 0.779 
60 
(49.18%) 
38 
(46.34%) 
0.691 
34 
(47.89%) 
0.862 
4 
(36.36%) 
0.182 
Pts with events, both whilst 
neutropenia and non-neutropenia 
(%). P value 0.503 
9 
(7.38%) 
 
8 
(9.76%) 
0.547 
8 
(11.27%) 
0.358 
0 
 
0.448 
 
Table A.6.5. Febrile events with proven or probable IFD whilst neutopenic or non-
neutropenic in different chitotriosidase genotypes. (P value: 1st column wild type:hete:homo, 3rd 
column wild type :mutant, 4th column wild type:hete, 5th wild type:homo). P value calculation by 
Chi square, figures    10 Fisher exact was used. 
Patients with fever and Fungal positive 
event 
Wild type; 
Total 
pts=122 
Mutant; 
Total=82 
Heterozygote
; Total 
pts=71 
Homozygote
; Total 
Pts=11 
Pts with only neutropenic events. 
(%).  
P value 0.582 
2 
(1.64) 
 
0 
Wt:Mut 
0.356 
0 
Wt:Het 0.398 
0 
Wt: Hom 
0.841 
Pts with only non-neutropenic events. 
(%) 
P value 0.618 
3 
(2.46) 
 
0 
Wt:Mut 
0.212 
0 
Wt:Het 0.250 
0 
Wt: Hom 
0.770 
Pts with total events either neutropenia 
or non-neutropenia 
(%). P value 0.283 
5 
(4.10) 
 
0 
Wt:Mut 
0.074 
0 
Wt:Het 0.098 
0 
Wt:Hom 
0.654 
Pts with events, both whilst 
neutropenia and non-neutropenia 
(%) 
0 0 0 0 
 
  
 
Table A.6.6. Proportion of patients out of each chitotriosidase genotype. Events of fever 
(with only possible IFD) whilst neutopenic or non-neutropenic.  %; Pts with event x100 / total 
genotype. (P value: 1st column wild type:hete:homo, 3rd column wild type :mutant, 4th column 
wild type:hete, 5th wild type:homo). P value calculation by Chi square, figures    10 Fisher exact 
was used. 
Fungal positive event 
Possible IFD 
Wild type; 
Total pts=122 
Mutant; 
Total=82 
Hetero; Total 
pts=71 
Homo; Total 
Pts=11 
Pts with FNE 
% 
P value 0.662 
4 
3.28 
 
1 
1.22 
Wt:Mut 0.257 
1 
1.41 
Wt:Het 0.249 
0 
 
Wt: Hom 0.645 
Pts with FNnE 
% 
P value 0.713 
1 
0.82 
 
0 
 
Wt:Mut 0.598 
0 
 
Wt:Het 0.632 
0 
 
Wt: Hom 0.917 
Pts with any febrile event 
% 
P value 0.475 
5 
4.10 
 
1 
1.22 
Wt:Mut 0.183 
1 
1.41 
Wt:Het 0.222 
0 
 
Wt: Hom 0.645 
Pt with both febrile events 
% 
0 0 0 0 
 
 
 
Table A.6.7. Febrile events due to viral pathogens whilst neutopenic or non-neutropenic in 
different chitotriosidase genotypes. %; Pts with event x100 / total genotype. (P value: 1st column 
wild type:hete:homo, 3rd column wild type :mutant, 4th column wild type:hete, 5th wild 
type:homo). P value calculation by Chi square, figures    10 Fisher exact was used. 
Patients with fever and viral 
positive event 
Wild type; 
Total =122 
Mutant; 
Total=82 
Heterozygote 
Total=71 
Homozygote; 
Total=11 
Pts with only neutropenic 
events. (%) 
P value 0.624 
1 
(0.82) 
 
2 
(2.44) 
Wt:Mut 0.354 
2 
(2.82) 
Wt:Het 0.305 
0 
 
Wt:Hom 
0.917 
Pts with only non-neutropenic 
events. (%) 
P value 1.000 
1 
(0.82) 
 
0 
 
Wt:Mut 0.598 
0 
 
Wt:Het 0.635 
0 
 
Wt:Hom 
0.917 
Pts with total events either 
neutropenia or non-neutropenia. 
(%) 
P value 0.701 
2 
(1.64) 
 
2 
(2.44) 
Wt:Mut 0.350 
2 
(2.82)     
Wt:Het 0.327 
0 
 
Wt:Hom 
0.841 
Pts with fever, both whilst 
neutropenia & non-neutropenia 
0 0 0 0 
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Table A.6.8. Febrile events without identifiable organism whilst neutopenic or non-
neutropenic in different chitotriosidase genotypes. Culture –ve: No organism grown in a febrile 
patient. %; Pts with event x100 / total genotype. (P value: 1st column wild type:hete:homo, 3rd 
column wild type :mutant, 4th column wild type:hete, 5th wild type:homo). P value calculation by 
Chi square, figures    10 Fisher exact was used. 
Fever and culture -ve event Wild type; 
Total =122 
Mutant 
Total=82 
Heterozygote 
Total pts=71 
Homozygote  
Total =11 
Pts with only neutropenic 
events.  
(%) 
P value 0.068 
27 
(23.13%) 
 
14 
(17.07%) 
Wt:Mut 0.377 
10 
(14.08%) 
Wt:Het 0.171 
4 
(36.36%) 
Wt:Hom 
0.154 
Pts with only non-neutropenic 
events. 
 (%).  
P value 0.243 
18 
(14.75%) 
 
10 
(12.20%) 
Wt:Mut 0.634 
9 
(12.68%) 
Wt:Het 0.720 
1 
(9.90%) 
Wt:Hom 
0.343 
Pts with total events either 
neutropenia or non-neutropenia. 
(%) 
P value 0.058 
59 
(48.36%)  
27 
(32.93%) 
Wt:Mut 0.029 
22 
(30.99%)     
Wt:Het 0.018   
5 
(45.45%)     
Wt:Hom 
0.242 
Pts with fever, both whilst 
neutropenia & non-neutropenia.  
(%).  
P value 0.214 
13 
(10.66%)  
3 
(3.66%)   
Wt:Mut 0.041 
3 
(4.23%)       
Wt:Het 0.067 
0 
0            
Wt:Hom 
0.308 
 
 
Table A.6.9. Proportion of episodes of neutropenia in which patients developed bacterial 
FNE, probable or proven IFD, possible fungal infection, viral infection or culture negative fever 
in all ChT genotypes. % calculated by Febrile EoN with type of cultures / Total EoN in each 
genotype. (P value: 1st column wild type:hete:homo, 3rd column wild type :mutant, 4th column 
wild type:hete, 5th wild type:homo). P value calculation by Chi square, figures    10 Fisher exact 
was used. 
Episodes of neutropenia with 
febrile events. 
Wild type; 
Total 
EoN=282 
Mutant; Total 
EoN=171 
Heterozygote 
Total 
EoN=135 
Homozygote; 
Total 
EoN=36 
Number of EoN with bacterial 
FNE. (%) 
P value 0.010 
69 
(24.47%) 
 
40 
(23.39%) 
Wt:Mut 0.795 
38 
(28.15%) 
Wt:het 0.421 
2 
(5.56%) 
Wt:hom 
0.004 
Number of EoN with probable/ 
proven fungal FNE. (%). 
P value 1.000 
2 
(0.71%) 
 
0 
 
Wt:Mut 0.387 
0 
 
Wt:het 0.457 
0 
 
Wt:hom 
0.786 
Number of EoN with viral FNE. 
(%). 
P value 0.412 
1 
(0.35%) 
2 
(1.17%)  
Wt:Mut 0.320 
2 
(1.46%)     
Wt:het 0.246 
0 
Wt:hom 
0.887 
Number of EoN with culture 
negative FNE. (%). 
P value 0.190 
49 
(17.38%) 
30 
(17.54%) 
Wt:Mut 0.964 
20 
(14.81%)  
Wt:het 0.510 
10 
(27.78%) 
Wt:hom 
0.131 
 
   
 
Table A.6.10. Total febrile events regardless neutropenia in different chitotriosidase 
genotypes, and the type of identifiable organism if present in each febrile event associated with 
neutropenia. (P value: 1st column wild type:hete:homo, 3rd column wild type :mutant, 4th column 
wild type:hete, 5th wild type:homo). P value by Chi square, figures    10 Fisher exact was used. 
Total febrile events=317 Wild type; 
Total 
events=199 
Mutant; Total 
events =117 
Heterozygote
Total 
events=101 
Homozygote; 
Total 
events=16 
Total bact +ve events 
Bacterial +ve/febrile event % 
P value 0.031 
101 
50.75% 
68 
58.12% 
Wt:Mut 0.205 
63 
62.38% 
Wt:Het 0.037 
5 
31.25% 
Wt:Hom 
0.069 
Total fung +ve events 
Fungal+ve/febrile event % 
P value 0.705 
5 
2.51 
0 
 
Wt:Mut 0.097 
0 
 
Wt:Het 0.126 
0 
 
Wt:Hom 
0.677 
Total viral +ve events 
Viral +ve/febrile event % 
P value 0.214 
2 
1.01 
2 
1.71 
Wt:Mut 0.328 
2 
1.98          
Wt:Het 0.301 
0 
 
Wt:Hom 
0.856 
Total culture -ve events 
Culture –ve / febrile event 
%P value 0.029 
91 
45.73 
47 
40.17 
Wt:Mut 0.336 
36 
35.64      
Wt:Het 0.095 
11 
68.75    
Wt:Hom 
0.076 
 
 
 
Table A.6.11. Total febrile events associated with neutropenia in different chitotriosidase 
genotypes, and the type of identifiable organism if present in each febrile event associated with 
neutropenia. (P value: 1st column wild type:hete:homo, 3rd column wild type :mutant, 4th column 
wild type:hete, 5th wild type:homo). P value calculation by Chi square, figures    10 Fisher exact 
was used. 
Total febrile neutropenic 
events 
Wild type; 
FNE=126 
Mutant; 
FNE=76 
Heterozygote; 
FNE=63 
Homozygote; 
FNE=13 
Number of Bact FNE 
Bacterial rate/FNE % 
P value 0.015 
74 
58.73% 
 
45 
59.21% 
Wt:Mut 0.946 
42 
67% 
Wt:Het 0.291 
3 
23% 
Wt:Hom 0.012 
Number of fung FNE 
Fungal rate / FNE% 
P value 0.609 
2 
1.6 
 
0 
 
Wt:Mut 0.388 
0 
 
Wt:Het 0.443 
0 
 
Wt:Hom 0.821 
Number of viral FNE 
Viral +ve / FNE% 
P value  0.393 
1 
0.8 
 
2 
2.63% 
Wt:Mut 0.317 
2 
3.2 
Wt:Het 0.258 
0 
 
Wt:Hom 0.906 
Number of culture -ve FNE 
Culture -ve rate / FNE% 
P value 0.007 
49 
38.89% 
 
29 
38.16% 
Wt:Mut 0.918 
19 
30.16% 
Wt:Het 0.238 
10 
77% 
Wt:Hom 0.008 
 
 
 
 
   
 Table A.6.12. Total febrile non-neutropenic events only in different chitotriosidase genotypes, 
and the type of identifiable organism if present in each febrile event associated with 
neutropenia. (P value:1st column wild type:hete:homo, 3rd column wild type :mutant, 4th column 
wild type:hete, 5th wild type:homo). P value by Chi square, figures    10 Fisher exact was used. 
Total febrile non-
neutropenic events 
Wild type 
FNnE=73 
Mutant 
FNnE=41 
HeterozygoteF
NnE=38 
Homozygote 
FNnE=3 
Number of bact FNnE 
Bacterial rate/FNnE% 
P value 0.144 
27 
37% 
 
23 
56 
Wt:Mut 0.048 
21 
55 
Wt:Het 0.065 
2 
67 
Wt: Hom 0.323 
Number of fung FNnE 
Fungal rate / FNnE% 
P value 0.585 
3 
41 
0 
 
Wt:Mut 0.259 
0 
 
Wt:Het 0.280 
0 
 
Wt:Hom 0.885 
Number of viral FNnE 
Viral +ve / FNnE% 
P value  1.000 
1 
1 
 
0 
 
Wt:Mut 0.640 
0 
 
Wt:Het 0.658 
0 
 
Wt:Hom 0.961 
Number of culture 
negative FNnE 
Culture -ve rate / FNnE% 
P value 0.392 
43 
59 
 
18 
44 
Wt:Mut 0.162 
17 
45 
Wt:Het 0.200 
1 
33 
Wt:Hom 0.323 
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